data_1xop_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1xop _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 CA--C 1.538 0.509 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -106.19 -10.74 16.32 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.94 -48.04 58.55 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.846 0.736 . . . . 0.0 112.621 -171.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -19.85 58.76 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.353 1.461 . . . . 0.0 112.76 178.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.8 mm -74.67 -8.57 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 C-N-CA 124.41 1.084 . . . . 0.0 110.884 177.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.09 -44.33 4.19 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 127.154 2.182 . . . . 0.0 109.694 160.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.03 -39.22 89.27 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 119.029 0.831 . . . . 0.0 113.264 -173.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -69.62 -26.62 64.52 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 118.164 0.982 . . . . 0.0 112.038 176.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mm -75.76 -35.54 31.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 C-N-CA 123.686 0.795 . . . . 0.0 108.901 178.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -78.79 -49.2 13.4 Favored 'General case' 0 CA--C 1.519 -0.231 0 C-N-CA 125.815 1.646 . . . . 0.0 108.158 -174.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -63.65 -14.69 54.25 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.788 0.435 . . . . 0.0 111.27 167.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.63 -55.51 4.55 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 172.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.411 ' C ' ' H ' ' A' ' 16' ' ' GLY . 11.2 t90 -62.54 -58.81 6.23 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 125.979 1.712 . . . . 0.0 109.711 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -80.39 23.59 0.49 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.009 0.924 . . . . 0.0 111.759 176.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.411 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -94.5 -19.76 31.48 Favored Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.799 1.19 . . . . 0.0 111.085 159.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 ptt? -162.81 60.62 0.2 Allowed 'General case' 0 C--N 1.346 0.429 0 CA-C-N 118.943 1.372 . . . . 0.0 112.007 -176.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt . . . . . 0 N--CA 1.464 0.226 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 158.876 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.0 mm? . . . . . 0 C--O 1.235 0.321 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -63.36 -20.65 65.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -175.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.19 -30.31 57.66 Favored Glycine 0 CA--C 1.532 1.113 0 CA-C-O 118.999 -0.889 . . . . 0.0 112.463 172.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.98 -32.24 25.09 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 119.118 1.459 . . . . 0.0 111.378 172.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.2 mm -65.87 -28.83 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 123.829 0.851 . . . . 0.0 111.934 178.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -81.55 -53.65 6.09 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 127.675 2.39 . . . . 0.0 110.139 165.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.82 -41.84 36.5 Favored Glycine 0 C--N 1.342 0.881 0 C-N-CA 125.668 1.604 . . . . 0.0 112.928 -173.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -75.53 -16.85 60.23 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.6 mt -81.4 -45.71 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.696 0.799 . . . . 0.0 108.896 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -82.46 -38.48 23.88 Favored 'General case' 0 CA--C 1.527 0.07 0 CA-C-O 118.194 -0.908 . . . . 0.0 111.082 -167.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -87.02 1.73 51.91 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.309 0.959 . . . . 0.0 111.059 162.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.78 -45.87 56.1 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 159.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -63.4 -64.9 0.77 Allowed 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 167.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -81.5 57.45 3.3 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.537 1.535 . . . . 0.0 108.544 -173.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -136.77 -42.48 0.1 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 126.886 2.184 . . . . 0.0 110.443 176.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -145.67 -6.81 0.6 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 115.307 1.595 . . . . 0.0 115.307 -179.082 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.8 mt . . . . . 0 N--CA 1.469 0.476 0 CA-C-N 119.751 1.16 . . . . 0.0 111.562 -175.145 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mp . . . . . 0 C--O 1.234 0.252 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -66.59 -23.8 66.25 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 -170.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -27.24 61.23 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.112 0.863 . . . . 0.0 112.83 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.71 -44.44 20.79 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 118.779 1.29 . . . . 0.0 110.385 172.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.0 mt -60.22 -38.66 78.13 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 C-N-CA 125.671 1.588 . . . . 0.0 111.785 -176.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -74.03 -58.69 3.13 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 127.613 2.365 . . . . 0.0 109.881 168.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -32.82 59.94 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 123.978 0.799 . . . . 0.0 113.883 -166.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.1 t80 -67.64 -36.84 81.52 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.193 0.997 . . . . 0.0 111.772 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.2 mt -71.0 -33.65 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 C-N-CA 124.363 1.065 . . . . 0.0 109.597 177.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -80.3 -50.48 10.12 Favored 'General case' 0 C--N 1.333 -0.149 0 C-N-CA 125.312 1.445 . . . . 0.0 108.179 -170.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -66.05 -19.15 65.76 Favored 'General case' 0 C--N 1.342 0.274 0 CA-C-O 119.394 -0.336 . . . . 0.0 110.691 168.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.08 -50.79 16.25 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 173.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.7 t90 -64.26 -61.32 2.32 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 125.051 1.34 . . . . 0.0 109.167 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -88.94 23.38 2.39 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.786 0.803 . . . . 0.0 111.53 -169.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.07 -13.33 34.05 Favored Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.338 1.447 . . . . 0.0 111.488 171.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.9 ttm -146.67 -34.94 0.27 Allowed 'General case' 0 C--N 1.341 0.238 0 CA-C-N 118.253 1.026 . . . . 0.0 113.724 -177.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.6 mt . . . . . 0 C--N 1.328 -0.333 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -162.962 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 121.302 0.573 . . . . 0.0 111.431 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -59.58 -26.46 65.44 Favored 'General case' 0 N--CA 1.463 0.193 0 O-C-N 121.678 -0.639 . . . . 0.0 111.934 -178.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.55 -26.18 66.22 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 125.285 1.422 . . . . 0.0 112.728 175.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.54 -62.63 1.45 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.37 1.085 . . . . 0.0 109.326 166.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 52.2 mt -61.07 -22.39 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 C-N-CA 126.345 1.858 . . . . 0.0 113.782 -160.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -132.42 -42.88 0.94 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 125.569 1.548 . . . . 0.0 111.028 172.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.94 -36.03 59.82 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 118.814 -0.992 . . . . 0.0 112.931 -175.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -77.35 -19.91 55.58 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 118.692 1.246 . . . . 0.0 112.583 176.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -82.29 -38.51 15.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.028 1.331 . . . . 0.0 108.755 174.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -73.18 -57.96 3.65 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 128.016 2.526 . . . . 0.0 107.593 -175.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -69.67 -7.76 41.84 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.045 0.538 . . . . 0.0 111.06 169.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.75 -59.42 4.07 Favored Glycine 0 C--N 1.34 0.777 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 169.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 18.8 t90 -60.27 -56.84 16.61 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 125.54 1.536 . . . . 0.0 109.739 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -85.03 23.65 1.2 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.632 0.773 . . . . 0.0 111.483 -177.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.94 9.82 11.26 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 127.886 2.66 . . . . 0.0 111.656 164.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.5 ptt? -129.93 -20.86 3.08 Favored 'General case' 0 C--N 1.344 0.367 0 CA-C-N 118.088 0.944 . . . . 0.0 113.491 164.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.0 mm . . . . . 0 N--CA 1.469 0.506 0 C-N-CA 123.617 0.767 . . . . 0.0 110.949 172.207 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 55.3 mt . . . . . 0 C--O 1.235 0.326 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -59.19 -26.06 64.49 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -174.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.12 -28.35 63.87 Favored Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.414 1.006 . . . . 0.0 112.778 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.26 -42.14 21.12 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 119.138 1.469 . . . . 0.0 110.516 171.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mt -59.22 -39.96 80.01 Favored 'Isoleucine or valine' 0 C--N 1.342 0.257 0 C-N-CA 124.823 1.249 . . . . 0.0 111.979 -176.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.55 -54.28 6.92 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 127.542 2.337 . . . . 0.0 110.116 169.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.58 -34.34 60.2 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 124.242 0.925 . . . . 0.0 113.642 -170.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -72.17 -23.17 61.24 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 118.407 1.103 . . . . 0.0 112.683 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -79.64 -38.84 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 124.323 1.049 . . . . 0.0 108.784 170.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.44 -55.36 7.15 Favored 'General case' 0 C--O 1.226 -0.17 0 C-N-CA 125.08 1.352 . . . . 0.0 109.052 -172.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -79.82 2.71 22.08 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.451 0.568 . . . . 0.0 111.595 167.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.79 -52.94 22.12 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 159.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -58.49 -63.37 1.3 Allowed 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.484 1.114 . . . . 0.0 108.592 169.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -80.66 56.91 2.78 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.154 2.182 . . . . 0.0 109.109 -176.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -173.29 -22.87 0.02 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.886 3.136 . . . . 0.0 110.794 178.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 33.5 mmt -93.39 -22.71 18.76 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 118.372 1.086 . . . . 0.0 112.569 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 N--CA 1.469 0.503 0 C-N-CA 124.557 1.143 . . . . 0.0 110.745 173.765 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.6 mp . . . . . 0 C--O 1.232 0.172 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 28.8 t80 -71.49 -12.59 61.46 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 176.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.79 -24.6 54.07 Favored Glycine 0 CA--C 1.533 1.188 0 C-N-CA 124.4 1.0 . . . . 0.0 113.523 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -78.31 -43.34 28.18 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.491 1.146 . . . . 0.0 110.83 171.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 18.6 mm -71.58 -9.33 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 126.07 1.748 . . . . 0.0 111.818 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.57 3.35 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 128.188 2.595 . . . . 0.0 109.484 168.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.66 -37.1 91.81 Favored Glycine 0 CA--C 1.529 0.92 0 CA-C-N 118.804 0.729 . . . . 0.0 112.8 -174.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 84.2 t80 -67.29 -25.63 66.13 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.638 0.719 . . . . 0.0 111.655 178.574 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 mm -66.47 -23.46 31.55 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-N 118.898 0.772 . . . . 0.0 109.9 177.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -104.82 -60.87 1.54 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 -172.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -64.25 -25.22 67.96 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 122.949 0.5 . . . . 0.0 112.304 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.85 0.77 86.04 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.078 174.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.458 ' C ' ' H ' ' A' ' 16' ' ' GLY . 8.4 t90 -127.44 -68.34 0.79 Allowed 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.78 1.632 . . . . 0.0 108.574 -176.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -74.16 23.79 0.08 Allowed 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.923 2.089 . . . . 0.0 112.394 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -98.24 -33.81 5.57 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 125.209 1.385 . . . . 0.0 111.367 162.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.1 mmm -153.65 64.76 0.73 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.825 1.313 . . . . 0.0 109.746 -173.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.7 mt . . . . . 0 N--CA 1.466 0.35 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 166.367 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.7 mm? . . . . . 0 N--CA 1.462 0.148 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -77.39 -12.96 60.02 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 179.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.71 -42.0 58.31 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.369 0.985 . . . . 0.0 112.986 -170.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.74 -22.41 61.61 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.298 1.439 . . . . 0.0 112.719 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mm -74.35 -5.47 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 C-N-CA 124.645 1.178 . . . . 0.0 110.811 176.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.37 -42.11 3.98 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 126.608 1.963 . . . . 0.0 109.706 160.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.68 -39.51 91.28 Favored Glycine 0 C--N 1.342 0.909 0 CA-C-N 119.23 0.923 . . . . 0.0 112.87 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -75.62 -15.28 60.36 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 117.843 0.821 . . . . 0.0 112.69 177.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.8 mm -85.66 -37.76 12.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 124.699 1.2 . . . . 0.0 108.724 174.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -72.62 -55.75 6.38 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 126.568 1.947 . . . . 0.0 107.886 -177.05 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -69.29 -6.62 30.59 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.558 0.743 . . . . 0.0 111.247 168.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.97 -57.49 3.72 Favored Glycine 0 C--N 1.341 0.82 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 169.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -57.02 -57.01 14.43 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 126.536 1.934 . . . . 0.0 109.283 175.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -83.27 24.38 0.81 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 123.944 0.897 . . . . 0.0 111.612 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -121.47 6.87 10.58 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 127.324 2.392 . . . . 0.0 111.331 164.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.8 mmt -126.58 -36.11 2.29 Favored 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.215 1.406 . . . . 0.0 111.767 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm . . . . . 0 N--CA 1.468 0.432 0 C-N-CA 124.887 1.275 . . . . 0.0 110.704 175.494 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.7 mp . . . . . 0 C--O 1.232 0.163 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -77.9 -12.01 59.94 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 177.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.91 -28.96 61.35 Favored Glycine 0 CA--C 1.531 1.045 0 C-N-CA 124.033 0.825 . . . . 0.0 113.583 -174.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.8 -33.52 27.23 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 118.572 1.186 . . . . 0.0 111.512 173.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.0 mm -73.66 -10.26 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 126.052 1.741 . . . . 0.0 111.609 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.81 -48.82 3.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 127.321 2.248 . . . . 0.0 109.632 164.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.38 -36.05 82.01 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 119.034 0.833 . . . . 0.0 113.33 -172.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -66.79 -31.2 71.67 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.439 1.12 . . . . 0.0 111.618 175.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mm -73.99 -18.14 17.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 124.484 1.114 . . . . 0.0 109.977 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -97.7 -61.21 1.42 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 125.324 1.45 . . . . 0.0 107.337 -174.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -61.65 -30.99 71.08 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.527 0.731 . . . . 0.0 111.761 176.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.43 0.61 63.71 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.122 -0.821 . . . . 0.0 113.433 177.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.44 ' C ' ' H ' ' A' ' 16' ' ' GLY . 17.9 t90 -130.39 -69.65 0.65 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.943 1.297 . . . . 0.0 108.568 -174.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -78.51 23.43 0.31 Allowed 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.294 1.038 . . . . 0.0 112.043 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -118.02 -2.71 16.08 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 127.416 2.436 . . . . 0.0 112.106 166.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 61.0 mtt -134.09 -10.05 2.62 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.977 1.389 . . . . 0.0 113.382 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.2 mm . . . . . 0 CA--C 1.538 0.491 0 C-N-CA 124.114 0.966 . . . . 0.0 111.957 177.611 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.4 mt . . . . . 0 C--O 1.232 0.157 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -103.0 -9.47 19.77 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.624 0.601 . . . . 0.0 112.624 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.3 -30.73 64.89 Favored Glycine 0 CA--C 1.532 1.108 0 O-C-N 121.399 -0.813 . . . . 0.0 113.945 -170.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.75 30.08 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.855 1.262 . . . . 0.0 111.658 175.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.4 mm -75.46 -5.62 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.814 1.646 . . . . 0.0 111.099 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -110.02 -46.21 3.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.28 1.832 . . . . 0.0 109.922 160.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.37 -36.39 83.58 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 119.23 0.923 . . . . 0.0 113.274 -172.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -74.37 -20.08 60.21 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.755 0.778 . . . . 0.0 112.482 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -81.67 -34.5 12.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 124.288 1.035 . . . . 0.0 109.001 174.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -73.98 -56.09 5.36 Favored 'General case' 0 N--CA 1.457 -0.125 0 C-N-CA 125.813 1.645 . . . . 0.0 107.644 -176.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -63.13 -21.27 66.08 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 122.857 0.463 . . . . 0.0 111.0 168.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.73 -9.9 86.66 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-O 119.338 -0.701 . . . . 0.0 112.948 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -114.03 -58.1 2.19 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.916 1.286 . . . . 0.0 109.499 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.8 23.89 0.16 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.928 1.291 . . . . 0.0 112.691 -174.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.37 49.95 3.08 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.146 1.832 . . . . 0.0 111.87 178.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.4 mtm 58.53 73.93 0.46 Allowed 'General case' 0 C--N 1.341 0.214 0 C-N-CA 127.192 2.197 . . . . 0.0 110.468 -175.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 90.6 mt . . . . . 0 CA--C 1.544 0.723 0 C-N-CA 126.892 2.077 . . . . 0.0 112.532 -179.38 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? . . . . . 0 C--O 1.231 0.128 0 N-CA-C 106.63 -1.618 . . . . 0.0 106.63 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -88.62 -9.15 53.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 122.878 0.471 . . . . 0.0 112.134 177.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.61 -32.34 61.29 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 123.976 0.798 . . . . 0.0 114.09 -168.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.19 -28.34 27.4 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.434 1.093 . . . . 0.0 111.952 175.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.2 mm -74.88 -10.92 14.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 125.681 1.592 . . . . 0.0 111.244 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.66 -49.16 3.48 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 126.896 2.078 . . . . 0.0 109.55 162.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.0 -35.88 78.45 Favored Glycine 0 C--N 1.342 0.875 0 CA-C-N 118.988 0.813 . . . . 0.0 113.286 -170.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -70.78 -28.04 64.37 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.338 1.069 . . . . 0.0 112.038 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mm -72.49 -25.28 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 119.066 0.848 . . . . 0.0 109.487 176.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -92.71 -65.6 0.99 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.639 1.575 . . . . 0.0 107.029 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.13 -24.56 67.45 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.623 0.769 . . . . 0.0 110.764 179.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -77.38 -3.29 82.16 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 118.855 -0.97 . . . . 0.0 113.198 176.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.7 t90 -130.78 -74.66 0.53 Allowed 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 118.509 1.155 . . . . 0.0 108.984 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -79.75 23.71 0.42 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.679 1.192 . . . . 0.0 112.404 -172.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.27 -16.43 57.39 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 118.186 -1.341 . . . . 0.0 112.319 170.303 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 45.6 mmm -141.07 9.57 2.12 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 118.612 1.206 . . . . 0.0 113.037 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 5.3 mm . . . . . 0 CA--C 1.536 0.405 0 O-C-N 120.898 -1.126 . . . . 0.0 112.217 -177.37 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.0 mm? . . . . . 0 N--CA 1.468 0.458 0 CA-C-O 121.614 0.721 . . . . 0.0 112.037 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -60.17 -26.65 66.49 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.661 0.615 . . . . 0.0 112.661 -170.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -63.56 -24.13 67.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.859 1.218 . . . . 0.0 112.732 177.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.03 -61.8 1.51 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 118.126 0.963 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 56.9 mt -60.15 -21.95 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 126.398 1.879 . . . . 0.0 113.589 -161.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -131.26 -43.59 1.04 Allowed 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 125.953 1.701 . . . . 0.0 110.84 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.27 -34.35 59.02 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-N 119.067 0.849 . . . . 0.0 113.342 -177.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.0 t80 -75.62 -23.59 56.41 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.624 1.212 . . . . 0.0 112.231 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mm -80.11 -35.12 15.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 125.19 1.396 . . . . 0.0 109.144 175.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -73.69 -59.13 2.86 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 128.026 2.53 . . . . 0.0 106.833 -176.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -62.46 -19.13 63.21 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 119.224 -0.417 . . . . 0.0 111.291 170.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.13 -54.24 9.44 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 175.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -62.37 -57.2 12.19 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.53 1.532 . . . . 0.0 109.713 176.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 -80.22 23.41 0.48 Allowed 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.543 1.537 . . . . 0.0 112.857 -166.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.63 -5.66 10.97 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.753 2.121 . . . . 0.0 112.193 166.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 95.7 mmm -127.31 -2.91 6.26 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.714 1.257 . . . . 0.0 113.102 -174.127 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.0 mt . . . . . 0 N--CA 1.469 0.48 0 C-N-CA 124.219 1.008 . . . . 0.0 110.579 -178.776 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? . . . . . 0 CA--C 1.538 0.513 0 CA-C-O 121.662 0.744 . . . . 0.0 112.52 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.3 t80 -58.86 -25.76 63.59 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 123.679 0.792 . . . . 0.0 112.399 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.49 -15.06 51.99 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 125.323 1.439 . . . . 0.0 113.447 172.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -106.31 -55.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.527 1.163 . . . . 0.0 109.867 164.491 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 30.7 mt -61.95 -18.58 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 124.645 1.178 . . . . 0.0 113.677 -167.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -125.02 -43.47 1.97 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 125.697 1.599 . . . . 0.0 110.766 166.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.58 -34.89 78.08 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 119.417 1.008 . . . . 0.0 113.252 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.9 t80 -79.06 -10.69 59.9 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.622 1.211 . . . . 0.0 112.494 175.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.5 mm -87.66 -39.86 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 C-N-CA 124.798 1.239 . . . . 0.0 108.218 169.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -70.5 -59.96 2.54 Favored 'General case' 0 N--CA 1.457 -0.102 0 C-N-CA 126.6 1.96 . . . . 0.0 109.035 -176.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -74.01 -3.01 26.65 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.876 -0.515 . . . . 0.0 111.648 166.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.44 -10.26 74.82 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.495 0.589 . . . . 0.0 112.348 161.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -116.6 -64.22 1.34 Allowed 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 107.226 177.487 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -80.84 59.3 3.66 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-O 122.4 1.095 . . . . 0.0 109.49 172.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -145.25 13.66 1.86 Allowed Glycine 0 CA--C 1.534 1.225 0 C-N-CA 125.918 1.723 . . . . 0.0 111.765 161.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 25.6 ptt? -170.43 -18.84 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 128.386 2.675 . . . . 0.0 114.111 175.261 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 51.9 mt . . . . . 0 N--CA 1.475 0.806 0 C-N-CA 124.568 1.147 . . . . 0.0 110.338 -176.976 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mp . . . . . 0 C--O 1.234 0.255 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -62.79 -22.79 66.86 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.676 0.79 . . . . 0.0 112.003 172.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.47 -21.47 57.46 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 125.241 1.401 . . . . 0.0 112.895 171.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -85.65 -65.04 1.05 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 118.762 1.281 . . . . 0.0 108.766 163.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 29.1 mt -60.98 -24.5 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 125.509 1.523 . . . . 0.0 113.987 -161.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.44 -47.25 1.87 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 125.83 1.652 . . . . 0.0 110.542 172.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.56 -32.76 65.34 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.935 -0.925 . . . . 0.0 113.631 -172.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -76.37 -23.93 54.15 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 119.136 1.468 . . . . 0.0 112.108 175.073 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mm -71.08 -31.37 44.6 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 O-C-N 120.987 -1.07 . . . . 0.0 108.814 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -101.99 -49.8 3.84 Favored 'General case' 0 C--O 1.225 -0.188 0 C-N-CA 123.805 0.842 . . . . 0.0 110.386 -171.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 25.5 m-80 -86.45 -19.77 29.13 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.4 0.546 . . . . 0.0 111.234 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -96.45 -62.71 0.94 Allowed Glycine 0 C--N 1.34 0.79 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -175.647 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 23.5 t90 -80.23 -68.55 0.67 Allowed 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -79.54 23.45 0.41 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -167.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.69 -6.5 11.43 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 126.828 2.156 . . . . 0.0 112.729 170.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 59.1 mmm -130.19 20.59 5.32 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 118.964 1.382 . . . . 0.0 112.087 -172.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.5 mm . . . . . 0 CA--C 1.537 0.46 0 C-N-CA 123.711 0.805 . . . . 0.0 111.216 -177.137 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.6 mm? . . . . . 0 C--O 1.234 0.276 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -61.49 -22.42 65.08 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.6 -26.22 56.78 Favored Glycine 0 CA--C 1.532 1.1 0 CA-C-O 118.926 -0.93 . . . . 0.0 112.903 172.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.74 -43.74 15.17 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 119.222 1.511 . . . . 0.0 110.356 171.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -64.1 -13.21 13.32 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 C-N-CA 126.653 1.981 . . . . 0.0 112.629 -177.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.39 -48.92 2.99 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 127.59 2.356 . . . . 0.0 110.204 170.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.29 -36.1 81.54 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-N 119.412 1.006 . . . . 0.0 113.082 -174.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -73.7 -18.8 60.96 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 118.031 0.916 . . . . 0.0 112.515 176.018 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -80.98 -39.02 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 CA-C-N 119.431 1.014 . . . . 0.0 108.299 172.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -69.81 -62.41 1.39 Allowed 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 126.598 1.959 . . . . 0.0 107.951 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -64.58 -16.97 63.51 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 119.415 -0.326 . . . . 0.0 111.165 169.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.89 -16.32 66.0 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.747 -1.03 . . . . 0.0 113.37 173.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -127.49 -44.96 1.51 Allowed 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.571 1.185 . . . . 0.0 111.807 174.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -81.13 23.64 0.57 Allowed 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 122.256 1.027 . . . . 0.0 112.164 -162.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.66 -10.94 42.39 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 125.603 1.573 . . . . 0.0 112.227 163.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.5 mmm -111.64 -9.85 14.13 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.851 1.325 . . . . 0.0 113.521 -169.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm . . . . . 0 CA--C 1.533 0.315 0 C-N-CA 124.055 0.942 . . . . 0.0 112.313 -171.51 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? . . . . . 0 N--CA 1.468 0.435 0 CA-C-O 121.616 0.722 . . . . 0.0 110.728 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -84.43 -11.79 55.57 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -178.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.18 -32.57 63.48 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 123.817 0.722 . . . . 0.0 113.167 -174.393 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.07 -33.24 26.45 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.53 1.132 . . . . 0.0 111.629 174.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.1 mm -73.9 -9.1 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 125.644 1.578 . . . . 0.0 111.665 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.39 -50.45 3.22 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 127.479 2.312 . . . . 0.0 109.588 163.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.46 77.98 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 118.994 0.815 . . . . 0.0 113.281 -171.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -69.86 -28.11 65.39 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.198 0.999 . . . . 0.0 112.117 176.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mm -72.47 -25.67 23.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 CA-C-N 118.931 0.787 . . . . 0.0 109.429 176.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -92.91 -63.57 1.2 Allowed 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.225 1.41 . . . . 0.0 107.57 -170.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -68.39 -22.53 64.63 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.156 0.583 . . . . 0.0 110.872 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.94 -6.96 80.52 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.349 -0.695 . . . . 0.0 112.758 174.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.9 t90 -114.1 -76.05 0.59 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.228 1.411 . . . . 0.0 107.436 171.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.67 56.09 3.71 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 122.207 1.003 . . . . 0.0 110.971 -171.776 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.98 -7.97 37.37 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-O 118.659 -1.078 . . . . 0.0 111.73 159.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.0 mmt -148.97 3.05 0.6 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.054 1.341 . . . . 0.0 113.287 -169.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.7 mm . . . . . 0 N--CA 1.464 0.229 0 CA-C-N 120.163 1.347 . . . . 0.0 108.779 -170.38 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.9 mt . . . . . 0 C--O 1.233 0.218 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -65.92 -16.09 63.55 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 176.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.59 -23.5 58.47 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.701 1.143 . . . . 0.0 112.665 167.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.53 -58.31 2.79 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 118.891 1.346 . . . . 0.0 109.152 164.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.8 mm -64.3 -21.49 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -162.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -134.42 -44.75 0.76 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.941 1.696 . . . . 0.0 110.972 172.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.34 -42.57 74.61 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.992 0.815 . . . . 0.0 112.878 -173.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -77.62 -15.9 58.91 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 112.466 177.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.1 mm -71.1 -38.0 69.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 O-C-N 120.453 -1.404 . . . . 0.0 107.867 171.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -94.17 -55.71 3.1 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -167.325 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.0 m-80 -76.62 -20.06 57.14 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.141 0.576 . . . . 0.0 110.71 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.54 -63.88 0.79 Allowed Glycine 0 C--N 1.341 0.86 0 CA-C-O 118.387 -1.229 . . . . 0.0 111.45 -171.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.427 ' C ' ' H ' ' A' ' 16' ' ' GLY . 7.6 t90 -69.42 -64.06 0.95 Allowed 'General case' 0 C--N 1.341 0.22 0 CA-C-N 118.636 1.218 . . . . 0.0 108.336 175.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -80.34 23.14 0.51 Allowed 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.561 0.696 . . . . 0.0 112.522 -174.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -99.3 -58.41 0.91 Allowed Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.816 2.151 . . . . 0.0 108.739 162.321 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.7 ptm -65.06 -18.05 64.97 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 118.38 1.09 . . . . 0.0 113.555 -179.375 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.6 mm . . . . . 0 CA--C 1.539 0.548 0 C-N-CA 123.735 0.814 . . . . 0.0 110.633 169.185 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? . . . . . 0 C--O 1.236 0.367 0 CA-C-O 121.101 0.477 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -62.34 -21.0 64.95 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -173.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.42 -28.73 55.98 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 119.04 -0.867 . . . . 0.0 112.673 173.255 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.31 -41.96 19.41 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 119.127 1.464 . . . . 0.0 110.654 172.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.6 mt -65.82 -10.57 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.486 1.914 . . . . 0.0 112.465 -177.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -114.04 -45.02 3.09 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 127.01 2.124 . . . . 0.0 110.824 168.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.93 -38.79 76.29 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.682 0.674 . . . . 0.0 112.837 -176.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -78.21 -11.46 59.93 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 117.789 0.794 . . . . 0.0 112.632 178.452 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 9.7 mm -86.7 -42.37 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-N 119.218 0.917 . . . . 0.0 108.782 176.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.7 pt-20 -78.53 -47.35 17.48 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 124.403 1.081 . . . . 0.0 108.706 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -74.16 -13.04 60.75 Favored 'General case' 0 C--N 1.344 0.361 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 170.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.95 -53.51 9.35 Favored Glycine 0 C--N 1.342 0.861 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 171.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.7 t90 -67.26 -62.65 1.32 Allowed 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 123.381 0.673 . . . . 0.0 109.275 178.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -90.76 23.35 3.14 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.431 0.634 . . . . 0.0 111.511 -165.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.13 -27.04 26.9 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.551 1.072 . . . . 0.0 111.339 171.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.4 ptm -159.21 -10.71 0.06 Allowed 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 -178.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.6 mt . . . . . 0 N--CA 1.467 0.388 0 CA-C-N 119.765 1.166 . . . . 0.0 111.647 -159.92 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.8 mm? . . . . . 0 CA--C 1.537 0.456 0 CA-C-O 121.496 0.665 . . . . 0.0 111.01 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.32 -19.96 65.79 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 121.129 -0.982 . . . . 0.0 112.154 178.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -23.14 54.96 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 125.109 1.338 . . . . 0.0 112.906 167.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.37 -47.83 6.7 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.869 1.334 . . . . 0.0 110.693 167.141 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.8 mm -64.24 -24.47 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.92 -44.79 0.58 Allowed 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 125.908 1.683 . . . . 0.0 111.092 175.177 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.8 -37.63 70.13 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-N 119.035 0.834 . . . . 0.0 113.315 -169.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -67.32 -32.1 72.83 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 124.22 1.008 . . . . 0.0 111.832 176.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mt -74.52 -29.06 23.13 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 C-N-CA 124.041 0.937 . . . . 0.0 109.351 175.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -81.58 -57.72 3.34 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 125.492 1.517 . . . . 0.0 108.366 -174.508 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.4 p30 -65.78 -18.42 65.32 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.561 0.619 . . . . 0.0 111.655 170.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.75 -2.57 76.77 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.369 -0.684 . . . . 0.0 113.114 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.442 ' C ' ' H ' ' A' ' 16' ' ' GLY . 13.4 t90 -128.26 -68.37 0.77 Allowed 'General case' 0 C--O 1.234 0.239 0 C-N-CA 125.534 1.534 . . . . 0.0 109.127 -178.595 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -77.36 23.71 0.2 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.595 1.558 . . . . 0.0 112.359 -176.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.442 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -118.58 -1.73 15.27 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 126.977 2.227 . . . . 0.0 112.112 167.618 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 78.9 mtm -134.93 -9.43 2.34 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 119.035 1.417 . . . . 0.0 114.142 -178.034 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.3 mm . . . . . 0 CA--C 1.537 0.459 0 CA-C-N 119.209 0.913 . . . . 0.0 110.402 170.151 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? . . . . . 0 CA--C 1.538 0.516 0 CA-C-O 121.895 0.855 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -62.55 -23.66 67.11 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -173.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.98 -29.84 59.66 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.217 0.913 . . . . 0.0 112.501 173.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.82 -35.07 22.55 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.877 1.339 . . . . 0.0 111.259 172.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.2 mm -62.91 -33.63 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 123.69 0.796 . . . . 0.0 111.908 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.41 -61.69 1.87 Allowed 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 127.307 2.243 . . . . 0.0 109.484 165.098 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.75 -32.99 66.51 Favored Glycine 0 C--N 1.341 0.83 0 C-N-CA 123.811 0.72 . . . . 0.0 114.003 -164.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -69.02 -31.05 69.58 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.254 1.027 . . . . 0.0 112.029 178.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.9 mt -73.2 -35.19 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 123.945 0.898 . . . . 0.0 109.26 174.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -78.89 -55.55 5.07 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 125.128 1.371 . . . . 0.0 108.226 -170.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.33 -20.96 66.63 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 122.803 0.441 . . . . 0.0 110.122 171.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.18 -57.23 8.74 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.2 t90 -62.29 -60.92 2.88 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.609 1.164 . . . . 0.0 109.046 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -85.61 23.71 1.34 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.384 0.673 . . . . 0.0 111.962 -169.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -122.76 -14.94 4.09 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 126.54 2.019 . . . . 0.0 112.098 165.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 26.4 mmt -112.0 -12.0 13.78 Favored 'General case' 0 C--N 1.343 0.316 0 CA-C-N 118.732 1.266 . . . . 0.0 112.246 178.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.1 mm . . . . . 0 CA--C 1.534 0.346 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 158.814 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? . . . . . 0 C--O 1.24 0.569 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -68.27 -19.36 64.71 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -174.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.59 -25.04 57.8 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 124.236 0.922 . . . . 0.0 112.939 176.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.51 -36.84 52.16 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.631 1.215 . . . . 0.0 110.909 172.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.3 mm -65.97 -51.39 61.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-O 122.339 1.066 . . . . 0.0 109.815 179.693 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.34 -52.88 60.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 112.35 -2.204 . . . . 0.0 109.495 169.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.84 -33.25 56.04 Favored Glycine 0 CA--C 1.53 0.976 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.949 -178.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -72.05 -28.11 63.13 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 118.464 1.132 . . . . 0.0 112.465 176.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -74.52 -37.17 43.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-N 119.484 1.038 . . . . 0.0 109.433 170.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -74.22 -56.07 5.32 Favored 'General case' 0 C--N 1.334 -0.105 0 C-N-CA 125.135 1.374 . . . . 0.0 108.646 -172.024 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.59 -7.52 33.52 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.103 0.561 . . . . 0.0 110.729 168.147 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.73 -54.35 7.44 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 168.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.09 -56.33 23.47 Favored 'General case' 0 C--O 1.233 0.19 0 C-N-CA 125.409 1.484 . . . . 0.0 108.221 173.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -81.9 23.33 0.7 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.212 -0.93 . . . . 0.0 112.13 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.25 -21.84 69.36 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 166.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.5 ttt -145.45 -36.15 0.29 Allowed 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.3 mm . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 120.968 0.413 . . . . 0.0 110.336 -159.095 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.2 mm? . . . . . 0 CA--C 1.541 0.626 0 CA-C-O 120.851 0.358 . . . . 0.0 110.303 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -114.52 -12.9 12.23 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -176.505 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.26 -34.72 81.43 Favored Glycine 0 CA--C 1.529 0.967 0 C-N-CA 123.533 0.587 . . . . 0.0 112.922 -174.381 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.25 -30.29 34.15 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.96 0.904 . . . . 0.0 111.659 174.573 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.1 mm -67.71 -39.34 81.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 C-N-CA 123.901 0.881 . . . . 0.0 110.793 -178.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.97 -56.76 7.8 Favored 'General case' 0 C--N 1.319 -0.761 0 C-N-CA 127.233 2.213 . . . . 0.0 109.687 164.692 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.53 -33.01 65.58 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.703 -169.271 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -67.4 -27.63 67.24 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.395 1.097 . . . . 0.0 111.989 178.04 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.87 -36.0 62.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 O-C-N 121.527 -0.733 . . . . 0.0 109.179 171.559 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.24 -58.9 2.99 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.354 1.461 . . . . 0.0 108.128 -168.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -68.51 -12.76 61.69 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.87 -0.586 . . . . 0.0 112.069 171.988 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.66 -56.82 5.27 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 169.708 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.2 t90 -65.24 -61.34 2.19 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.513 1.125 . . . . 0.0 109.42 -178.415 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -86.69 23.7 1.62 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-O 121.363 0.601 . . . . 0.0 111.469 -172.412 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.38 -38.15 6.79 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.724 1.154 . . . . 0.0 111.21 173.135 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 91.1 mmm -143.33 -9.51 0.75 Allowed 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.804 1.409 . . . . 0.0 114.804 -173.352 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.1 mt . . . . . 0 N--CA 1.466 0.374 0 CA-C-N 119.691 1.132 . . . . 0.0 111.54 -161.558 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? . . . . . 0 C--O 1.235 0.291 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -61.61 -24.68 66.85 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 112.776 0.658 . . . . 0.0 112.776 -178.201 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.8 -26.72 60.77 Favored Glycine 0 CA--C 1.533 1.176 0 C-N-CA 124.179 0.895 . . . . 0.0 112.814 173.64 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.11 -34.75 37.63 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 118.95 1.375 . . . . 0.0 110.864 173.292 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.6 mm -63.14 -53.57 44.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-O 122.484 1.135 . . . . 0.0 109.694 177.227 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -51.17 -55.24 18.93 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 112.273 -2.24 . . . . 0.0 108.994 169.134 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.38 -33.97 33.05 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.09 0.853 . . . . 0.0 113.249 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -72.62 -39.91 66.88 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.439 1.12 . . . . 0.0 111.892 177.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 mt -65.65 -35.29 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 119.164 0.893 . . . . 0.0 109.955 171.55 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -79.57 -55.54 4.95 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 125.59 1.556 . . . . 0.0 108.781 -166.878 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -71.29 -13.28 61.84 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.759 169.591 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.51 -51.16 54.65 Favored Glycine 0 C--N 1.343 0.951 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 169.76 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.4 ' C ' ' H ' ' A' ' 16' ' ' GLY . 21.2 t90 -65.57 -62.05 1.74 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 124.038 0.935 . . . . 0.0 109.308 173.355 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.42 23.54 0.39 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.385 1.474 . . . . 0.0 112.929 -168.331 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -130.96 2.09 5.53 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 127.399 2.428 . . . . 0.0 111.922 171.022 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 56.9 mtt -137.47 0.76 2.31 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 118.947 1.373 . . . . 0.0 113.431 -175.465 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.0 mt . . . . . 0 N--CA 1.472 0.635 0 CA-C-N 119.65 1.114 . . . . 0.0 110.829 -177.187 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.3 mm? . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 121.954 0.883 . . . . 0.0 113.062 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -63.41 -22.83 67.12 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -174.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.4 -28.62 62.28 Favored Glycine 0 CA--C 1.532 1.121 0 C-N-CA 124.103 0.859 . . . . 0.0 112.518 173.757 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.56 -30.82 29.39 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 118.847 1.324 . . . . 0.0 111.465 173.653 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.0 mm -62.59 -51.63 69.82 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-O 122.219 1.009 . . . . 0.0 109.756 175.68 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.81 -53.9 49.24 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 127.299 2.239 . . . . 0.0 109.485 169.24 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.29 -35.4 42.96 Favored Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.024 0.821 . . . . 0.0 113.059 -179.838 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 90.8 t80 -74.9 -22.65 58.5 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.011 0.906 . . . . 0.0 112.725 178.611 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -76.06 -41.23 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-N 119.577 1.08 . . . . 0.0 109.175 165.647 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -72.66 -55.15 7.26 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 125.042 1.337 . . . . 0.0 109.37 -167.597 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -80.54 -2.98 48.45 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 118.217 0.462 . . . . 0.0 111.258 167.901 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.43 -54.86 31.07 Favored Glycine 0 C--N 1.34 0.764 0 N-CA-C 109.035 -1.626 . . . . 0.0 109.035 162.846 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.1 t90 -64.1 -64.99 0.74 Allowed 'General case' 0 C--O 1.237 0.429 0 C-N-CA 123.776 0.83 . . . . 0.0 108.847 171.617 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -89.68 60.77 5.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 122.689 1.233 . . . . 0.0 108.937 -170.44 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.78 -32.05 0.02 OUTLIER Glycine 0 CA--C 1.524 0.642 0 CA-C-N 114.156 -1.383 . . . . 0.0 112.259 170.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 85.2 mmm -96.11 -12.36 24.9 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 118.282 1.041 . . . . 0.0 112.227 171.471 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.7 mt . . . . . 0 CA--C 1.53 0.191 0 C-N-CA 125.435 1.494 . . . . 0.0 108.642 -169.748 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 5.3 mp . . . . . 0 CA--C 1.539 0.549 0 CA-C-O 121.202 0.525 . . . . 0.0 111.617 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -60.54 -20.23 59.7 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.287 -0.883 . . . . 0.0 111.855 171.157 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.71 -29.46 61.4 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.407 1.003 . . . . 0.0 112.495 170.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.81 -33.7 34.55 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.978 1.389 . . . . 0.0 111.429 172.757 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.8 mm -60.05 -53.87 42.62 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-O 122.277 1.037 . . . . 0.0 109.695 174.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.67 -51.99 61.41 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 127.753 2.421 . . . . 0.0 109.767 170.841 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.7 -36.69 49.57 Favored Glycine 0 CA--C 1.534 1.259 0 CA-C-N 118.422 0.555 . . . . 0.0 113.133 177.136 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -77.54 -14.99 59.53 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.739 0.816 . . . . 0.0 113.093 177.9 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mt -82.93 -38.96 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 119.904 1.229 . . . . 0.0 109.496 164.088 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -65.21 -64.15 0.93 Allowed 'General case' 0 CA--C 1.521 -0.152 0 C-N-CA 125.908 1.683 . . . . 0.0 108.204 -173.879 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -79.69 2.51 22.42 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 118.148 0.431 . . . . 0.0 111.461 169.189 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.96 -57.02 12.98 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 162.461 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.6 t90 -68.99 -56.58 7.36 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 171.255 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -78.48 41.84 0.41 Allowed 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.059 0.944 . . . . 0.0 110.878 -177.548 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.67 41.87 2.99 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.548 2.023 . . . . 0.0 109.034 162.49 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.4 tmm? 57.46 29.05 16.4 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.568 1.947 . . . . 0.0 113.133 -174.858 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 70.0 mt . . . . . 0 N--CA 1.467 0.389 0 O-C-N 121.459 -0.775 . . . . 0.0 109.242 169.768 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.1 mt . . . . . 0 N--CA 1.468 0.432 0 CA-C-O 121.364 0.602 . . . . 0.0 112.167 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -66.06 -19.62 65.91 Favored 'General case' 0 CA--C 1.537 0.456 0 O-C-N 121.023 -1.048 . . . . 0.0 112.435 179.473 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.34 -21.54 54.1 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 124.742 1.163 . . . . 0.0 112.852 167.136 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.49 -53.02 4.38 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.904 1.352 . . . . 0.0 110.307 164.719 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.1 mm -62.95 -20.8 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -166.427 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -133.6 -47.51 0.82 Allowed 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 125.932 1.693 . . . . 0.0 110.635 170.488 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.87 -31.84 65.21 Favored Glycine 0 CA--C 1.531 1.064 0 CA-C-O 119.333 -0.704 . . . . 0.0 113.935 -168.301 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 t80 -70.48 -33.08 70.84 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.278 1.039 . . . . 0.0 111.567 175.808 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.89 -21.54 22.49 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 124.605 1.162 . . . . 0.0 109.795 177.6 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -92.84 -63.32 1.24 Allowed 'General case' 0 C--O 1.231 0.094 0 C-N-CA 125.255 1.422 . . . . 0.0 107.22 -174.551 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -65.62 -27.81 68.67 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.837 0.855 . . . . 0.0 111.058 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.6 -18.21 66.6 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.904 -0.942 . . . . 0.0 112.311 177.042 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.2 t90 -80.77 -67.49 0.77 Allowed 'General case' 0 C--O 1.237 0.403 0 CA-C-N 118.481 1.141 . . . . 0.0 108.229 168.605 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -84.57 23.36 1.15 Allowed 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 121.374 0.607 . . . . 0.0 112.599 -162.828 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.88 -32.45 12.8 Favored Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.477 1.037 . . . . 0.0 111.614 175.096 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.7 mmt -151.14 -33.63 0.15 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -176.019 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 45.8 mt . . . . . 0 N--CA 1.466 0.373 0 C-N-CA 124.3 1.04 . . . . 0.0 112.189 -158.68 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -67.29 165.78 15.63 Favored 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 138.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -106.19 -10.74 16.32 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.94 -48.04 58.55 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.846 0.736 . . . . 0.0 112.621 -171.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -19.85 58.76 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.353 1.461 . . . . 0.0 112.76 178.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.8 mm -74.67 -8.57 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 C-N-CA 124.41 1.084 . . . . 0.0 110.884 177.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.09 -44.33 4.19 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 127.154 2.182 . . . . 0.0 109.694 160.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.03 -39.22 89.27 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 119.029 0.831 . . . . 0.0 113.264 -173.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -69.62 -26.62 64.52 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 118.164 0.982 . . . . 0.0 112.038 176.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mm -75.76 -35.54 31.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 C-N-CA 123.686 0.795 . . . . 0.0 108.901 178.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -78.79 -49.2 13.4 Favored 'General case' 0 CA--C 1.519 -0.231 0 C-N-CA 125.815 1.646 . . . . 0.0 108.158 -174.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -63.65 -14.69 54.25 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.788 0.435 . . . . 0.0 111.27 167.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.63 -55.51 4.55 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 172.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.411 ' C ' ' H ' ' A' ' 16' ' ' GLY . 11.2 t90 -62.54 -58.81 6.23 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 125.979 1.712 . . . . 0.0 109.711 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -80.39 23.59 0.49 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.009 0.924 . . . . 0.0 111.759 176.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.411 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -94.5 -19.76 31.48 Favored Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.799 1.19 . . . . 0.0 111.085 159.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 ptt? -162.81 60.62 0.2 Allowed 'General case' 0 C--N 1.346 0.429 0 CA-C-N 118.943 1.372 . . . . 0.0 112.007 -176.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt -70.88 -67.77 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 158.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -61.43 143.63 55.52 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 171.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.26 0 C-N-CA 125.476 1.513 . . . . 0.0 114.071 -175.488 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.477 0.895 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -65.53 154.75 37.76 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 118.391 0.541 . . . . 0.0 109.633 177.194 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -63.36 -20.65 65.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -175.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.19 -30.31 57.66 Favored Glycine 0 CA--C 1.532 1.113 0 CA-C-O 118.999 -0.889 . . . . 0.0 112.463 172.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.98 -32.24 25.09 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 119.118 1.459 . . . . 0.0 111.378 172.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.2 mm -65.87 -28.83 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 123.829 0.851 . . . . 0.0 111.934 178.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -81.55 -53.65 6.09 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 127.675 2.39 . . . . 0.0 110.139 165.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.82 -41.84 36.5 Favored Glycine 0 C--N 1.342 0.881 0 C-N-CA 125.668 1.604 . . . . 0.0 112.928 -173.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -75.53 -16.85 60.23 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.6 mt -81.4 -45.71 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.696 0.799 . . . . 0.0 108.896 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -82.46 -38.48 23.88 Favored 'General case' 0 CA--C 1.527 0.07 0 CA-C-O 118.194 -0.908 . . . . 0.0 111.082 -167.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -87.02 1.73 51.91 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.309 0.959 . . . . 0.0 111.059 162.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.78 -45.87 56.1 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 159.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -63.4 -64.9 0.77 Allowed 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 167.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -81.5 57.45 3.3 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.537 1.535 . . . . 0.0 108.544 -173.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -136.77 -42.48 0.1 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 126.886 2.184 . . . . 0.0 110.443 176.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -145.67 -6.81 0.6 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 115.307 1.595 . . . . 0.0 115.307 -179.082 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.8 mt -66.82 -53.98 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 119.751 1.16 . . . . 0.0 111.562 -175.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -157.83 164.98 36.44 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 -172.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 1.495 0 C-N-CA 127.731 2.586 . . . . 0.0 112.448 170.195 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.2 m . . . . . 0 N--CA 1.476 0.837 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mp -136.35 144.09 44.43 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 174.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -66.59 -23.8 66.25 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 -170.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -27.24 61.23 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.112 0.863 . . . . 0.0 112.83 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.71 -44.44 20.79 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 118.779 1.29 . . . . 0.0 110.385 172.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.0 mt -60.22 -38.66 78.13 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 C-N-CA 125.671 1.588 . . . . 0.0 111.785 -176.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -74.03 -58.69 3.13 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 127.613 2.365 . . . . 0.0 109.881 168.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -32.82 59.94 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 123.978 0.799 . . . . 0.0 113.883 -166.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.1 t80 -67.64 -36.84 81.52 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.193 0.997 . . . . 0.0 111.772 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.2 mt -71.0 -33.65 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 C-N-CA 124.363 1.065 . . . . 0.0 109.597 177.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -80.3 -50.48 10.12 Favored 'General case' 0 C--N 1.333 -0.149 0 C-N-CA 125.312 1.445 . . . . 0.0 108.179 -170.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -66.05 -19.15 65.76 Favored 'General case' 0 C--N 1.342 0.274 0 CA-C-O 119.394 -0.336 . . . . 0.0 110.691 168.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.08 -50.79 16.25 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 173.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.7 t90 -64.26 -61.32 2.32 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 125.051 1.34 . . . . 0.0 109.167 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -88.94 23.38 2.39 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.786 0.803 . . . . 0.0 111.53 -169.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.07 -13.33 34.05 Favored Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.338 1.447 . . . . 0.0 111.488 171.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.9 ttm -146.67 -34.94 0.27 Allowed 'General case' 0 C--N 1.341 0.238 0 CA-C-N 118.253 1.026 . . . . 0.0 113.724 -177.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.6 mt -95.87 -85.29 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -162.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -75.82 144.51 41.26 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -175.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.559 0 CA-C-O 118.341 -1.255 . . . . 0.0 114.134 -165.256 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 19.1 m . . . . . 0 N--CA 1.476 0.849 0 CA-C-O 116.604 -1.665 . . . . 0.0 107.397 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.8 mp 63.95 170.61 0.17 Allowed 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 126.346 1.859 . . . . 0.0 111.431 -171.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -59.58 -26.46 65.44 Favored 'General case' 0 N--CA 1.463 0.193 0 O-C-N 121.678 -0.639 . . . . 0.0 111.934 -178.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.55 -26.18 66.22 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 125.285 1.422 . . . . 0.0 112.728 175.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.54 -62.63 1.45 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.37 1.085 . . . . 0.0 109.326 166.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 52.2 mt -61.07 -22.39 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 C-N-CA 126.345 1.858 . . . . 0.0 113.782 -160.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -132.42 -42.88 0.94 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 125.569 1.548 . . . . 0.0 111.028 172.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.94 -36.03 59.82 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 118.814 -0.992 . . . . 0.0 112.931 -175.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -77.35 -19.91 55.58 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 118.692 1.246 . . . . 0.0 112.583 176.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -82.29 -38.51 15.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.028 1.331 . . . . 0.0 108.755 174.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -73.18 -57.96 3.65 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 128.016 2.526 . . . . 0.0 107.593 -175.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -69.67 -7.76 41.84 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.045 0.538 . . . . 0.0 111.06 169.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.75 -59.42 4.07 Favored Glycine 0 C--N 1.34 0.777 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 169.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 18.8 t90 -60.27 -56.84 16.61 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 125.54 1.536 . . . . 0.0 109.739 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -85.03 23.65 1.2 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.632 0.773 . . . . 0.0 111.483 -177.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.94 9.82 11.26 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 127.886 2.66 . . . . 0.0 111.656 164.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.5 ptt? -129.93 -20.86 3.08 Favored 'General case' 0 C--N 1.344 0.367 0 CA-C-N 118.088 0.944 . . . . 0.0 113.491 164.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.0 mm -61.68 -29.4 46.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 123.617 0.767 . . . . 0.0 110.949 172.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -78.66 3.74 15.55 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 125.365 1.466 . . . . 0.0 113.12 174.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.043 0 C-N-CA 126.076 1.798 . . . . 0.0 113.783 -179.249 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 30.8 m . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 55.3 mt -131.13 165.01 24.23 Favored 'General case' 0 C--O 1.235 0.326 0 C-N-CA 125.704 1.601 . . . . 0.0 106.987 166.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -59.19 -26.06 64.49 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -174.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.12 -28.35 63.87 Favored Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.414 1.006 . . . . 0.0 112.778 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.26 -42.14 21.12 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 119.138 1.469 . . . . 0.0 110.516 171.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mt -59.22 -39.96 80.01 Favored 'Isoleucine or valine' 0 C--N 1.342 0.257 0 C-N-CA 124.823 1.249 . . . . 0.0 111.979 -176.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.55 -54.28 6.92 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 127.542 2.337 . . . . 0.0 110.116 169.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.58 -34.34 60.2 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 124.242 0.925 . . . . 0.0 113.642 -170.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -72.17 -23.17 61.24 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 118.407 1.103 . . . . 0.0 112.683 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -79.64 -38.84 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 124.323 1.049 . . . . 0.0 108.784 170.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.44 -55.36 7.15 Favored 'General case' 0 C--O 1.226 -0.17 0 C-N-CA 125.08 1.352 . . . . 0.0 109.052 -172.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -79.82 2.71 22.08 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.451 0.568 . . . . 0.0 111.595 167.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.79 -52.94 22.12 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 159.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -58.49 -63.37 1.3 Allowed 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.484 1.114 . . . . 0.0 108.592 169.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -80.66 56.91 2.78 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.154 2.182 . . . . 0.0 109.109 -176.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -173.29 -22.87 0.02 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.886 3.136 . . . . 0.0 110.794 178.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 33.5 mmt -93.39 -22.71 18.76 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 118.372 1.086 . . . . 0.0 112.569 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.2 mm -54.46 -42.6 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.557 1.143 . . . . 0.0 110.745 173.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -98.32 4.37 48.66 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 127.324 2.25 . . . . 0.0 112.614 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.799 0 C-N-CA 125.185 1.374 . . . . 0.0 110.761 176.137 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.475 0.819 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.6 mp -140.06 154.11 46.98 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 176.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 28.8 t80 -71.49 -12.59 61.46 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 176.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.79 -24.6 54.07 Favored Glycine 0 CA--C 1.533 1.188 0 C-N-CA 124.4 1.0 . . . . 0.0 113.523 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -78.31 -43.34 28.18 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.491 1.146 . . . . 0.0 110.83 171.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 18.6 mm -71.58 -9.33 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 126.07 1.748 . . . . 0.0 111.818 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.57 3.35 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 128.188 2.595 . . . . 0.0 109.484 168.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.66 -37.1 91.81 Favored Glycine 0 CA--C 1.529 0.92 0 CA-C-N 118.804 0.729 . . . . 0.0 112.8 -174.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 84.2 t80 -67.29 -25.63 66.13 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.638 0.719 . . . . 0.0 111.655 178.574 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 mm -66.47 -23.46 31.55 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-N 118.898 0.772 . . . . 0.0 109.9 177.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -104.82 -60.87 1.54 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 -172.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -64.25 -25.22 67.96 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 122.949 0.5 . . . . 0.0 112.304 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.85 0.77 86.04 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.078 174.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.458 ' C ' ' H ' ' A' ' 16' ' ' GLY . 8.4 t90 -127.44 -68.34 0.79 Allowed 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.78 1.632 . . . . 0.0 108.574 -176.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -74.16 23.79 0.08 Allowed 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.923 2.089 . . . . 0.0 112.394 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -98.24 -33.81 5.57 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 125.209 1.385 . . . . 0.0 111.367 162.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.1 mmm -153.65 64.76 0.73 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.825 1.313 . . . . 0.0 109.746 -173.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.7 mt -71.74 -54.59 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 166.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.8 t0 -80.24 155.56 27.28 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.808 0.813 . . . . 0.0 111.118 -174.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.271 0 C-N-CA 126.996 2.236 . . . . 0.0 112.11 169.899 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.477 0.919 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -113.14 153.42 28.29 Favored 'General case' 0 N--CA 1.462 0.148 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 171.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -77.39 -12.96 60.02 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 179.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.71 -42.0 58.31 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.369 0.985 . . . . 0.0 112.986 -170.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.74 -22.41 61.61 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.298 1.439 . . . . 0.0 112.719 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mm -74.35 -5.47 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 C-N-CA 124.645 1.178 . . . . 0.0 110.811 176.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.37 -42.11 3.98 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 126.608 1.963 . . . . 0.0 109.706 160.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.68 -39.51 91.28 Favored Glycine 0 C--N 1.342 0.909 0 CA-C-N 119.23 0.923 . . . . 0.0 112.87 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -75.62 -15.28 60.36 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 117.843 0.821 . . . . 0.0 112.69 177.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.8 mm -85.66 -37.76 12.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 124.699 1.2 . . . . 0.0 108.724 174.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -72.62 -55.75 6.38 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 126.568 1.947 . . . . 0.0 107.886 -177.05 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -69.29 -6.62 30.59 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.558 0.743 . . . . 0.0 111.247 168.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.97 -57.49 3.72 Favored Glycine 0 C--N 1.341 0.82 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 169.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -57.02 -57.01 14.43 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 126.536 1.934 . . . . 0.0 109.283 175.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -83.27 24.38 0.81 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 123.944 0.897 . . . . 0.0 111.612 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -121.47 6.87 10.58 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 127.324 2.392 . . . . 0.0 111.331 164.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.8 mmt -126.58 -36.11 2.29 Favored 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.215 1.406 . . . . 0.0 111.767 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm -61.6 -35.48 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 C-N-CA 124.887 1.275 . . . . 0.0 110.704 175.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -91.51 4.15 53.27 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 126.443 1.897 . . . . 0.0 112.353 177.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.922 0 C-N-CA 126.174 1.845 . . . . 0.0 115.185 -159.191 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 48.7 t . . . . . 0 N--CA 1.476 0.839 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.7 mp -139.06 154.06 48.14 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 172.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -77.9 -12.01 59.94 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 177.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.91 -28.96 61.35 Favored Glycine 0 CA--C 1.531 1.045 0 C-N-CA 124.033 0.825 . . . . 0.0 113.583 -174.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.8 -33.52 27.23 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 118.572 1.186 . . . . 0.0 111.512 173.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.0 mm -73.66 -10.26 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 126.052 1.741 . . . . 0.0 111.609 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.81 -48.82 3.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 127.321 2.248 . . . . 0.0 109.632 164.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.38 -36.05 82.01 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 119.034 0.833 . . . . 0.0 113.33 -172.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -66.79 -31.2 71.67 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.439 1.12 . . . . 0.0 111.618 175.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mm -73.99 -18.14 17.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 124.484 1.114 . . . . 0.0 109.977 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -97.7 -61.21 1.42 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 125.324 1.45 . . . . 0.0 107.337 -174.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -61.65 -30.99 71.08 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.527 0.731 . . . . 0.0 111.761 176.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.43 0.61 63.71 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.122 -0.821 . . . . 0.0 113.433 177.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.44 ' C ' ' H ' ' A' ' 16' ' ' GLY . 17.9 t90 -130.39 -69.65 0.65 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.943 1.297 . . . . 0.0 108.568 -174.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -78.51 23.43 0.31 Allowed 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.294 1.038 . . . . 0.0 112.043 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -118.02 -2.71 16.08 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 127.416 2.436 . . . . 0.0 112.106 166.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 61.0 mtt -134.09 -10.05 2.62 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.977 1.389 . . . . 0.0 113.382 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.2 mm -68.87 -27.07 34.25 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 C-N-CA 124.114 0.966 . . . . 0.0 111.957 177.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -70.14 109.3 4.54 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.972 0.805 . . . . 0.0 110.122 176.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.902 0 C-N-CA 125.447 1.499 . . . . 0.0 111.144 169.249 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 19.3 m . . . . . 0 N--CA 1.476 0.863 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.4 mt -139.07 160.15 40.47 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 125.442 1.497 . . . . 0.0 107.706 174.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -103.0 -9.47 19.77 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.624 0.601 . . . . 0.0 112.624 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.3 -30.73 64.89 Favored Glycine 0 CA--C 1.532 1.108 0 O-C-N 121.399 -0.813 . . . . 0.0 113.945 -170.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.75 30.08 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.855 1.262 . . . . 0.0 111.658 175.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.4 mm -75.46 -5.62 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.814 1.646 . . . . 0.0 111.099 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -110.02 -46.21 3.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.28 1.832 . . . . 0.0 109.922 160.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.37 -36.39 83.58 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 119.23 0.923 . . . . 0.0 113.274 -172.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -74.37 -20.08 60.21 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.755 0.778 . . . . 0.0 112.482 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -81.67 -34.5 12.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 124.288 1.035 . . . . 0.0 109.001 174.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -73.98 -56.09 5.36 Favored 'General case' 0 N--CA 1.457 -0.125 0 C-N-CA 125.813 1.645 . . . . 0.0 107.644 -176.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -63.13 -21.27 66.08 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 122.857 0.463 . . . . 0.0 111.0 168.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.73 -9.9 86.66 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-O 119.338 -0.701 . . . . 0.0 112.948 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -114.03 -58.1 2.19 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.916 1.286 . . . . 0.0 109.499 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.8 23.89 0.16 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.928 1.291 . . . . 0.0 112.691 -174.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.37 49.95 3.08 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.146 1.832 . . . . 0.0 111.87 178.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.4 mtm 58.53 73.93 0.46 Allowed 'General case' 0 C--N 1.341 0.214 0 C-N-CA 127.192 2.197 . . . . 0.0 110.468 -175.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 90.6 mt -52.53 -27.81 11.67 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.723 0 C-N-CA 126.892 2.077 . . . . 0.0 112.532 -179.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.8 t70 63.69 -168.45 0.2 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.613 1.565 . . . . 0.0 110.119 -166.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.172 0 C-N-CA 125.303 1.43 . . . . 0.0 113.679 178.975 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.9 m . . . . . 0 N--CA 1.477 0.904 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -127.57 154.52 45.1 Favored 'General case' 0 C--O 1.231 0.128 0 N-CA-C 106.63 -1.618 . . . . 0.0 106.63 169.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -88.62 -9.15 53.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 122.878 0.471 . . . . 0.0 112.134 177.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.61 -32.34 61.29 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 123.976 0.798 . . . . 0.0 114.09 -168.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.19 -28.34 27.4 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.434 1.093 . . . . 0.0 111.952 175.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.2 mm -74.88 -10.92 14.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 125.681 1.592 . . . . 0.0 111.244 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.66 -49.16 3.48 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 126.896 2.078 . . . . 0.0 109.55 162.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.0 -35.88 78.45 Favored Glycine 0 C--N 1.342 0.875 0 CA-C-N 118.988 0.813 . . . . 0.0 113.286 -170.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -70.78 -28.04 64.37 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.338 1.069 . . . . 0.0 112.038 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mm -72.49 -25.28 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 119.066 0.848 . . . . 0.0 109.487 176.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -92.71 -65.6 0.99 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.639 1.575 . . . . 0.0 107.029 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.13 -24.56 67.45 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.623 0.769 . . . . 0.0 110.764 179.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -77.38 -3.29 82.16 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 118.855 -0.97 . . . . 0.0 113.198 176.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.7 t90 -130.78 -74.66 0.53 Allowed 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 118.509 1.155 . . . . 0.0 108.984 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -79.75 23.71 0.42 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.679 1.192 . . . . 0.0 112.404 -172.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.27 -16.43 57.39 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 118.186 -1.341 . . . . 0.0 112.319 170.303 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 45.6 mmm -141.07 9.57 2.12 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 118.612 1.206 . . . . 0.0 113.037 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 5.3 mm -65.89 -28.98 45.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 O-C-N 120.898 -1.126 . . . . 0.0 112.217 -177.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 49.55 14.75 0.12 Allowed 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 129.049 2.94 . . . . 0.0 116.703 162.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.089 0 C-N-CA 125.35 1.452 . . . . 0.0 115.172 -170.153 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.6 m . . . . . 0 N--CA 1.478 0.939 0 CA-C-O 118.489 -0.767 . . . . 0.0 109.391 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.0 mm? 61.37 167.56 0.1 Allowed 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 127.222 2.209 . . . . 0.0 112.037 -170.155 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -60.17 -26.65 66.49 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.661 0.615 . . . . 0.0 112.661 -170.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -63.56 -24.13 67.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.859 1.218 . . . . 0.0 112.732 177.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.03 -61.8 1.51 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 118.126 0.963 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 56.9 mt -60.15 -21.95 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 126.398 1.879 . . . . 0.0 113.589 -161.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -131.26 -43.59 1.04 Allowed 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 125.953 1.701 . . . . 0.0 110.84 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.27 -34.35 59.02 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-N 119.067 0.849 . . . . 0.0 113.342 -177.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.0 t80 -75.62 -23.59 56.41 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.624 1.212 . . . . 0.0 112.231 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mm -80.11 -35.12 15.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 125.19 1.396 . . . . 0.0 109.144 175.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -73.69 -59.13 2.86 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 128.026 2.53 . . . . 0.0 106.833 -176.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -62.46 -19.13 63.21 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 119.224 -0.417 . . . . 0.0 111.291 170.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.13 -54.24 9.44 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 175.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -62.37 -57.2 12.19 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.53 1.532 . . . . 0.0 109.713 176.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 -80.22 23.41 0.48 Allowed 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.543 1.537 . . . . 0.0 112.857 -166.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.63 -5.66 10.97 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.753 2.121 . . . . 0.0 112.193 166.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 95.7 mmm -127.31 -2.91 6.26 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.714 1.257 . . . . 0.0 113.102 -174.127 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.0 mt -52.77 -47.74 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 C-N-CA 124.219 1.008 . . . . 0.0 110.579 -178.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -117.71 89.26 3.08 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 126.384 1.874 . . . . 0.0 106.124 174.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 0.381 0 N-CA-C 107.116 -2.394 . . . . 0.0 107.116 -173.011 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 N--CA 1.476 0.864 0 CA-C-O 118.675 -0.679 . . . . 0.0 109.295 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? 59.31 -179.02 0.08 Allowed 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 126.145 1.778 . . . . 0.0 112.52 179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.3 t80 -58.86 -25.76 63.59 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 123.679 0.792 . . . . 0.0 112.399 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.49 -15.06 51.99 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 125.323 1.439 . . . . 0.0 113.447 172.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -106.31 -55.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.527 1.163 . . . . 0.0 109.867 164.491 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 30.7 mt -61.95 -18.58 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 124.645 1.178 . . . . 0.0 113.677 -167.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -125.02 -43.47 1.97 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 125.697 1.599 . . . . 0.0 110.766 166.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.58 -34.89 78.08 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 119.417 1.008 . . . . 0.0 113.252 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.9 t80 -79.06 -10.69 59.9 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.622 1.211 . . . . 0.0 112.494 175.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.5 mm -87.66 -39.86 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 C-N-CA 124.798 1.239 . . . . 0.0 108.218 169.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -70.5 -59.96 2.54 Favored 'General case' 0 N--CA 1.457 -0.102 0 C-N-CA 126.6 1.96 . . . . 0.0 109.035 -176.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -74.01 -3.01 26.65 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.876 -0.515 . . . . 0.0 111.648 166.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.44 -10.26 74.82 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.495 0.589 . . . . 0.0 112.348 161.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -116.6 -64.22 1.34 Allowed 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 107.226 177.487 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -80.84 59.3 3.66 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-O 122.4 1.095 . . . . 0.0 109.49 172.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -145.25 13.66 1.86 Allowed Glycine 0 CA--C 1.534 1.225 0 C-N-CA 125.918 1.723 . . . . 0.0 111.765 161.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 25.6 ptt? -170.43 -18.84 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 128.386 2.675 . . . . 0.0 114.111 175.261 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 51.9 mt -100.78 -22.84 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 124.568 1.147 . . . . 0.0 110.338 -176.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -49.86 114.1 1.0 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 127.806 2.442 . . . . 0.0 109.598 164.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.721 0 N-CA-C 107.099 -2.4 . . . . 0.0 107.099 -162.714 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 61.1 t . . . . . 0 N--CA 1.476 0.855 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mp -140.3 157.52 45.44 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 174.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -62.79 -22.79 66.86 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.676 0.79 . . . . 0.0 112.003 172.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.47 -21.47 57.46 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 125.241 1.401 . . . . 0.0 112.895 171.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -85.65 -65.04 1.05 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 118.762 1.281 . . . . 0.0 108.766 163.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 29.1 mt -60.98 -24.5 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 125.509 1.523 . . . . 0.0 113.987 -161.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.44 -47.25 1.87 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 125.83 1.652 . . . . 0.0 110.542 172.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.56 -32.76 65.34 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.935 -0.925 . . . . 0.0 113.631 -172.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -76.37 -23.93 54.15 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 119.136 1.468 . . . . 0.0 112.108 175.073 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mm -71.08 -31.37 44.6 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 O-C-N 120.987 -1.07 . . . . 0.0 108.814 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -101.99 -49.8 3.84 Favored 'General case' 0 C--O 1.225 -0.188 0 C-N-CA 123.805 0.842 . . . . 0.0 110.386 -171.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 25.5 m-80 -86.45 -19.77 29.13 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.4 0.546 . . . . 0.0 111.234 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -96.45 -62.71 0.94 Allowed Glycine 0 C--N 1.34 0.79 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -175.647 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 23.5 t90 -80.23 -68.55 0.67 Allowed 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -79.54 23.45 0.41 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -167.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.69 -6.5 11.43 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 126.828 2.156 . . . . 0.0 112.729 170.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 59.1 mmm -130.19 20.59 5.32 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 118.964 1.382 . . . . 0.0 112.087 -172.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.5 mm -68.94 -27.38 35.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 C-N-CA 123.711 0.805 . . . . 0.0 111.216 -177.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 50.14 4.03 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 131.103 3.761 . . . . 0.0 117.846 169.045 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.009 0 C-N-CA 128.953 3.168 . . . . 0.0 112.695 178.17 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.478 0.935 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -122.96 158.93 29.38 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 170.326 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -61.49 -22.42 65.08 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.6 -26.22 56.78 Favored Glycine 0 CA--C 1.532 1.1 0 CA-C-O 118.926 -0.93 . . . . 0.0 112.903 172.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.74 -43.74 15.17 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 119.222 1.511 . . . . 0.0 110.356 171.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -64.1 -13.21 13.32 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 C-N-CA 126.653 1.981 . . . . 0.0 112.629 -177.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.39 -48.92 2.99 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 127.59 2.356 . . . . 0.0 110.204 170.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.29 -36.1 81.54 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-N 119.412 1.006 . . . . 0.0 113.082 -174.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -73.7 -18.8 60.96 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 118.031 0.916 . . . . 0.0 112.515 176.018 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -80.98 -39.02 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 CA-C-N 119.431 1.014 . . . . 0.0 108.299 172.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -69.81 -62.41 1.39 Allowed 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 126.598 1.959 . . . . 0.0 107.951 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -64.58 -16.97 63.51 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 119.415 -0.326 . . . . 0.0 111.165 169.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.89 -16.32 66.0 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.747 -1.03 . . . . 0.0 113.37 173.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -127.49 -44.96 1.51 Allowed 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.571 1.185 . . . . 0.0 111.807 174.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -81.13 23.64 0.57 Allowed 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 122.256 1.027 . . . . 0.0 112.164 -162.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.66 -10.94 42.39 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 125.603 1.573 . . . . 0.0 112.227 163.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.5 mmm -111.64 -9.85 14.13 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.851 1.325 . . . . 0.0 113.521 -169.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -85.51 -24.38 6.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 C-N-CA 124.055 0.942 . . . . 0.0 112.313 -171.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -70.96 151.02 45.11 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-O 122.151 0.977 . . . . 0.0 110.935 -178.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.051 0 C-N-CA 125.48 1.514 . . . . 0.0 111.8 166.065 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.4 m . . . . . 0 N--CA 1.477 0.899 0 CA-C-O 118.424 -0.798 . . . . 0.0 108.868 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 64.24 154.65 0.06 Allowed 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 127.342 2.257 . . . . 0.0 110.728 -161.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -84.43 -11.79 55.57 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -178.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.18 -32.57 63.48 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 123.817 0.722 . . . . 0.0 113.167 -174.393 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.07 -33.24 26.45 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.53 1.132 . . . . 0.0 111.629 174.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.1 mm -73.9 -9.1 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 125.644 1.578 . . . . 0.0 111.665 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.39 -50.45 3.22 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 127.479 2.312 . . . . 0.0 109.588 163.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.46 77.98 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 118.994 0.815 . . . . 0.0 113.281 -171.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -69.86 -28.11 65.39 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.198 0.999 . . . . 0.0 112.117 176.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mm -72.47 -25.67 23.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 CA-C-N 118.931 0.787 . . . . 0.0 109.429 176.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -92.91 -63.57 1.2 Allowed 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.225 1.41 . . . . 0.0 107.57 -170.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -68.39 -22.53 64.63 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.156 0.583 . . . . 0.0 110.872 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.94 -6.96 80.52 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.349 -0.695 . . . . 0.0 112.758 174.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.9 t90 -114.1 -76.05 0.59 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.228 1.411 . . . . 0.0 107.436 171.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.67 56.09 3.71 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 122.207 1.003 . . . . 0.0 110.971 -171.776 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.98 -7.97 37.37 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-O 118.659 -1.078 . . . . 0.0 111.73 159.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.0 mmt -148.97 3.05 0.6 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.054 1.341 . . . . 0.0 113.287 -169.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.7 mm -88.94 -46.87 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 120.163 1.347 . . . . 0.0 108.779 -170.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.2 t70 50.41 -143.85 0.56 Allowed 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 124.524 1.13 . . . . 0.0 109.854 -168.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.163 0 C-N-CA 126.034 1.778 . . . . 0.0 112.184 -169.309 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.7 p . . . . . 0 N--CA 1.477 0.892 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.9 mt -136.13 162.92 31.59 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 125.006 1.323 . . . . 0.0 108.231 176.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -65.92 -16.09 63.55 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 176.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.59 -23.5 58.47 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.701 1.143 . . . . 0.0 112.665 167.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.53 -58.31 2.79 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 118.891 1.346 . . . . 0.0 109.152 164.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.8 mm -64.3 -21.49 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -162.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -134.42 -44.75 0.76 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.941 1.696 . . . . 0.0 110.972 172.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.34 -42.57 74.61 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.992 0.815 . . . . 0.0 112.878 -173.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -77.62 -15.9 58.91 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 112.466 177.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.1 mm -71.1 -38.0 69.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 O-C-N 120.453 -1.404 . . . . 0.0 107.867 171.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -94.17 -55.71 3.1 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -167.325 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.0 m-80 -76.62 -20.06 57.14 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.141 0.576 . . . . 0.0 110.71 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.54 -63.88 0.79 Allowed Glycine 0 C--N 1.341 0.86 0 CA-C-O 118.387 -1.229 . . . . 0.0 111.45 -171.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.427 ' C ' ' H ' ' A' ' 16' ' ' GLY . 7.6 t90 -69.42 -64.06 0.95 Allowed 'General case' 0 C--N 1.341 0.22 0 CA-C-N 118.636 1.218 . . . . 0.0 108.336 175.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -80.34 23.14 0.51 Allowed 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.561 0.696 . . . . 0.0 112.522 -174.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -99.3 -58.41 0.91 Allowed Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.816 2.151 . . . . 0.0 108.739 162.321 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.7 ptm -65.06 -18.05 64.97 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 118.38 1.09 . . . . 0.0 113.555 -179.375 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.6 mm -57.55 -31.37 38.99 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 123.735 0.814 . . . . 0.0 110.633 169.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.7 t0 -79.47 63.27 4.02 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 119.365 0.984 . . . . 0.0 110.332 175.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.105 0 CA-C-O 118.715 -1.047 . . . . 0.0 114.225 170.769 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 22.1 m . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 117.67 -1.157 . . . . 0.0 108.097 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -64.29 154.71 34.38 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 119.529 1.058 . . . . 0.0 110.233 -177.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -62.34 -21.0 64.95 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -173.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.42 -28.73 55.98 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 119.04 -0.867 . . . . 0.0 112.673 173.255 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.31 -41.96 19.41 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 119.127 1.464 . . . . 0.0 110.654 172.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.6 mt -65.82 -10.57 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.486 1.914 . . . . 0.0 112.465 -177.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -114.04 -45.02 3.09 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 127.01 2.124 . . . . 0.0 110.824 168.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.93 -38.79 76.29 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.682 0.674 . . . . 0.0 112.837 -176.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -78.21 -11.46 59.93 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 117.789 0.794 . . . . 0.0 112.632 178.452 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 9.7 mm -86.7 -42.37 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-N 119.218 0.917 . . . . 0.0 108.782 176.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.7 pt-20 -78.53 -47.35 17.48 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 124.403 1.081 . . . . 0.0 108.706 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -74.16 -13.04 60.75 Favored 'General case' 0 C--N 1.344 0.361 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 170.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.95 -53.51 9.35 Favored Glycine 0 C--N 1.342 0.861 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 171.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.7 t90 -67.26 -62.65 1.32 Allowed 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 123.381 0.673 . . . . 0.0 109.275 178.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -90.76 23.35 3.14 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.431 0.634 . . . . 0.0 111.511 -165.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.13 -27.04 26.9 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.551 1.072 . . . . 0.0 111.339 171.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.4 ptm -159.21 -10.71 0.06 Allowed 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 -178.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.6 mt -92.21 -44.3 14.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 119.765 1.166 . . . . 0.0 111.647 -159.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -72.29 148.89 44.98 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.453 0.57 . . . . 0.0 111.316 -174.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.914 0 C-N-CA 124.966 1.269 . . . . 0.0 113.17 -176.471 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . 0.284 12.5 p . . . . . 0 N--CA 1.475 0.818 0 CA-C-O 116.348 -1.786 . . . . 0.0 107.577 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.8 mm? 62.03 174.26 0.13 Allowed 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 126.885 2.074 . . . . 0.0 111.01 -170.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.32 -19.96 65.79 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 121.129 -0.982 . . . . 0.0 112.154 178.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -23.14 54.96 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 125.109 1.338 . . . . 0.0 112.906 167.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.37 -47.83 6.7 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.869 1.334 . . . . 0.0 110.693 167.141 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.8 mm -64.24 -24.47 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.92 -44.79 0.58 Allowed 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 125.908 1.683 . . . . 0.0 111.092 175.177 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.8 -37.63 70.13 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-N 119.035 0.834 . . . . 0.0 113.315 -169.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -67.32 -32.1 72.83 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 124.22 1.008 . . . . 0.0 111.832 176.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mt -74.52 -29.06 23.13 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 C-N-CA 124.041 0.937 . . . . 0.0 109.351 175.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -81.58 -57.72 3.34 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 125.492 1.517 . . . . 0.0 108.366 -174.508 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.4 p30 -65.78 -18.42 65.32 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.561 0.619 . . . . 0.0 111.655 170.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.75 -2.57 76.77 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.369 -0.684 . . . . 0.0 113.114 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.442 ' C ' ' H ' ' A' ' 16' ' ' GLY . 13.4 t90 -128.26 -68.37 0.77 Allowed 'General case' 0 C--O 1.234 0.239 0 C-N-CA 125.534 1.534 . . . . 0.0 109.127 -178.595 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -77.36 23.71 0.2 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.595 1.558 . . . . 0.0 112.359 -176.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.442 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -118.58 -1.73 15.27 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 126.977 2.227 . . . . 0.0 112.112 167.618 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 78.9 mtm -134.93 -9.43 2.34 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 119.035 1.417 . . . . 0.0 114.142 -178.034 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.3 mm -61.41 -33.91 58.9 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 CA-C-N 119.209 0.913 . . . . 0.0 110.402 170.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -108.44 89.72 3.08 Favored 'General case' 0 C--N 1.339 0.124 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 159.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.003 0 C-N-CA 125.16 1.362 . . . . 0.0 112.331 -178.267 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? 59.35 168.44 0.07 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 127.047 2.139 . . . . 0.0 112.504 -169.64 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -62.55 -23.66 67.11 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -173.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.98 -29.84 59.66 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.217 0.913 . . . . 0.0 112.501 173.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.82 -35.07 22.55 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.877 1.339 . . . . 0.0 111.259 172.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.2 mm -62.91 -33.63 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 123.69 0.796 . . . . 0.0 111.908 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.41 -61.69 1.87 Allowed 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 127.307 2.243 . . . . 0.0 109.484 165.098 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.75 -32.99 66.51 Favored Glycine 0 C--N 1.341 0.83 0 C-N-CA 123.811 0.72 . . . . 0.0 114.003 -164.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -69.02 -31.05 69.58 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.254 1.027 . . . . 0.0 112.029 178.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.9 mt -73.2 -35.19 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 123.945 0.898 . . . . 0.0 109.26 174.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -78.89 -55.55 5.07 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 125.128 1.371 . . . . 0.0 108.226 -170.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.33 -20.96 66.63 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 122.803 0.441 . . . . 0.0 110.122 171.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.18 -57.23 8.74 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.2 t90 -62.29 -60.92 2.88 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.609 1.164 . . . . 0.0 109.046 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -85.61 23.71 1.34 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.384 0.673 . . . . 0.0 111.962 -169.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -122.76 -14.94 4.09 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 126.54 2.019 . . . . 0.0 112.098 165.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 26.4 mmt -112.0 -12.0 13.78 Favored 'General case' 0 C--N 1.343 0.316 0 CA-C-N 118.732 1.266 . . . . 0.0 112.246 178.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.1 mm -63.03 -63.14 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 158.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -153.61 176.92 11.52 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 126.414 1.886 . . . . 0.0 107.015 -170.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.047 0 C-N-CA 126.71 2.1 . . . . 0.0 112.878 179.227 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.474 0.743 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -61.77 155.27 23.38 Favored 'General case' 0 C--O 1.24 0.569 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 152.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -68.27 -19.36 64.71 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -174.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.59 -25.04 57.8 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 124.236 0.922 . . . . 0.0 112.939 176.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.51 -36.84 52.16 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.631 1.215 . . . . 0.0 110.909 172.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.3 mm -65.97 -51.39 61.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-O 122.339 1.066 . . . . 0.0 109.815 179.693 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.34 -52.88 60.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 112.35 -2.204 . . . . 0.0 109.495 169.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.84 -33.25 56.04 Favored Glycine 0 CA--C 1.53 0.976 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.949 -178.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -72.05 -28.11 63.13 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 118.464 1.132 . . . . 0.0 112.465 176.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -74.52 -37.17 43.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-N 119.484 1.038 . . . . 0.0 109.433 170.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -74.22 -56.07 5.32 Favored 'General case' 0 C--N 1.334 -0.105 0 C-N-CA 125.135 1.374 . . . . 0.0 108.646 -172.024 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.59 -7.52 33.52 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.103 0.561 . . . . 0.0 110.729 168.147 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.73 -54.35 7.44 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 168.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.09 -56.33 23.47 Favored 'General case' 0 C--O 1.233 0.19 0 C-N-CA 125.409 1.484 . . . . 0.0 108.221 173.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -81.9 23.33 0.7 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.212 -0.93 . . . . 0.0 112.13 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.25 -21.84 69.36 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 166.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.5 ttt -145.45 -36.15 0.29 Allowed 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.3 mm -74.98 -65.34 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.968 0.413 . . . . 0.0 110.336 -159.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -82.85 4.2 26.49 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 -165.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.296 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 158.803 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.0 t . . . . . 0 N--CA 1.477 0.876 0 CA-C-O 116.715 -1.612 . . . . 0.0 106.727 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 58.34 173.48 0.06 Allowed 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 125.924 1.69 . . . . 0.0 110.303 -157.075 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -114.52 -12.9 12.23 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -176.505 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.26 -34.72 81.43 Favored Glycine 0 CA--C 1.529 0.967 0 C-N-CA 123.533 0.587 . . . . 0.0 112.922 -174.381 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.25 -30.29 34.15 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.96 0.904 . . . . 0.0 111.659 174.573 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.1 mm -67.71 -39.34 81.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 C-N-CA 123.901 0.881 . . . . 0.0 110.793 -178.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.97 -56.76 7.8 Favored 'General case' 0 C--N 1.319 -0.761 0 C-N-CA 127.233 2.213 . . . . 0.0 109.687 164.692 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.53 -33.01 65.58 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.703 -169.271 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -67.4 -27.63 67.24 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.395 1.097 . . . . 0.0 111.989 178.04 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.87 -36.0 62.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 O-C-N 121.527 -0.733 . . . . 0.0 109.179 171.559 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.24 -58.9 2.99 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.354 1.461 . . . . 0.0 108.128 -168.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -68.51 -12.76 61.69 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.87 -0.586 . . . . 0.0 112.069 171.988 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.66 -56.82 5.27 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 169.708 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.2 t90 -65.24 -61.34 2.19 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.513 1.125 . . . . 0.0 109.42 -178.415 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -86.69 23.7 1.62 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-O 121.363 0.601 . . . . 0.0 111.469 -172.412 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.38 -38.15 6.79 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.724 1.154 . . . . 0.0 111.21 173.135 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 91.1 mmm -143.33 -9.51 0.75 Allowed 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.804 1.409 . . . . 0.0 114.804 -173.352 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.1 mt -104.74 -56.8 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 119.691 1.132 . . . . 0.0 111.54 -161.558 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.63 178.47 4.84 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 114.762 1.393 . . . . 0.0 114.762 -158.51 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.216 0 C-N-CA 125.096 1.331 . . . . 0.0 114.604 178.037 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 N--CA 1.477 0.915 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -125.84 159.28 32.88 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 172.632 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -61.61 -24.68 66.85 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 112.776 0.658 . . . . 0.0 112.776 -178.201 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.8 -26.72 60.77 Favored Glycine 0 CA--C 1.533 1.176 0 C-N-CA 124.179 0.895 . . . . 0.0 112.814 173.64 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.11 -34.75 37.63 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 118.95 1.375 . . . . 0.0 110.864 173.292 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.6 mm -63.14 -53.57 44.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-O 122.484 1.135 . . . . 0.0 109.694 177.227 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -51.17 -55.24 18.93 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 112.273 -2.24 . . . . 0.0 108.994 169.134 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.38 -33.97 33.05 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.09 0.853 . . . . 0.0 113.249 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -72.62 -39.91 66.88 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.439 1.12 . . . . 0.0 111.892 177.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 mt -65.65 -35.29 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 119.164 0.893 . . . . 0.0 109.955 171.55 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -79.57 -55.54 4.95 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 125.59 1.556 . . . . 0.0 108.781 -166.878 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -71.29 -13.28 61.84 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.759 169.591 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.51 -51.16 54.65 Favored Glycine 0 C--N 1.343 0.951 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 169.76 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.4 ' C ' ' H ' ' A' ' 16' ' ' GLY . 21.2 t90 -65.57 -62.05 1.74 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 124.038 0.935 . . . . 0.0 109.308 173.355 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.42 23.54 0.39 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.385 1.474 . . . . 0.0 112.929 -168.331 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 14' ' ' TRP . . . -130.96 2.09 5.53 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 127.399 2.428 . . . . 0.0 111.922 171.022 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 56.9 mtt -137.47 0.76 2.31 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 118.947 1.373 . . . . 0.0 113.431 -175.465 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.0 mt -59.1 -47.72 89.14 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 119.65 1.114 . . . . 0.0 110.829 -177.187 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.4 t0 27.32 80.86 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 128.831 2.852 . . . . 0.0 114.875 -167.316 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.458 0 CA-C-O 118.064 -1.409 . . . . 0.0 114.79 171.52 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 52.8 t . . . . . 0 N--CA 1.473 0.717 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.3 mm? 59.77 170.38 0.08 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 127.317 2.247 . . . . 0.0 113.062 -169.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -63.41 -22.83 67.12 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -174.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.4 -28.62 62.28 Favored Glycine 0 CA--C 1.532 1.121 0 C-N-CA 124.103 0.859 . . . . 0.0 112.518 173.757 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.56 -30.82 29.39 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 118.847 1.324 . . . . 0.0 111.465 173.653 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.0 mm -62.59 -51.63 69.82 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-O 122.219 1.009 . . . . 0.0 109.756 175.68 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.81 -53.9 49.24 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 127.299 2.239 . . . . 0.0 109.485 169.24 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.29 -35.4 42.96 Favored Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.024 0.821 . . . . 0.0 113.059 -179.838 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 90.8 t80 -74.9 -22.65 58.5 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.011 0.906 . . . . 0.0 112.725 178.611 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -76.06 -41.23 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-N 119.577 1.08 . . . . 0.0 109.175 165.647 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -72.66 -55.15 7.26 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 125.042 1.337 . . . . 0.0 109.37 -167.597 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -80.54 -2.98 48.45 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 118.217 0.462 . . . . 0.0 111.258 167.901 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.43 -54.86 31.07 Favored Glycine 0 C--N 1.34 0.764 0 N-CA-C 109.035 -1.626 . . . . 0.0 109.035 162.846 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.1 t90 -64.1 -64.99 0.74 Allowed 'General case' 0 C--O 1.237 0.429 0 C-N-CA 123.776 0.83 . . . . 0.0 108.847 171.617 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -89.68 60.77 5.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 122.689 1.233 . . . . 0.0 108.937 -170.44 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.78 -32.05 0.02 OUTLIER Glycine 0 CA--C 1.524 0.642 0 CA-C-N 114.156 -1.383 . . . . 0.0 112.259 170.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 85.2 mmm -96.11 -12.36 24.9 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 118.282 1.041 . . . . 0.0 112.227 171.471 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.7 mt -135.06 -63.14 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.435 1.494 . . . . 0.0 108.642 -169.748 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 62.39 144.38 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.881 2.473 . . . . 0.0 113.209 -167.027 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.244 0 N-CA-C 116.52 1.368 . . . . 0.0 116.52 -179.041 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 N--CA 1.477 0.918 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 5.3 mp 59.34 -177.7 0.09 Allowed 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 125.492 1.517 . . . . 0.0 111.617 -174.595 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -60.54 -20.23 59.7 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.287 -0.883 . . . . 0.0 111.855 171.157 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.71 -29.46 61.4 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.407 1.003 . . . . 0.0 112.495 170.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.81 -33.7 34.55 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.978 1.389 . . . . 0.0 111.429 172.757 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.8 mm -60.05 -53.87 42.62 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-O 122.277 1.037 . . . . 0.0 109.695 174.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.67 -51.99 61.41 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 127.753 2.421 . . . . 0.0 109.767 170.841 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.7 -36.69 49.57 Favored Glycine 0 CA--C 1.534 1.259 0 CA-C-N 118.422 0.555 . . . . 0.0 113.133 177.136 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -77.54 -14.99 59.53 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.739 0.816 . . . . 0.0 113.093 177.9 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mt -82.93 -38.96 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 119.904 1.229 . . . . 0.0 109.496 164.088 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -65.21 -64.15 0.93 Allowed 'General case' 0 CA--C 1.521 -0.152 0 C-N-CA 125.908 1.683 . . . . 0.0 108.204 -173.879 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -79.69 2.51 22.42 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 118.148 0.431 . . . . 0.0 111.461 169.189 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.96 -57.02 12.98 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 162.461 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.6 t90 -68.99 -56.58 7.36 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 171.255 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -78.48 41.84 0.41 Allowed 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.059 0.944 . . . . 0.0 110.878 -177.548 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.67 41.87 2.99 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.548 2.023 . . . . 0.0 109.034 162.49 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.4 tmm? 57.46 29.05 16.4 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.568 1.947 . . . . 0.0 113.133 -174.858 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 70.0 mt -68.74 -51.2 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 O-C-N 121.459 -0.775 . . . . 0.0 109.242 169.768 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -57.87 151.72 17.44 Favored 'General case' 0 C--N 1.342 0.252 0 C-N-CA 123.565 0.746 . . . . 0.0 112.928 -169.272 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.336 0.559 0 C-N-CA 125.329 1.443 . . . . 0.0 110.716 174.265 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.1 mt 59.6 173.52 0.08 Allowed 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 126.084 1.754 . . . . 0.0 112.167 -168.815 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -66.06 -19.62 65.91 Favored 'General case' 0 CA--C 1.537 0.456 0 O-C-N 121.023 -1.048 . . . . 0.0 112.435 179.473 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.34 -21.54 54.1 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 124.742 1.163 . . . . 0.0 112.852 167.136 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.49 -53.02 4.38 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.904 1.352 . . . . 0.0 110.307 164.719 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.1 mm -62.95 -20.8 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -166.427 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -133.6 -47.51 0.82 Allowed 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 125.932 1.693 . . . . 0.0 110.635 170.488 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.87 -31.84 65.21 Favored Glycine 0 CA--C 1.531 1.064 0 CA-C-O 119.333 -0.704 . . . . 0.0 113.935 -168.301 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 t80 -70.48 -33.08 70.84 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.278 1.039 . . . . 0.0 111.567 175.808 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.89 -21.54 22.49 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 124.605 1.162 . . . . 0.0 109.795 177.6 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -92.84 -63.32 1.24 Allowed 'General case' 0 C--O 1.231 0.094 0 C-N-CA 125.255 1.422 . . . . 0.0 107.22 -174.551 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -65.62 -27.81 68.67 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.837 0.855 . . . . 0.0 111.058 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.6 -18.21 66.6 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.904 -0.942 . . . . 0.0 112.311 177.042 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 12.2 t90 -80.77 -67.49 0.77 Allowed 'General case' 0 C--O 1.237 0.403 0 CA-C-N 118.481 1.141 . . . . 0.0 108.229 168.605 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -84.57 23.36 1.15 Allowed 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 121.374 0.607 . . . . 0.0 112.599 -162.828 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.88 -32.45 12.8 Favored Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.477 1.037 . . . . 0.0 111.614 175.096 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.7 mmt -151.14 -33.63 0.15 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -176.019 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 45.8 mt -58.1 -45.17 88.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 C-N-CA 124.3 1.04 . . . . 0.0 112.189 -158.68 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -97.06 3.87 51.63 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.298 0.639 . . . . 0.0 111.636 -177.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.922 0 C-N-CA 127.573 2.511 . . . . 0.0 114.847 -162.519 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 CA--C 1.538 0.509 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -106.19 -10.74 16.32 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.94 -48.04 58.55 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.846 0.736 . . . . 0.0 112.621 -171.023 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -19.85 58.76 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.353 1.461 . . . . 0.0 112.76 178.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.8 mm -74.67 -8.57 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 C-N-CA 124.41 1.084 . . . . 0.0 110.884 177.12 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.09 -44.33 4.19 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 127.154 2.182 . . . . 0.0 109.694 160.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.03 -39.22 89.27 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 119.029 0.831 . . . . 0.0 113.264 -173.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -69.62 -26.62 64.52 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 118.164 0.982 . . . . 0.0 112.038 176.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mm -75.76 -35.54 31.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 C-N-CA 123.686 0.795 . . . . 0.0 108.901 178.344 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -78.79 -49.2 13.4 Favored 'General case' 0 CA--C 1.519 -0.231 0 C-N-CA 125.815 1.646 . . . . 0.0 108.158 -174.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -63.65 -14.69 54.25 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.788 0.435 . . . . 0.0 111.27 167.134 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.63 -55.51 4.55 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 172.105 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -62.54 -58.81 6.23 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 125.979 1.712 . . . . 0.0 109.711 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -80.39 23.59 0.49 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.009 0.924 . . . . 0.0 111.759 176.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.5 -19.76 31.48 Favored Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.799 1.19 . . . . 0.0 111.085 159.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 ptt? -162.81 60.62 0.2 Allowed 'General case' 0 C--N 1.346 0.429 0 CA-C-N 118.943 1.372 . . . . 0.0 112.007 -176.398 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt . . . . . 0 N--CA 1.464 0.226 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 158.876 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.0 mm? . . . . . 0 C--O 1.235 0.321 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -63.36 -20.65 65.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -175.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.19 -30.31 57.66 Favored Glycine 0 CA--C 1.532 1.113 0 CA-C-O 118.999 -0.889 . . . . 0.0 112.463 172.707 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.98 -32.24 25.09 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 119.118 1.459 . . . . 0.0 111.378 172.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.2 mm -65.87 -28.83 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 123.829 0.851 . . . . 0.0 111.934 178.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -81.55 -53.65 6.09 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 127.675 2.39 . . . . 0.0 110.139 165.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.82 -41.84 36.5 Favored Glycine 0 C--N 1.342 0.881 0 C-N-CA 125.668 1.604 . . . . 0.0 112.928 -173.401 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -75.53 -16.85 60.23 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.144 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.6 mt -81.4 -45.71 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.696 0.799 . . . . 0.0 108.896 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -82.46 -38.48 23.88 Favored 'General case' 0 CA--C 1.527 0.07 0 CA-C-O 118.194 -0.908 . . . . 0.0 111.082 -167.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -87.02 1.73 51.91 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.309 0.959 . . . . 0.0 111.059 162.068 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.78 -45.87 56.1 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 159.156 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.404 ' HA ' HD12 ' A' ' 18' ' ' ILE . 0.3 OUTLIER -63.4 -64.9 0.77 Allowed 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 167.972 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -81.5 57.45 3.3 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.537 1.535 . . . . 0.0 108.544 -173.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -136.77 -42.48 0.1 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 126.886 2.184 . . . . 0.0 110.443 176.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -145.67 -6.81 0.6 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 115.307 1.595 . . . . 0.0 115.307 -179.082 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.404 HD12 ' HA ' ' A' ' 14' ' ' TRP . 11.8 mt . . . . . 0 N--CA 1.469 0.476 0 CA-C-N 119.751 1.16 . . . . 0.0 111.562 -175.145 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mp . . . . . 0 C--O 1.234 0.252 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -66.59 -23.8 66.25 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 -170.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -27.24 61.23 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.112 0.863 . . . . 0.0 112.83 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.71 -44.44 20.79 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 118.779 1.29 . . . . 0.0 110.385 172.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.0 mt -60.22 -38.66 78.13 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 C-N-CA 125.671 1.588 . . . . 0.0 111.785 -176.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -74.03 -58.69 3.13 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 127.613 2.365 . . . . 0.0 109.881 168.328 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -32.82 59.94 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 123.978 0.799 . . . . 0.0 113.883 -166.343 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.1 t80 -67.64 -36.84 81.52 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.193 0.997 . . . . 0.0 111.772 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.2 mt -71.0 -33.65 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 C-N-CA 124.363 1.065 . . . . 0.0 109.597 177.223 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -80.3 -50.48 10.12 Favored 'General case' 0 C--N 1.333 -0.149 0 C-N-CA 125.312 1.445 . . . . 0.0 108.179 -170.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -66.05 -19.15 65.76 Favored 'General case' 0 C--N 1.342 0.274 0 CA-C-O 119.394 -0.336 . . . . 0.0 110.691 168.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.08 -50.79 16.25 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 173.763 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.7 t90 -64.26 -61.32 2.32 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 125.051 1.34 . . . . 0.0 109.167 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -88.94 23.38 2.39 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.786 0.803 . . . . 0.0 111.53 -169.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.07 -13.33 34.05 Favored Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.338 1.447 . . . . 0.0 111.488 171.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.9 ttm -146.67 -34.94 0.27 Allowed 'General case' 0 C--N 1.341 0.238 0 CA-C-N 118.253 1.026 . . . . 0.0 113.724 -177.363 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.6 mt . . . . . 0 C--N 1.328 -0.333 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -162.962 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 121.302 0.573 . . . . 0.0 111.431 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -59.58 -26.46 65.44 Favored 'General case' 0 N--CA 1.463 0.193 0 O-C-N 121.678 -0.639 . . . . 0.0 111.934 -178.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.55 -26.18 66.22 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 125.285 1.422 . . . . 0.0 112.728 175.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.54 -62.63 1.45 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.37 1.085 . . . . 0.0 109.326 166.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 52.2 mt -61.07 -22.39 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 C-N-CA 126.345 1.858 . . . . 0.0 113.782 -160.316 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -132.42 -42.88 0.94 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 125.569 1.548 . . . . 0.0 111.028 172.274 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.94 -36.03 59.82 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 118.814 -0.992 . . . . 0.0 112.931 -175.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -77.35 -19.91 55.58 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 118.692 1.246 . . . . 0.0 112.583 176.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -82.29 -38.51 15.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.028 1.331 . . . . 0.0 108.755 174.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -73.18 -57.96 3.65 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 128.016 2.526 . . . . 0.0 107.593 -175.049 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -69.67 -7.76 41.84 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.045 0.538 . . . . 0.0 111.06 169.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.75 -59.42 4.07 Favored Glycine 0 C--N 1.34 0.777 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 169.039 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 18.8 t90 -60.27 -56.84 16.61 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 125.54 1.536 . . . . 0.0 109.739 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -85.03 23.65 1.2 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.632 0.773 . . . . 0.0 111.483 -177.004 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.94 9.82 11.26 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 127.886 2.66 . . . . 0.0 111.656 164.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.5 ptt? -129.93 -20.86 3.08 Favored 'General case' 0 C--N 1.344 0.367 0 CA-C-N 118.088 0.944 . . . . 0.0 113.491 164.064 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.0 mm . . . . . 0 N--CA 1.469 0.506 0 C-N-CA 123.617 0.767 . . . . 0.0 110.949 172.207 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 55.3 mt . . . . . 0 C--O 1.235 0.326 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -59.19 -26.06 64.49 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -174.511 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.12 -28.35 63.87 Favored Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.414 1.006 . . . . 0.0 112.778 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.26 -42.14 21.12 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 119.138 1.469 . . . . 0.0 110.516 171.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mt -59.22 -39.96 80.01 Favored 'Isoleucine or valine' 0 C--N 1.342 0.257 0 C-N-CA 124.823 1.249 . . . . 0.0 111.979 -176.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.55 -54.28 6.92 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 127.542 2.337 . . . . 0.0 110.116 169.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.58 -34.34 60.2 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 124.242 0.925 . . . . 0.0 113.642 -170.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -72.17 -23.17 61.24 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 118.407 1.103 . . . . 0.0 112.683 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -79.64 -38.84 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 124.323 1.049 . . . . 0.0 108.784 170.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.44 -55.36 7.15 Favored 'General case' 0 C--O 1.226 -0.17 0 C-N-CA 125.08 1.352 . . . . 0.0 109.052 -172.287 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -79.82 2.71 22.08 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.451 0.568 . . . . 0.0 111.595 167.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.79 -52.94 22.12 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 159.252 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -58.49 -63.37 1.3 Allowed 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.484 1.114 . . . . 0.0 108.592 169.259 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -80.66 56.91 2.78 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.154 2.182 . . . . 0.0 109.109 -176.127 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -173.29 -22.87 0.02 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.886 3.136 . . . . 0.0 110.794 178.343 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 33.5 mmt -93.39 -22.71 18.76 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 118.372 1.086 . . . . 0.0 112.569 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 N--CA 1.469 0.503 0 C-N-CA 124.557 1.143 . . . . 0.0 110.745 173.765 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.6 mp . . . . . 0 C--O 1.232 0.172 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 28.8 t80 -71.49 -12.59 61.46 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 176.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.79 -24.6 54.07 Favored Glycine 0 CA--C 1.533 1.188 0 C-N-CA 124.4 1.0 . . . . 0.0 113.523 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -78.31 -43.34 28.18 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.491 1.146 . . . . 0.0 110.83 171.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 18.6 mm -71.58 -9.33 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 126.07 1.748 . . . . 0.0 111.818 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.57 3.35 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 128.188 2.595 . . . . 0.0 109.484 168.144 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.66 -37.1 91.81 Favored Glycine 0 CA--C 1.529 0.92 0 CA-C-N 118.804 0.729 . . . . 0.0 112.8 -174.477 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 84.2 t80 -67.29 -25.63 66.13 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.638 0.719 . . . . 0.0 111.655 178.574 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 mm -66.47 -23.46 31.55 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-N 118.898 0.772 . . . . 0.0 109.9 177.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -104.82 -60.87 1.54 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 -172.588 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -64.25 -25.22 67.96 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 122.949 0.5 . . . . 0.0 112.304 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.85 0.77 86.04 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.078 174.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -127.44 -68.34 0.79 Allowed 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.78 1.632 . . . . 0.0 108.574 -176.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -74.16 23.79 0.08 Allowed 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.923 2.089 . . . . 0.0 112.394 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.24 -33.81 5.57 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 125.209 1.385 . . . . 0.0 111.367 162.286 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.1 mmm -153.65 64.76 0.73 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.825 1.313 . . . . 0.0 109.746 -173.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.7 mt . . . . . 0 N--CA 1.466 0.35 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 166.367 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.7 mm? . . . . . 0 N--CA 1.462 0.148 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -77.39 -12.96 60.02 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 179.294 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.71 -42.0 58.31 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.369 0.985 . . . . 0.0 112.986 -170.589 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.74 -22.41 61.61 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.298 1.439 . . . . 0.0 112.719 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mm -74.35 -5.47 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 C-N-CA 124.645 1.178 . . . . 0.0 110.811 176.68 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.37 -42.11 3.98 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 126.608 1.963 . . . . 0.0 109.706 160.731 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.68 -39.51 91.28 Favored Glycine 0 C--N 1.342 0.909 0 CA-C-N 119.23 0.923 . . . . 0.0 112.87 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -75.62 -15.28 60.36 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 117.843 0.821 . . . . 0.0 112.69 177.074 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.8 mm -85.66 -37.76 12.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 124.699 1.2 . . . . 0.0 108.724 174.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -72.62 -55.75 6.38 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 126.568 1.947 . . . . 0.0 107.886 -177.05 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -69.29 -6.62 30.59 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.558 0.743 . . . . 0.0 111.247 168.561 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.97 -57.49 3.72 Favored Glycine 0 C--N 1.341 0.82 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 169.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -57.02 -57.01 14.43 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 126.536 1.934 . . . . 0.0 109.283 175.563 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -83.27 24.38 0.81 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 123.944 0.897 . . . . 0.0 111.612 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -121.47 6.87 10.58 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 127.324 2.392 . . . . 0.0 111.331 164.281 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.8 mmt -126.58 -36.11 2.29 Favored 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.215 1.406 . . . . 0.0 111.767 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm . . . . . 0 N--CA 1.468 0.432 0 C-N-CA 124.887 1.275 . . . . 0.0 110.704 175.494 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.7 mp . . . . . 0 C--O 1.232 0.163 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -77.9 -12.01 59.94 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 177.616 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.91 -28.96 61.35 Favored Glycine 0 CA--C 1.531 1.045 0 C-N-CA 124.033 0.825 . . . . 0.0 113.583 -174.055 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.8 -33.52 27.23 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 118.572 1.186 . . . . 0.0 111.512 173.75 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.0 mm -73.66 -10.26 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 126.052 1.741 . . . . 0.0 111.609 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.81 -48.82 3.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 127.321 2.248 . . . . 0.0 109.632 164.464 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.38 -36.05 82.01 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 119.034 0.833 . . . . 0.0 113.33 -172.635 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -66.79 -31.2 71.67 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.439 1.12 . . . . 0.0 111.618 175.487 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mm -73.99 -18.14 17.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 124.484 1.114 . . . . 0.0 109.977 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -97.7 -61.21 1.42 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 125.324 1.45 . . . . 0.0 107.337 -174.271 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -61.65 -30.99 71.08 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.527 0.731 . . . . 0.0 111.761 176.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.43 0.61 63.71 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.122 -0.821 . . . . 0.0 113.433 177.005 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 17.9 t90 -130.39 -69.65 0.65 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.943 1.297 . . . . 0.0 108.568 -174.203 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -78.51 23.43 0.31 Allowed 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.294 1.038 . . . . 0.0 112.043 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.02 -2.71 16.08 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 127.416 2.436 . . . . 0.0 112.106 166.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 61.0 mtt -134.09 -10.05 2.62 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.977 1.389 . . . . 0.0 113.382 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.2 mm . . . . . 0 CA--C 1.538 0.491 0 C-N-CA 124.114 0.966 . . . . 0.0 111.957 177.611 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.4 mt . . . . . 0 C--O 1.232 0.157 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -103.0 -9.47 19.77 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.624 0.601 . . . . 0.0 112.624 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.3 -30.73 64.89 Favored Glycine 0 CA--C 1.532 1.108 0 O-C-N 121.399 -0.813 . . . . 0.0 113.945 -170.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.75 30.08 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.855 1.262 . . . . 0.0 111.658 175.12 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.4 mm -75.46 -5.62 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.814 1.646 . . . . 0.0 111.099 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -110.02 -46.21 3.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.28 1.832 . . . . 0.0 109.922 160.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.37 -36.39 83.58 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 119.23 0.923 . . . . 0.0 113.274 -172.3 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -74.37 -20.08 60.21 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.755 0.778 . . . . 0.0 112.482 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -81.67 -34.5 12.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 124.288 1.035 . . . . 0.0 109.001 174.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -73.98 -56.09 5.36 Favored 'General case' 0 N--CA 1.457 -0.125 0 C-N-CA 125.813 1.645 . . . . 0.0 107.644 -176.105 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -63.13 -21.27 66.08 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 122.857 0.463 . . . . 0.0 111.0 168.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.73 -9.9 86.66 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-O 119.338 -0.701 . . . . 0.0 112.948 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -114.03 -58.1 2.19 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.916 1.286 . . . . 0.0 109.499 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.8 23.89 0.16 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.928 1.291 . . . . 0.0 112.691 -174.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.37 49.95 3.08 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.146 1.832 . . . . 0.0 111.87 178.352 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.4 mtm 58.53 73.93 0.46 Allowed 'General case' 0 C--N 1.341 0.214 0 C-N-CA 127.192 2.197 . . . . 0.0 110.468 -175.31 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 90.6 mt . . . . . 0 CA--C 1.544 0.723 0 C-N-CA 126.892 2.077 . . . . 0.0 112.532 -179.38 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? . . . . . 0 C--O 1.231 0.128 0 N-CA-C 106.63 -1.618 . . . . 0.0 106.63 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -88.62 -9.15 53.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 122.878 0.471 . . . . 0.0 112.134 177.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.61 -32.34 61.29 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 123.976 0.798 . . . . 0.0 114.09 -168.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.19 -28.34 27.4 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.434 1.093 . . . . 0.0 111.952 175.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.2 mm -74.88 -10.92 14.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 125.681 1.592 . . . . 0.0 111.244 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.66 -49.16 3.48 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 126.896 2.078 . . . . 0.0 109.55 162.26 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.0 -35.88 78.45 Favored Glycine 0 C--N 1.342 0.875 0 CA-C-N 118.988 0.813 . . . . 0.0 113.286 -170.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -70.78 -28.04 64.37 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.338 1.069 . . . . 0.0 112.038 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mm -72.49 -25.28 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 119.066 0.848 . . . . 0.0 109.487 176.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -92.71 -65.6 0.99 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.639 1.575 . . . . 0.0 107.029 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.13 -24.56 67.45 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.623 0.769 . . . . 0.0 110.764 179.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -77.38 -3.29 82.16 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 118.855 -0.97 . . . . 0.0 113.198 176.369 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.7 t90 -130.78 -74.66 0.53 Allowed 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 118.509 1.155 . . . . 0.0 108.984 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -79.75 23.71 0.42 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.679 1.192 . . . . 0.0 112.404 -172.354 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.27 -16.43 57.39 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 118.186 -1.341 . . . . 0.0 112.319 170.303 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 45.6 mmm -141.07 9.57 2.12 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 118.612 1.206 . . . . 0.0 113.037 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 5.3 mm . . . . . 0 CA--C 1.536 0.405 0 O-C-N 120.898 -1.126 . . . . 0.0 112.217 -177.37 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.0 mm? . . . . . 0 N--CA 1.468 0.458 0 CA-C-O 121.614 0.721 . . . . 0.0 112.037 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -60.17 -26.65 66.49 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.661 0.615 . . . . 0.0 112.661 -170.593 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -63.56 -24.13 67.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.859 1.218 . . . . 0.0 112.732 177.047 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.03 -61.8 1.51 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 118.126 0.963 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 56.9 mt -60.15 -21.95 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 126.398 1.879 . . . . 0.0 113.589 -161.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -131.26 -43.59 1.04 Allowed 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 125.953 1.701 . . . . 0.0 110.84 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.27 -34.35 59.02 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-N 119.067 0.849 . . . . 0.0 113.342 -177.407 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.0 t80 -75.62 -23.59 56.41 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.624 1.212 . . . . 0.0 112.231 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mm -80.11 -35.12 15.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 125.19 1.396 . . . . 0.0 109.144 175.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -73.69 -59.13 2.86 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 128.026 2.53 . . . . 0.0 106.833 -176.021 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -62.46 -19.13 63.21 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 119.224 -0.417 . . . . 0.0 111.291 170.266 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.13 -54.24 9.44 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 175.474 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -62.37 -57.2 12.19 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.53 1.532 . . . . 0.0 109.713 176.624 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 -80.22 23.41 0.48 Allowed 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.543 1.537 . . . . 0.0 112.857 -166.11 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.63 -5.66 10.97 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.753 2.121 . . . . 0.0 112.193 166.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 95.7 mmm -127.31 -2.91 6.26 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.714 1.257 . . . . 0.0 113.102 -174.127 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.0 mt . . . . . 0 N--CA 1.469 0.48 0 C-N-CA 124.219 1.008 . . . . 0.0 110.579 -178.776 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? . . . . . 0 CA--C 1.538 0.513 0 CA-C-O 121.662 0.744 . . . . 0.0 112.52 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.3 t80 -58.86 -25.76 63.59 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 123.679 0.792 . . . . 0.0 112.399 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.49 -15.06 51.99 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 125.323 1.439 . . . . 0.0 113.447 172.349 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -106.31 -55.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.527 1.163 . . . . 0.0 109.867 164.491 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 30.7 mt -61.95 -18.58 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 124.645 1.178 . . . . 0.0 113.677 -167.5 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -125.02 -43.47 1.97 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 125.697 1.599 . . . . 0.0 110.766 166.162 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.58 -34.89 78.08 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 119.417 1.008 . . . . 0.0 113.252 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.9 t80 -79.06 -10.69 59.9 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.622 1.211 . . . . 0.0 112.494 175.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.5 mm -87.66 -39.86 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 C-N-CA 124.798 1.239 . . . . 0.0 108.218 169.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -70.5 -59.96 2.54 Favored 'General case' 0 N--CA 1.457 -0.102 0 C-N-CA 126.6 1.96 . . . . 0.0 109.035 -176.57 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -74.01 -3.01 26.65 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.876 -0.515 . . . . 0.0 111.648 166.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.44 -10.26 74.82 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.495 0.589 . . . . 0.0 112.348 161.745 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -116.6 -64.22 1.34 Allowed 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 107.226 177.487 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -80.84 59.3 3.66 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-O 122.4 1.095 . . . . 0.0 109.49 172.366 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -145.25 13.66 1.86 Allowed Glycine 0 CA--C 1.534 1.225 0 C-N-CA 125.918 1.723 . . . . 0.0 111.765 161.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 25.6 ptt? -170.43 -18.84 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 128.386 2.675 . . . . 0.0 114.111 175.261 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 51.9 mt . . . . . 0 N--CA 1.475 0.806 0 C-N-CA 124.568 1.147 . . . . 0.0 110.338 -176.976 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mp . . . . . 0 C--O 1.234 0.255 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -62.79 -22.79 66.86 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.676 0.79 . . . . 0.0 112.003 172.772 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.47 -21.47 57.46 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 125.241 1.401 . . . . 0.0 112.895 171.288 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -85.65 -65.04 1.05 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 118.762 1.281 . . . . 0.0 108.766 163.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 29.1 mt -60.98 -24.5 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 125.509 1.523 . . . . 0.0 113.987 -161.108 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.44 -47.25 1.87 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 125.83 1.652 . . . . 0.0 110.542 172.531 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.56 -32.76 65.34 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.935 -0.925 . . . . 0.0 113.631 -172.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -76.37 -23.93 54.15 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 119.136 1.468 . . . . 0.0 112.108 175.073 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mm -71.08 -31.37 44.6 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 O-C-N 120.987 -1.07 . . . . 0.0 108.814 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -101.99 -49.8 3.84 Favored 'General case' 0 C--O 1.225 -0.188 0 C-N-CA 123.805 0.842 . . . . 0.0 110.386 -171.084 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 25.5 m-80 -86.45 -19.77 29.13 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.4 0.546 . . . . 0.0 111.234 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -96.45 -62.71 0.94 Allowed Glycine 0 C--N 1.34 0.79 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -175.647 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 23.5 t90 -80.23 -68.55 0.67 Allowed 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -79.54 23.45 0.41 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -167.592 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.69 -6.5 11.43 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 126.828 2.156 . . . . 0.0 112.729 170.371 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 59.1 mmm -130.19 20.59 5.32 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 118.964 1.382 . . . . 0.0 112.087 -172.737 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.5 mm . . . . . 0 CA--C 1.537 0.46 0 C-N-CA 123.711 0.805 . . . . 0.0 111.216 -177.137 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.6 mm? . . . . . 0 C--O 1.234 0.276 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -61.49 -22.42 65.08 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.676 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.6 -26.22 56.78 Favored Glycine 0 CA--C 1.532 1.1 0 CA-C-O 118.926 -0.93 . . . . 0.0 112.903 172.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.74 -43.74 15.17 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 119.222 1.511 . . . . 0.0 110.356 171.588 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -64.1 -13.21 13.32 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 C-N-CA 126.653 1.981 . . . . 0.0 112.629 -177.651 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.39 -48.92 2.99 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 127.59 2.356 . . . . 0.0 110.204 170.412 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.29 -36.1 81.54 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-N 119.412 1.006 . . . . 0.0 113.082 -174.503 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -73.7 -18.8 60.96 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 118.031 0.916 . . . . 0.0 112.515 176.018 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -80.98 -39.02 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 CA-C-N 119.431 1.014 . . . . 0.0 108.299 172.263 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -69.81 -62.41 1.39 Allowed 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 126.598 1.959 . . . . 0.0 107.951 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -64.58 -16.97 63.51 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 119.415 -0.326 . . . . 0.0 111.165 169.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.89 -16.32 66.0 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.747 -1.03 . . . . 0.0 113.37 173.556 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -127.49 -44.96 1.51 Allowed 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.571 1.185 . . . . 0.0 111.807 174.438 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -81.13 23.64 0.57 Allowed 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 122.256 1.027 . . . . 0.0 112.164 -162.262 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.66 -10.94 42.39 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 125.603 1.573 . . . . 0.0 112.227 163.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.5 mmm -111.64 -9.85 14.13 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.851 1.325 . . . . 0.0 113.521 -169.179 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm . . . . . 0 CA--C 1.533 0.315 0 C-N-CA 124.055 0.942 . . . . 0.0 112.313 -171.51 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? . . . . . 0 N--CA 1.468 0.435 0 CA-C-O 121.616 0.722 . . . . 0.0 110.728 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -84.43 -11.79 55.57 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -178.669 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.18 -32.57 63.48 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 123.817 0.722 . . . . 0.0 113.167 -174.393 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.07 -33.24 26.45 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.53 1.132 . . . . 0.0 111.629 174.279 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.1 mm -73.9 -9.1 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 125.644 1.578 . . . . 0.0 111.665 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.39 -50.45 3.22 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 127.479 2.312 . . . . 0.0 109.588 163.187 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.46 77.98 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 118.994 0.815 . . . . 0.0 113.281 -171.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -69.86 -28.11 65.39 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.198 0.999 . . . . 0.0 112.117 176.17 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mm -72.47 -25.67 23.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 CA-C-N 118.931 0.787 . . . . 0.0 109.429 176.226 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -92.91 -63.57 1.2 Allowed 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.225 1.41 . . . . 0.0 107.57 -170.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -68.39 -22.53 64.63 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.156 0.583 . . . . 0.0 110.872 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.94 -6.96 80.52 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.349 -0.695 . . . . 0.0 112.758 174.043 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.9 t90 -114.1 -76.05 0.59 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.228 1.411 . . . . 0.0 107.436 171.646 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.67 56.09 3.71 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 122.207 1.003 . . . . 0.0 110.971 -171.776 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.98 -7.97 37.37 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-O 118.659 -1.078 . . . . 0.0 111.73 159.245 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.0 mmt -148.97 3.05 0.6 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.054 1.341 . . . . 0.0 113.287 -169.127 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.7 mm . . . . . 0 N--CA 1.464 0.229 0 CA-C-N 120.163 1.347 . . . . 0.0 108.779 -170.38 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.9 mt . . . . . 0 C--O 1.233 0.218 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -65.92 -16.09 63.55 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 176.717 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.59 -23.5 58.47 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.701 1.143 . . . . 0.0 112.665 167.171 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.53 -58.31 2.79 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 118.891 1.346 . . . . 0.0 109.152 164.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.8 mm -64.3 -21.49 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -162.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -134.42 -44.75 0.76 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.941 1.696 . . . . 0.0 110.972 172.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.34 -42.57 74.61 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.992 0.815 . . . . 0.0 112.878 -173.721 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -77.62 -15.9 58.91 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 112.466 177.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.1 mm -71.1 -38.0 69.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 O-C-N 120.453 -1.404 . . . . 0.0 107.867 171.719 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -94.17 -55.71 3.1 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -167.325 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.0 m-80 -76.62 -20.06 57.14 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.141 0.576 . . . . 0.0 110.71 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.54 -63.88 0.79 Allowed Glycine 0 C--N 1.341 0.86 0 CA-C-O 118.387 -1.229 . . . . 0.0 111.45 -171.65 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -69.42 -64.06 0.95 Allowed 'General case' 0 C--N 1.341 0.22 0 CA-C-N 118.636 1.218 . . . . 0.0 108.336 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -80.34 23.14 0.51 Allowed 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.561 0.696 . . . . 0.0 112.522 -174.532 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -99.3 -58.41 0.91 Allowed Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.816 2.151 . . . . 0.0 108.739 162.321 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.7 ptm -65.06 -18.05 64.97 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 118.38 1.09 . . . . 0.0 113.555 -179.375 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.6 mm . . . . . 0 CA--C 1.539 0.548 0 C-N-CA 123.735 0.814 . . . . 0.0 110.633 169.185 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? . . . . . 0 C--O 1.236 0.367 0 CA-C-O 121.101 0.477 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -62.34 -21.0 64.95 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -173.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.42 -28.73 55.98 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 119.04 -0.867 . . . . 0.0 112.673 173.255 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.31 -41.96 19.41 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 119.127 1.464 . . . . 0.0 110.654 172.555 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.6 mt -65.82 -10.57 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.486 1.914 . . . . 0.0 112.465 -177.592 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -114.04 -45.02 3.09 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 127.01 2.124 . . . . 0.0 110.824 168.154 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.93 -38.79 76.29 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.682 0.674 . . . . 0.0 112.837 -176.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -78.21 -11.46 59.93 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 117.789 0.794 . . . . 0.0 112.632 178.452 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 9.7 mm -86.7 -42.37 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-N 119.218 0.917 . . . . 0.0 108.782 176.397 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.7 pt-20 -78.53 -47.35 17.48 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 124.403 1.081 . . . . 0.0 108.706 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -74.16 -13.04 60.75 Favored 'General case' 0 C--N 1.344 0.361 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 170.365 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.95 -53.51 9.35 Favored Glycine 0 C--N 1.342 0.861 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 171.518 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.536 ' HA ' HD12 ' A' ' 18' ' ' ILE . 22.7 t90 -67.26 -62.65 1.32 Allowed 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 123.381 0.673 . . . . 0.0 109.275 178.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -90.76 23.35 3.14 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.431 0.634 . . . . 0.0 111.511 -165.866 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.13 -27.04 26.9 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.551 1.072 . . . . 0.0 111.339 171.157 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.4 ptm -159.21 -10.71 0.06 Allowed 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 -178.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.536 HD12 ' HA ' ' A' ' 14' ' ' TRP . 58.6 mt . . . . . 0 N--CA 1.467 0.388 0 CA-C-N 119.765 1.166 . . . . 0.0 111.647 -159.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.8 mm? . . . . . 0 CA--C 1.537 0.456 0 CA-C-O 121.496 0.665 . . . . 0.0 111.01 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.32 -19.96 65.79 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 121.129 -0.982 . . . . 0.0 112.154 178.66 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -23.14 54.96 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 125.109 1.338 . . . . 0.0 112.906 167.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.37 -47.83 6.7 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.869 1.334 . . . . 0.0 110.693 167.141 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.8 mm -64.24 -24.47 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.138 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.92 -44.79 0.58 Allowed 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 125.908 1.683 . . . . 0.0 111.092 175.177 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.8 -37.63 70.13 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-N 119.035 0.834 . . . . 0.0 113.315 -169.521 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -67.32 -32.1 72.83 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 124.22 1.008 . . . . 0.0 111.832 176.683 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mt -74.52 -29.06 23.13 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 C-N-CA 124.041 0.937 . . . . 0.0 109.351 175.283 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -81.58 -57.72 3.34 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 125.492 1.517 . . . . 0.0 108.366 -174.508 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.4 p30 -65.78 -18.42 65.32 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.561 0.619 . . . . 0.0 111.655 170.716 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.75 -2.57 76.77 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.369 -0.684 . . . . 0.0 113.114 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.4 t90 -128.26 -68.37 0.77 Allowed 'General case' 0 C--O 1.234 0.239 0 C-N-CA 125.534 1.534 . . . . 0.0 109.127 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -77.36 23.71 0.2 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.595 1.558 . . . . 0.0 112.359 -176.091 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.58 -1.73 15.27 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 126.977 2.227 . . . . 0.0 112.112 167.618 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 78.9 mtm -134.93 -9.43 2.34 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 119.035 1.417 . . . . 0.0 114.142 -178.034 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.3 mm . . . . . 0 CA--C 1.537 0.459 0 CA-C-N 119.209 0.913 . . . . 0.0 110.402 170.151 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? . . . . . 0 CA--C 1.538 0.516 0 CA-C-O 121.895 0.855 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -62.55 -23.66 67.11 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -173.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.98 -29.84 59.66 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.217 0.913 . . . . 0.0 112.501 173.839 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.82 -35.07 22.55 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.877 1.339 . . . . 0.0 111.259 172.63 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.2 mm -62.91 -33.63 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 123.69 0.796 . . . . 0.0 111.908 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.41 -61.69 1.87 Allowed 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 127.307 2.243 . . . . 0.0 109.484 165.098 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.75 -32.99 66.51 Favored Glycine 0 C--N 1.341 0.83 0 C-N-CA 123.811 0.72 . . . . 0.0 114.003 -164.417 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -69.02 -31.05 69.58 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.254 1.027 . . . . 0.0 112.029 178.47 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.9 mt -73.2 -35.19 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 123.945 0.898 . . . . 0.0 109.26 174.472 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -78.89 -55.55 5.07 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 125.128 1.371 . . . . 0.0 108.226 -170.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.33 -20.96 66.63 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 122.803 0.441 . . . . 0.0 110.122 171.205 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.18 -57.23 8.74 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.2 t90 -62.29 -60.92 2.88 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.609 1.164 . . . . 0.0 109.046 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -85.61 23.71 1.34 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.384 0.673 . . . . 0.0 111.962 -169.274 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -122.76 -14.94 4.09 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 126.54 2.019 . . . . 0.0 112.098 165.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 26.4 mmt -112.0 -12.0 13.78 Favored 'General case' 0 C--N 1.343 0.316 0 CA-C-N 118.732 1.266 . . . . 0.0 112.246 178.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.1 mm . . . . . 0 CA--C 1.534 0.346 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 158.814 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? . . . . . 0 C--O 1.24 0.569 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -68.27 -19.36 64.71 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -174.47 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.59 -25.04 57.8 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 124.236 0.922 . . . . 0.0 112.939 176.766 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.51 -36.84 52.16 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.631 1.215 . . . . 0.0 110.909 172.775 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.3 mm -65.97 -51.39 61.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-O 122.339 1.066 . . . . 0.0 109.815 179.693 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.34 -52.88 60.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 112.35 -2.204 . . . . 0.0 109.495 169.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.84 -33.25 56.04 Favored Glycine 0 CA--C 1.53 0.976 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.949 -178.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -72.05 -28.11 63.13 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 118.464 1.132 . . . . 0.0 112.465 176.604 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -74.52 -37.17 43.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-N 119.484 1.038 . . . . 0.0 109.433 170.668 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -74.22 -56.07 5.32 Favored 'General case' 0 C--N 1.334 -0.105 0 C-N-CA 125.135 1.374 . . . . 0.0 108.646 -172.024 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.59 -7.52 33.52 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.103 0.561 . . . . 0.0 110.729 168.147 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.73 -54.35 7.44 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 168.36 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.09 -56.33 23.47 Favored 'General case' 0 C--O 1.233 0.19 0 C-N-CA 125.409 1.484 . . . . 0.0 108.221 173.782 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -81.9 23.33 0.7 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.212 -0.93 . . . . 0.0 112.13 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.25 -21.84 69.36 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 166.71 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.5 ttt -145.45 -36.15 0.29 Allowed 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.3 mm . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 120.968 0.413 . . . . 0.0 110.336 -159.095 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.2 mm? . . . . . 0 CA--C 1.541 0.626 0 CA-C-O 120.851 0.358 . . . . 0.0 110.303 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -114.52 -12.9 12.23 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -176.505 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.26 -34.72 81.43 Favored Glycine 0 CA--C 1.529 0.967 0 C-N-CA 123.533 0.587 . . . . 0.0 112.922 -174.381 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.25 -30.29 34.15 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.96 0.904 . . . . 0.0 111.659 174.573 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.1 mm -67.71 -39.34 81.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 C-N-CA 123.901 0.881 . . . . 0.0 110.793 -178.878 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.97 -56.76 7.8 Favored 'General case' 0 C--N 1.319 -0.761 0 C-N-CA 127.233 2.213 . . . . 0.0 109.687 164.692 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.53 -33.01 65.58 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.703 -169.271 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -67.4 -27.63 67.24 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.395 1.097 . . . . 0.0 111.989 178.04 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.87 -36.0 62.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 O-C-N 121.527 -0.733 . . . . 0.0 109.179 171.559 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.24 -58.9 2.99 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.354 1.461 . . . . 0.0 108.128 -168.808 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -68.51 -12.76 61.69 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.87 -0.586 . . . . 0.0 112.069 171.988 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.66 -56.82 5.27 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 169.708 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.2 t90 -65.24 -61.34 2.19 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.513 1.125 . . . . 0.0 109.42 -178.415 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -86.69 23.7 1.62 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-O 121.363 0.601 . . . . 0.0 111.469 -172.412 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.38 -38.15 6.79 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.724 1.154 . . . . 0.0 111.21 173.135 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 91.1 mmm -143.33 -9.51 0.75 Allowed 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.804 1.409 . . . . 0.0 114.804 -173.352 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.1 mt . . . . . 0 N--CA 1.466 0.374 0 CA-C-N 119.691 1.132 . . . . 0.0 111.54 -161.558 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? . . . . . 0 C--O 1.235 0.291 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -61.61 -24.68 66.85 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 112.776 0.658 . . . . 0.0 112.776 -178.201 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.8 -26.72 60.77 Favored Glycine 0 CA--C 1.533 1.176 0 C-N-CA 124.179 0.895 . . . . 0.0 112.814 173.64 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.11 -34.75 37.63 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 118.95 1.375 . . . . 0.0 110.864 173.292 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.6 mm -63.14 -53.57 44.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-O 122.484 1.135 . . . . 0.0 109.694 177.227 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -51.17 -55.24 18.93 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 112.273 -2.24 . . . . 0.0 108.994 169.134 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.38 -33.97 33.05 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.09 0.853 . . . . 0.0 113.249 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -72.62 -39.91 66.88 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.439 1.12 . . . . 0.0 111.892 177.985 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 mt -65.65 -35.29 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 119.164 0.893 . . . . 0.0 109.955 171.55 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -79.57 -55.54 4.95 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 125.59 1.556 . . . . 0.0 108.781 -166.878 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -71.29 -13.28 61.84 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.759 169.591 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.51 -51.16 54.65 Favored Glycine 0 C--N 1.343 0.951 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 169.76 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.2 t90 -65.57 -62.05 1.74 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 124.038 0.935 . . . . 0.0 109.308 173.355 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.42 23.54 0.39 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.385 1.474 . . . . 0.0 112.929 -168.331 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.96 2.09 5.53 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 127.399 2.428 . . . . 0.0 111.922 171.022 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 56.9 mtt -137.47 0.76 2.31 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 118.947 1.373 . . . . 0.0 113.431 -175.465 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.0 mt . . . . . 0 N--CA 1.472 0.635 0 CA-C-N 119.65 1.114 . . . . 0.0 110.829 -177.187 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.3 mm? . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 121.954 0.883 . . . . 0.0 113.062 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -63.41 -22.83 67.12 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -174.232 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.4 -28.62 62.28 Favored Glycine 0 CA--C 1.532 1.121 0 C-N-CA 124.103 0.859 . . . . 0.0 112.518 173.757 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.56 -30.82 29.39 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 118.847 1.324 . . . . 0.0 111.465 173.653 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.0 mm -62.59 -51.63 69.82 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-O 122.219 1.009 . . . . 0.0 109.756 175.68 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.81 -53.9 49.24 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 127.299 2.239 . . . . 0.0 109.485 169.24 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.29 -35.4 42.96 Favored Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.024 0.821 . . . . 0.0 113.059 -179.838 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 90.8 t80 -74.9 -22.65 58.5 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.011 0.906 . . . . 0.0 112.725 178.611 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -76.06 -41.23 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-N 119.577 1.08 . . . . 0.0 109.175 165.647 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -72.66 -55.15 7.26 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 125.042 1.337 . . . . 0.0 109.37 -167.597 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -80.54 -2.98 48.45 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 118.217 0.462 . . . . 0.0 111.258 167.901 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.43 -54.86 31.07 Favored Glycine 0 C--N 1.34 0.764 0 N-CA-C 109.035 -1.626 . . . . 0.0 109.035 162.846 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.1 t90 -64.1 -64.99 0.74 Allowed 'General case' 0 C--O 1.237 0.429 0 C-N-CA 123.776 0.83 . . . . 0.0 108.847 171.617 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -89.68 60.77 5.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 122.689 1.233 . . . . 0.0 108.937 -170.44 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.78 -32.05 0.02 OUTLIER Glycine 0 CA--C 1.524 0.642 0 CA-C-N 114.156 -1.383 . . . . 0.0 112.259 170.808 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 85.2 mmm -96.11 -12.36 24.9 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 118.282 1.041 . . . . 0.0 112.227 171.471 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.7 mt . . . . . 0 CA--C 1.53 0.191 0 C-N-CA 125.435 1.494 . . . . 0.0 108.642 -169.748 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 5.3 mp . . . . . 0 CA--C 1.539 0.549 0 CA-C-O 121.202 0.525 . . . . 0.0 111.617 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -60.54 -20.23 59.7 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.287 -0.883 . . . . 0.0 111.855 171.157 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.71 -29.46 61.4 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.407 1.003 . . . . 0.0 112.495 170.632 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.81 -33.7 34.55 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.978 1.389 . . . . 0.0 111.429 172.757 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.8 mm -60.05 -53.87 42.62 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-O 122.277 1.037 . . . . 0.0 109.695 174.98 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.67 -51.99 61.41 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 127.753 2.421 . . . . 0.0 109.767 170.841 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.7 -36.69 49.57 Favored Glycine 0 CA--C 1.534 1.259 0 CA-C-N 118.422 0.555 . . . . 0.0 113.133 177.136 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -77.54 -14.99 59.53 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.739 0.816 . . . . 0.0 113.093 177.9 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mt -82.93 -38.96 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 119.904 1.229 . . . . 0.0 109.496 164.088 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -65.21 -64.15 0.93 Allowed 'General case' 0 CA--C 1.521 -0.152 0 C-N-CA 125.908 1.683 . . . . 0.0 108.204 -173.879 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -79.69 2.51 22.42 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 118.148 0.431 . . . . 0.0 111.461 169.189 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.96 -57.02 12.98 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 162.461 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.6 t90 -68.99 -56.58 7.36 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 171.255 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -78.48 41.84 0.41 Allowed 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.059 0.944 . . . . 0.0 110.878 -177.548 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.67 41.87 2.99 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.548 2.023 . . . . 0.0 109.034 162.49 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.4 tmm? 57.46 29.05 16.4 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.568 1.947 . . . . 0.0 113.133 -174.858 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 70.0 mt . . . . . 0 N--CA 1.467 0.389 0 O-C-N 121.459 -0.775 . . . . 0.0 109.242 169.768 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.1 mt . . . . . 0 N--CA 1.468 0.432 0 CA-C-O 121.364 0.602 . . . . 0.0 112.167 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -66.06 -19.62 65.91 Favored 'General case' 0 CA--C 1.537 0.456 0 O-C-N 121.023 -1.048 . . . . 0.0 112.435 179.473 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.34 -21.54 54.1 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 124.742 1.163 . . . . 0.0 112.852 167.136 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.49 -53.02 4.38 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.904 1.352 . . . . 0.0 110.307 164.719 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.1 mm -62.95 -20.8 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -166.427 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -133.6 -47.51 0.82 Allowed 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 125.932 1.693 . . . . 0.0 110.635 170.488 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.87 -31.84 65.21 Favored Glycine 0 CA--C 1.531 1.064 0 CA-C-O 119.333 -0.704 . . . . 0.0 113.935 -168.301 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 t80 -70.48 -33.08 70.84 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.278 1.039 . . . . 0.0 111.567 175.808 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.89 -21.54 22.49 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 124.605 1.162 . . . . 0.0 109.795 177.6 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -92.84 -63.32 1.24 Allowed 'General case' 0 C--O 1.231 0.094 0 C-N-CA 125.255 1.422 . . . . 0.0 107.22 -174.551 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -65.62 -27.81 68.67 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.837 0.855 . . . . 0.0 111.058 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.6 -18.21 66.6 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.904 -0.942 . . . . 0.0 112.311 177.042 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.495 ' HA ' HD12 ' A' ' 18' ' ' ILE . 12.2 t90 -80.77 -67.49 0.77 Allowed 'General case' 0 C--O 1.237 0.403 0 CA-C-N 118.481 1.141 . . . . 0.0 108.229 168.605 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -84.57 23.36 1.15 Allowed 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 121.374 0.607 . . . . 0.0 112.599 -162.828 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.88 -32.45 12.8 Favored Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.477 1.037 . . . . 0.0 111.614 175.096 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.7 mmt -151.14 -33.63 0.15 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -176.019 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.495 HD12 ' HA ' ' A' ' 14' ' ' TRP . 45.8 mt . . . . . 0 N--CA 1.466 0.373 0 C-N-CA 124.3 1.04 . . . . 0.0 112.189 -158.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -67.29 165.78 15.63 Favored 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 138.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -106.19 -10.74 16.32 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.94 -48.04 58.55 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.846 0.736 . . . . 0.0 112.621 -171.023 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -19.85 58.76 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.353 1.461 . . . . 0.0 112.76 178.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.8 mm -74.67 -8.57 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 C-N-CA 124.41 1.084 . . . . 0.0 110.884 177.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.09 -44.33 4.19 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 127.154 2.182 . . . . 0.0 109.694 160.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.03 -39.22 89.27 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 119.029 0.831 . . . . 0.0 113.264 -173.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -69.62 -26.62 64.52 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 118.164 0.982 . . . . 0.0 112.038 176.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mm -75.76 -35.54 31.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 C-N-CA 123.686 0.795 . . . . 0.0 108.901 178.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -78.79 -49.2 13.4 Favored 'General case' 0 CA--C 1.519 -0.231 0 C-N-CA 125.815 1.646 . . . . 0.0 108.158 -174.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -63.65 -14.69 54.25 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.788 0.435 . . . . 0.0 111.27 167.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.63 -55.51 4.55 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 172.105 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -62.54 -58.81 6.23 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 125.979 1.712 . . . . 0.0 109.711 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -80.39 23.59 0.49 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.009 0.924 . . . . 0.0 111.759 176.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.5 -19.76 31.48 Favored Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.799 1.19 . . . . 0.0 111.085 159.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 ptt? -162.81 60.62 0.2 Allowed 'General case' 0 C--N 1.346 0.429 0 CA-C-N 118.943 1.372 . . . . 0.0 112.007 -176.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt -70.88 -67.77 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 158.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -61.43 143.63 55.52 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 171.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.26 0 C-N-CA 125.476 1.513 . . . . 0.0 114.071 -175.488 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.477 0.895 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -65.53 154.75 37.76 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 118.391 0.541 . . . . 0.0 109.633 177.194 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -63.36 -20.65 65.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -175.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.19 -30.31 57.66 Favored Glycine 0 CA--C 1.532 1.113 0 CA-C-O 118.999 -0.889 . . . . 0.0 112.463 172.707 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.98 -32.24 25.09 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 119.118 1.459 . . . . 0.0 111.378 172.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.2 mm -65.87 -28.83 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 123.829 0.851 . . . . 0.0 111.934 178.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -81.55 -53.65 6.09 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 127.675 2.39 . . . . 0.0 110.139 165.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.82 -41.84 36.5 Favored Glycine 0 C--N 1.342 0.881 0 C-N-CA 125.668 1.604 . . . . 0.0 112.928 -173.401 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -75.53 -16.85 60.23 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.144 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.6 mt -81.4 -45.71 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.696 0.799 . . . . 0.0 108.896 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -82.46 -38.48 23.88 Favored 'General case' 0 CA--C 1.527 0.07 0 CA-C-O 118.194 -0.908 . . . . 0.0 111.082 -167.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -87.02 1.73 51.91 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.309 0.959 . . . . 0.0 111.059 162.068 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.78 -45.87 56.1 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 159.156 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.404 ' HA ' HD12 ' A' ' 18' ' ' ILE . 0.3 OUTLIER -63.4 -64.9 0.77 Allowed 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 167.972 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -81.5 57.45 3.3 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.537 1.535 . . . . 0.0 108.544 -173.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -136.77 -42.48 0.1 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 126.886 2.184 . . . . 0.0 110.443 176.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -145.67 -6.81 0.6 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 115.307 1.595 . . . . 0.0 115.307 -179.082 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.404 HD12 ' HA ' ' A' ' 14' ' ' TRP . 11.8 mt -66.82 -53.98 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 119.751 1.16 . . . . 0.0 111.562 -175.145 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -157.83 164.98 36.44 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 -172.567 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 1.495 0 C-N-CA 127.731 2.586 . . . . 0.0 112.448 170.195 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.2 m . . . . . 0 N--CA 1.476 0.837 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mp -136.35 144.09 44.43 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 174.565 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -66.59 -23.8 66.25 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 -170.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -27.24 61.23 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.112 0.863 . . . . 0.0 112.83 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.71 -44.44 20.79 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 118.779 1.29 . . . . 0.0 110.385 172.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.0 mt -60.22 -38.66 78.13 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 C-N-CA 125.671 1.588 . . . . 0.0 111.785 -176.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -74.03 -58.69 3.13 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 127.613 2.365 . . . . 0.0 109.881 168.328 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -32.82 59.94 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 123.978 0.799 . . . . 0.0 113.883 -166.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.1 t80 -67.64 -36.84 81.52 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.193 0.997 . . . . 0.0 111.772 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.2 mt -71.0 -33.65 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 C-N-CA 124.363 1.065 . . . . 0.0 109.597 177.223 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -80.3 -50.48 10.12 Favored 'General case' 0 C--N 1.333 -0.149 0 C-N-CA 125.312 1.445 . . . . 0.0 108.179 -170.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -66.05 -19.15 65.76 Favored 'General case' 0 C--N 1.342 0.274 0 CA-C-O 119.394 -0.336 . . . . 0.0 110.691 168.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.08 -50.79 16.25 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 173.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.7 t90 -64.26 -61.32 2.32 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 125.051 1.34 . . . . 0.0 109.167 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -88.94 23.38 2.39 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.786 0.803 . . . . 0.0 111.53 -169.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.07 -13.33 34.05 Favored Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.338 1.447 . . . . 0.0 111.488 171.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.9 ttm -146.67 -34.94 0.27 Allowed 'General case' 0 C--N 1.341 0.238 0 CA-C-N 118.253 1.026 . . . . 0.0 113.724 -177.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.6 mt -95.87 -85.29 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -162.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -75.82 144.51 41.26 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -175.205 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.559 0 CA-C-O 118.341 -1.255 . . . . 0.0 114.134 -165.256 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 19.1 m . . . . . 0 N--CA 1.476 0.849 0 CA-C-O 116.604 -1.665 . . . . 0.0 107.397 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.8 mp 63.95 170.61 0.17 Allowed 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 126.346 1.859 . . . . 0.0 111.431 -171.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -59.58 -26.46 65.44 Favored 'General case' 0 N--CA 1.463 0.193 0 O-C-N 121.678 -0.639 . . . . 0.0 111.934 -178.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.55 -26.18 66.22 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 125.285 1.422 . . . . 0.0 112.728 175.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.54 -62.63 1.45 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.37 1.085 . . . . 0.0 109.326 166.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 52.2 mt -61.07 -22.39 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 C-N-CA 126.345 1.858 . . . . 0.0 113.782 -160.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -132.42 -42.88 0.94 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 125.569 1.548 . . . . 0.0 111.028 172.274 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.94 -36.03 59.82 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 118.814 -0.992 . . . . 0.0 112.931 -175.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -77.35 -19.91 55.58 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 118.692 1.246 . . . . 0.0 112.583 176.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -82.29 -38.51 15.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.028 1.331 . . . . 0.0 108.755 174.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -73.18 -57.96 3.65 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 128.016 2.526 . . . . 0.0 107.593 -175.049 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -69.67 -7.76 41.84 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.045 0.538 . . . . 0.0 111.06 169.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.75 -59.42 4.07 Favored Glycine 0 C--N 1.34 0.777 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 169.039 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 18.8 t90 -60.27 -56.84 16.61 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 125.54 1.536 . . . . 0.0 109.739 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -85.03 23.65 1.2 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.632 0.773 . . . . 0.0 111.483 -177.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.94 9.82 11.26 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 127.886 2.66 . . . . 0.0 111.656 164.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.5 ptt? -129.93 -20.86 3.08 Favored 'General case' 0 C--N 1.344 0.367 0 CA-C-N 118.088 0.944 . . . . 0.0 113.491 164.064 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.0 mm -61.68 -29.4 46.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 123.617 0.767 . . . . 0.0 110.949 172.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -78.66 3.74 15.55 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 125.365 1.466 . . . . 0.0 113.12 174.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.043 0 C-N-CA 126.076 1.798 . . . . 0.0 113.783 -179.249 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 30.8 m . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 55.3 mt -131.13 165.01 24.23 Favored 'General case' 0 C--O 1.235 0.326 0 C-N-CA 125.704 1.601 . . . . 0.0 106.987 166.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -59.19 -26.06 64.49 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -174.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.12 -28.35 63.87 Favored Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.414 1.006 . . . . 0.0 112.778 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.26 -42.14 21.12 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 119.138 1.469 . . . . 0.0 110.516 171.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mt -59.22 -39.96 80.01 Favored 'Isoleucine or valine' 0 C--N 1.342 0.257 0 C-N-CA 124.823 1.249 . . . . 0.0 111.979 -176.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.55 -54.28 6.92 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 127.542 2.337 . . . . 0.0 110.116 169.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.58 -34.34 60.2 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 124.242 0.925 . . . . 0.0 113.642 -170.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -72.17 -23.17 61.24 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 118.407 1.103 . . . . 0.0 112.683 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -79.64 -38.84 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 124.323 1.049 . . . . 0.0 108.784 170.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.44 -55.36 7.15 Favored 'General case' 0 C--O 1.226 -0.17 0 C-N-CA 125.08 1.352 . . . . 0.0 109.052 -172.287 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -79.82 2.71 22.08 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.451 0.568 . . . . 0.0 111.595 167.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.79 -52.94 22.12 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 159.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -58.49 -63.37 1.3 Allowed 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.484 1.114 . . . . 0.0 108.592 169.259 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -80.66 56.91 2.78 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.154 2.182 . . . . 0.0 109.109 -176.127 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -173.29 -22.87 0.02 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.886 3.136 . . . . 0.0 110.794 178.343 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 33.5 mmt -93.39 -22.71 18.76 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 118.372 1.086 . . . . 0.0 112.569 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.2 mm -54.46 -42.6 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.557 1.143 . . . . 0.0 110.745 173.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -98.32 4.37 48.66 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 127.324 2.25 . . . . 0.0 112.614 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.799 0 C-N-CA 125.185 1.374 . . . . 0.0 110.761 176.137 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.475 0.819 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.6 mp -140.06 154.11 46.98 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 176.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 28.8 t80 -71.49 -12.59 61.46 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 176.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.79 -24.6 54.07 Favored Glycine 0 CA--C 1.533 1.188 0 C-N-CA 124.4 1.0 . . . . 0.0 113.523 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -78.31 -43.34 28.18 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.491 1.146 . . . . 0.0 110.83 171.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 18.6 mm -71.58 -9.33 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 126.07 1.748 . . . . 0.0 111.818 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.57 3.35 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 128.188 2.595 . . . . 0.0 109.484 168.144 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.66 -37.1 91.81 Favored Glycine 0 CA--C 1.529 0.92 0 CA-C-N 118.804 0.729 . . . . 0.0 112.8 -174.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 84.2 t80 -67.29 -25.63 66.13 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.638 0.719 . . . . 0.0 111.655 178.574 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 mm -66.47 -23.46 31.55 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-N 118.898 0.772 . . . . 0.0 109.9 177.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -104.82 -60.87 1.54 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 -172.588 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -64.25 -25.22 67.96 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 122.949 0.5 . . . . 0.0 112.304 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.85 0.77 86.04 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.078 174.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -127.44 -68.34 0.79 Allowed 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.78 1.632 . . . . 0.0 108.574 -176.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -74.16 23.79 0.08 Allowed 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.923 2.089 . . . . 0.0 112.394 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.24 -33.81 5.57 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 125.209 1.385 . . . . 0.0 111.367 162.286 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.1 mmm -153.65 64.76 0.73 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.825 1.313 . . . . 0.0 109.746 -173.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.7 mt -71.74 -54.59 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 166.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.8 t0 -80.24 155.56 27.28 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.808 0.813 . . . . 0.0 111.118 -174.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.271 0 C-N-CA 126.996 2.236 . . . . 0.0 112.11 169.899 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.477 0.919 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -113.14 153.42 28.29 Favored 'General case' 0 N--CA 1.462 0.148 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 171.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -77.39 -12.96 60.02 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 179.294 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.71 -42.0 58.31 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.369 0.985 . . . . 0.0 112.986 -170.589 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.74 -22.41 61.61 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.298 1.439 . . . . 0.0 112.719 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mm -74.35 -5.47 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 C-N-CA 124.645 1.178 . . . . 0.0 110.811 176.68 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.37 -42.11 3.98 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 126.608 1.963 . . . . 0.0 109.706 160.731 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.68 -39.51 91.28 Favored Glycine 0 C--N 1.342 0.909 0 CA-C-N 119.23 0.923 . . . . 0.0 112.87 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -75.62 -15.28 60.36 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 117.843 0.821 . . . . 0.0 112.69 177.074 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.8 mm -85.66 -37.76 12.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 124.699 1.2 . . . . 0.0 108.724 174.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -72.62 -55.75 6.38 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 126.568 1.947 . . . . 0.0 107.886 -177.05 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -69.29 -6.62 30.59 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.558 0.743 . . . . 0.0 111.247 168.561 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.97 -57.49 3.72 Favored Glycine 0 C--N 1.341 0.82 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 169.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -57.02 -57.01 14.43 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 126.536 1.934 . . . . 0.0 109.283 175.563 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -83.27 24.38 0.81 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 123.944 0.897 . . . . 0.0 111.612 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -121.47 6.87 10.58 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 127.324 2.392 . . . . 0.0 111.331 164.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.8 mmt -126.58 -36.11 2.29 Favored 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.215 1.406 . . . . 0.0 111.767 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm -61.6 -35.48 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 C-N-CA 124.887 1.275 . . . . 0.0 110.704 175.494 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -91.51 4.15 53.27 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 126.443 1.897 . . . . 0.0 112.353 177.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.922 0 C-N-CA 126.174 1.845 . . . . 0.0 115.185 -159.191 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 48.7 t . . . . . 0 N--CA 1.476 0.839 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.7 mp -139.06 154.06 48.14 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 172.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -77.9 -12.01 59.94 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 177.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.91 -28.96 61.35 Favored Glycine 0 CA--C 1.531 1.045 0 C-N-CA 124.033 0.825 . . . . 0.0 113.583 -174.055 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.8 -33.52 27.23 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 118.572 1.186 . . . . 0.0 111.512 173.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.0 mm -73.66 -10.26 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 126.052 1.741 . . . . 0.0 111.609 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.81 -48.82 3.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 127.321 2.248 . . . . 0.0 109.632 164.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.38 -36.05 82.01 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 119.034 0.833 . . . . 0.0 113.33 -172.635 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -66.79 -31.2 71.67 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.439 1.12 . . . . 0.0 111.618 175.487 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mm -73.99 -18.14 17.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 124.484 1.114 . . . . 0.0 109.977 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -97.7 -61.21 1.42 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 125.324 1.45 . . . . 0.0 107.337 -174.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -61.65 -30.99 71.08 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.527 0.731 . . . . 0.0 111.761 176.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.43 0.61 63.71 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.122 -0.821 . . . . 0.0 113.433 177.005 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 17.9 t90 -130.39 -69.65 0.65 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.943 1.297 . . . . 0.0 108.568 -174.203 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -78.51 23.43 0.31 Allowed 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.294 1.038 . . . . 0.0 112.043 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.02 -2.71 16.08 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 127.416 2.436 . . . . 0.0 112.106 166.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 61.0 mtt -134.09 -10.05 2.62 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.977 1.389 . . . . 0.0 113.382 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.2 mm -68.87 -27.07 34.25 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 C-N-CA 124.114 0.966 . . . . 0.0 111.957 177.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -70.14 109.3 4.54 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.972 0.805 . . . . 0.0 110.122 176.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.902 0 C-N-CA 125.447 1.499 . . . . 0.0 111.144 169.249 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 19.3 m . . . . . 0 N--CA 1.476 0.863 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.4 mt -139.07 160.15 40.47 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 125.442 1.497 . . . . 0.0 107.706 174.678 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -103.0 -9.47 19.77 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.624 0.601 . . . . 0.0 112.624 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.3 -30.73 64.89 Favored Glycine 0 CA--C 1.532 1.108 0 O-C-N 121.399 -0.813 . . . . 0.0 113.945 -170.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.75 30.08 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.855 1.262 . . . . 0.0 111.658 175.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.4 mm -75.46 -5.62 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.814 1.646 . . . . 0.0 111.099 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -110.02 -46.21 3.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.28 1.832 . . . . 0.0 109.922 160.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.37 -36.39 83.58 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 119.23 0.923 . . . . 0.0 113.274 -172.3 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -74.37 -20.08 60.21 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.755 0.778 . . . . 0.0 112.482 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -81.67 -34.5 12.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 124.288 1.035 . . . . 0.0 109.001 174.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -73.98 -56.09 5.36 Favored 'General case' 0 N--CA 1.457 -0.125 0 C-N-CA 125.813 1.645 . . . . 0.0 107.644 -176.105 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -63.13 -21.27 66.08 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 122.857 0.463 . . . . 0.0 111.0 168.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.73 -9.9 86.66 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-O 119.338 -0.701 . . . . 0.0 112.948 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -114.03 -58.1 2.19 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.916 1.286 . . . . 0.0 109.499 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.8 23.89 0.16 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.928 1.291 . . . . 0.0 112.691 -174.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.37 49.95 3.08 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.146 1.832 . . . . 0.0 111.87 178.352 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.4 mtm 58.53 73.93 0.46 Allowed 'General case' 0 C--N 1.341 0.214 0 C-N-CA 127.192 2.197 . . . . 0.0 110.468 -175.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 90.6 mt -52.53 -27.81 11.67 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.723 0 C-N-CA 126.892 2.077 . . . . 0.0 112.532 -179.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.8 t70 63.69 -168.45 0.2 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.613 1.565 . . . . 0.0 110.119 -166.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.172 0 C-N-CA 125.303 1.43 . . . . 0.0 113.679 178.975 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.9 m . . . . . 0 N--CA 1.477 0.904 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -127.57 154.52 45.1 Favored 'General case' 0 C--O 1.231 0.128 0 N-CA-C 106.63 -1.618 . . . . 0.0 106.63 169.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -88.62 -9.15 53.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 122.878 0.471 . . . . 0.0 112.134 177.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.61 -32.34 61.29 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 123.976 0.798 . . . . 0.0 114.09 -168.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.19 -28.34 27.4 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.434 1.093 . . . . 0.0 111.952 175.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.2 mm -74.88 -10.92 14.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 125.681 1.592 . . . . 0.0 111.244 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.66 -49.16 3.48 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 126.896 2.078 . . . . 0.0 109.55 162.26 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.0 -35.88 78.45 Favored Glycine 0 C--N 1.342 0.875 0 CA-C-N 118.988 0.813 . . . . 0.0 113.286 -170.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -70.78 -28.04 64.37 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.338 1.069 . . . . 0.0 112.038 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mm -72.49 -25.28 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 119.066 0.848 . . . . 0.0 109.487 176.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -92.71 -65.6 0.99 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.639 1.575 . . . . 0.0 107.029 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.13 -24.56 67.45 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.623 0.769 . . . . 0.0 110.764 179.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -77.38 -3.29 82.16 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 118.855 -0.97 . . . . 0.0 113.198 176.369 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.7 t90 -130.78 -74.66 0.53 Allowed 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 118.509 1.155 . . . . 0.0 108.984 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -79.75 23.71 0.42 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.679 1.192 . . . . 0.0 112.404 -172.354 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.27 -16.43 57.39 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 118.186 -1.341 . . . . 0.0 112.319 170.303 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 45.6 mmm -141.07 9.57 2.12 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 118.612 1.206 . . . . 0.0 113.037 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 5.3 mm -65.89 -28.98 45.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 O-C-N 120.898 -1.126 . . . . 0.0 112.217 -177.37 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 49.55 14.75 0.12 Allowed 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 129.049 2.94 . . . . 0.0 116.703 162.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.089 0 C-N-CA 125.35 1.452 . . . . 0.0 115.172 -170.153 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.6 m . . . . . 0 N--CA 1.478 0.939 0 CA-C-O 118.489 -0.767 . . . . 0.0 109.391 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.0 mm? 61.37 167.56 0.1 Allowed 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 127.222 2.209 . . . . 0.0 112.037 -170.155 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -60.17 -26.65 66.49 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.661 0.615 . . . . 0.0 112.661 -170.593 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -63.56 -24.13 67.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.859 1.218 . . . . 0.0 112.732 177.047 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.03 -61.8 1.51 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 118.126 0.963 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 56.9 mt -60.15 -21.95 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 126.398 1.879 . . . . 0.0 113.589 -161.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -131.26 -43.59 1.04 Allowed 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 125.953 1.701 . . . . 0.0 110.84 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.27 -34.35 59.02 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-N 119.067 0.849 . . . . 0.0 113.342 -177.407 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.0 t80 -75.62 -23.59 56.41 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.624 1.212 . . . . 0.0 112.231 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mm -80.11 -35.12 15.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 125.19 1.396 . . . . 0.0 109.144 175.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -73.69 -59.13 2.86 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 128.026 2.53 . . . . 0.0 106.833 -176.021 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -62.46 -19.13 63.21 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 119.224 -0.417 . . . . 0.0 111.291 170.266 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.13 -54.24 9.44 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 175.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -62.37 -57.2 12.19 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.53 1.532 . . . . 0.0 109.713 176.624 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 -80.22 23.41 0.48 Allowed 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.543 1.537 . . . . 0.0 112.857 -166.11 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.63 -5.66 10.97 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.753 2.121 . . . . 0.0 112.193 166.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 95.7 mmm -127.31 -2.91 6.26 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.714 1.257 . . . . 0.0 113.102 -174.127 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.0 mt -52.77 -47.74 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 C-N-CA 124.219 1.008 . . . . 0.0 110.579 -178.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -117.71 89.26 3.08 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 126.384 1.874 . . . . 0.0 106.124 174.052 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 0.381 0 N-CA-C 107.116 -2.394 . . . . 0.0 107.116 -173.011 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 N--CA 1.476 0.864 0 CA-C-O 118.675 -0.679 . . . . 0.0 109.295 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? 59.31 -179.02 0.08 Allowed 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 126.145 1.778 . . . . 0.0 112.52 179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.3 t80 -58.86 -25.76 63.59 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 123.679 0.792 . . . . 0.0 112.399 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.49 -15.06 51.99 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 125.323 1.439 . . . . 0.0 113.447 172.349 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -106.31 -55.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.527 1.163 . . . . 0.0 109.867 164.491 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 30.7 mt -61.95 -18.58 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 124.645 1.178 . . . . 0.0 113.677 -167.5 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -125.02 -43.47 1.97 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 125.697 1.599 . . . . 0.0 110.766 166.162 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.58 -34.89 78.08 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 119.417 1.008 . . . . 0.0 113.252 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.9 t80 -79.06 -10.69 59.9 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.622 1.211 . . . . 0.0 112.494 175.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.5 mm -87.66 -39.86 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 C-N-CA 124.798 1.239 . . . . 0.0 108.218 169.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -70.5 -59.96 2.54 Favored 'General case' 0 N--CA 1.457 -0.102 0 C-N-CA 126.6 1.96 . . . . 0.0 109.035 -176.57 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -74.01 -3.01 26.65 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.876 -0.515 . . . . 0.0 111.648 166.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.44 -10.26 74.82 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.495 0.589 . . . . 0.0 112.348 161.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -116.6 -64.22 1.34 Allowed 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 107.226 177.487 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -80.84 59.3 3.66 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-O 122.4 1.095 . . . . 0.0 109.49 172.366 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -145.25 13.66 1.86 Allowed Glycine 0 CA--C 1.534 1.225 0 C-N-CA 125.918 1.723 . . . . 0.0 111.765 161.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 25.6 ptt? -170.43 -18.84 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 128.386 2.675 . . . . 0.0 114.111 175.261 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 51.9 mt -100.78 -22.84 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 124.568 1.147 . . . . 0.0 110.338 -176.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -49.86 114.1 1.0 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 127.806 2.442 . . . . 0.0 109.598 164.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.721 0 N-CA-C 107.099 -2.4 . . . . 0.0 107.099 -162.714 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 61.1 t . . . . . 0 N--CA 1.476 0.855 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mp -140.3 157.52 45.44 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 174.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -62.79 -22.79 66.86 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.676 0.79 . . . . 0.0 112.003 172.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.47 -21.47 57.46 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 125.241 1.401 . . . . 0.0 112.895 171.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -85.65 -65.04 1.05 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 118.762 1.281 . . . . 0.0 108.766 163.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 29.1 mt -60.98 -24.5 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 125.509 1.523 . . . . 0.0 113.987 -161.108 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.44 -47.25 1.87 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 125.83 1.652 . . . . 0.0 110.542 172.531 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.56 -32.76 65.34 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.935 -0.925 . . . . 0.0 113.631 -172.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -76.37 -23.93 54.15 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 119.136 1.468 . . . . 0.0 112.108 175.073 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mm -71.08 -31.37 44.6 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 O-C-N 120.987 -1.07 . . . . 0.0 108.814 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -101.99 -49.8 3.84 Favored 'General case' 0 C--O 1.225 -0.188 0 C-N-CA 123.805 0.842 . . . . 0.0 110.386 -171.084 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 25.5 m-80 -86.45 -19.77 29.13 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.4 0.546 . . . . 0.0 111.234 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -96.45 -62.71 0.94 Allowed Glycine 0 C--N 1.34 0.79 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -175.647 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 23.5 t90 -80.23 -68.55 0.67 Allowed 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -79.54 23.45 0.41 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -167.592 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.69 -6.5 11.43 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 126.828 2.156 . . . . 0.0 112.729 170.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 59.1 mmm -130.19 20.59 5.32 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 118.964 1.382 . . . . 0.0 112.087 -172.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.5 mm -68.94 -27.38 35.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 C-N-CA 123.711 0.805 . . . . 0.0 111.216 -177.137 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 50.14 4.03 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 131.103 3.761 . . . . 0.0 117.846 169.045 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.009 0 C-N-CA 128.953 3.168 . . . . 0.0 112.695 178.17 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.478 0.935 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -122.96 158.93 29.38 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 170.326 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -61.49 -22.42 65.08 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.6 -26.22 56.78 Favored Glycine 0 CA--C 1.532 1.1 0 CA-C-O 118.926 -0.93 . . . . 0.0 112.903 172.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.74 -43.74 15.17 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 119.222 1.511 . . . . 0.0 110.356 171.588 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -64.1 -13.21 13.32 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 C-N-CA 126.653 1.981 . . . . 0.0 112.629 -177.651 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.39 -48.92 2.99 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 127.59 2.356 . . . . 0.0 110.204 170.412 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.29 -36.1 81.54 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-N 119.412 1.006 . . . . 0.0 113.082 -174.503 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -73.7 -18.8 60.96 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 118.031 0.916 . . . . 0.0 112.515 176.018 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -80.98 -39.02 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 CA-C-N 119.431 1.014 . . . . 0.0 108.299 172.263 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -69.81 -62.41 1.39 Allowed 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 126.598 1.959 . . . . 0.0 107.951 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -64.58 -16.97 63.51 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 119.415 -0.326 . . . . 0.0 111.165 169.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.89 -16.32 66.0 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.747 -1.03 . . . . 0.0 113.37 173.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -127.49 -44.96 1.51 Allowed 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.571 1.185 . . . . 0.0 111.807 174.438 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -81.13 23.64 0.57 Allowed 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 122.256 1.027 . . . . 0.0 112.164 -162.262 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.66 -10.94 42.39 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 125.603 1.573 . . . . 0.0 112.227 163.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.5 mmm -111.64 -9.85 14.13 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.851 1.325 . . . . 0.0 113.521 -169.179 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -85.51 -24.38 6.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 C-N-CA 124.055 0.942 . . . . 0.0 112.313 -171.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -70.96 151.02 45.11 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-O 122.151 0.977 . . . . 0.0 110.935 -178.447 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.051 0 C-N-CA 125.48 1.514 . . . . 0.0 111.8 166.065 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.4 m . . . . . 0 N--CA 1.477 0.899 0 CA-C-O 118.424 -0.798 . . . . 0.0 108.868 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 64.24 154.65 0.06 Allowed 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 127.342 2.257 . . . . 0.0 110.728 -161.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -84.43 -11.79 55.57 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -178.669 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.18 -32.57 63.48 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 123.817 0.722 . . . . 0.0 113.167 -174.393 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.07 -33.24 26.45 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.53 1.132 . . . . 0.0 111.629 174.279 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.1 mm -73.9 -9.1 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 125.644 1.578 . . . . 0.0 111.665 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.39 -50.45 3.22 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 127.479 2.312 . . . . 0.0 109.588 163.187 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.46 77.98 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 118.994 0.815 . . . . 0.0 113.281 -171.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -69.86 -28.11 65.39 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.198 0.999 . . . . 0.0 112.117 176.17 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mm -72.47 -25.67 23.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 CA-C-N 118.931 0.787 . . . . 0.0 109.429 176.226 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -92.91 -63.57 1.2 Allowed 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.225 1.41 . . . . 0.0 107.57 -170.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -68.39 -22.53 64.63 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.156 0.583 . . . . 0.0 110.872 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.94 -6.96 80.52 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.349 -0.695 . . . . 0.0 112.758 174.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.9 t90 -114.1 -76.05 0.59 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.228 1.411 . . . . 0.0 107.436 171.646 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.67 56.09 3.71 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 122.207 1.003 . . . . 0.0 110.971 -171.776 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.98 -7.97 37.37 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-O 118.659 -1.078 . . . . 0.0 111.73 159.245 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.0 mmt -148.97 3.05 0.6 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.054 1.341 . . . . 0.0 113.287 -169.127 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.7 mm -88.94 -46.87 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 120.163 1.347 . . . . 0.0 108.779 -170.38 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.2 t70 50.41 -143.85 0.56 Allowed 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 124.524 1.13 . . . . 0.0 109.854 -168.436 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.163 0 C-N-CA 126.034 1.778 . . . . 0.0 112.184 -169.309 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.7 p . . . . . 0 N--CA 1.477 0.892 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.9 mt -136.13 162.92 31.59 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 125.006 1.323 . . . . 0.0 108.231 176.372 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -65.92 -16.09 63.55 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 176.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.59 -23.5 58.47 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.701 1.143 . . . . 0.0 112.665 167.171 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.53 -58.31 2.79 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 118.891 1.346 . . . . 0.0 109.152 164.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.8 mm -64.3 -21.49 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -162.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -134.42 -44.75 0.76 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.941 1.696 . . . . 0.0 110.972 172.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.34 -42.57 74.61 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.992 0.815 . . . . 0.0 112.878 -173.721 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -77.62 -15.9 58.91 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 112.466 177.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.1 mm -71.1 -38.0 69.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 O-C-N 120.453 -1.404 . . . . 0.0 107.867 171.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -94.17 -55.71 3.1 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -167.325 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.0 m-80 -76.62 -20.06 57.14 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.141 0.576 . . . . 0.0 110.71 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.54 -63.88 0.79 Allowed Glycine 0 C--N 1.341 0.86 0 CA-C-O 118.387 -1.229 . . . . 0.0 111.45 -171.65 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -69.42 -64.06 0.95 Allowed 'General case' 0 C--N 1.341 0.22 0 CA-C-N 118.636 1.218 . . . . 0.0 108.336 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -80.34 23.14 0.51 Allowed 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.561 0.696 . . . . 0.0 112.522 -174.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -99.3 -58.41 0.91 Allowed Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.816 2.151 . . . . 0.0 108.739 162.321 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.7 ptm -65.06 -18.05 64.97 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 118.38 1.09 . . . . 0.0 113.555 -179.375 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.6 mm -57.55 -31.37 38.99 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 123.735 0.814 . . . . 0.0 110.633 169.185 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.7 t0 -79.47 63.27 4.02 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 119.365 0.984 . . . . 0.0 110.332 175.065 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.105 0 CA-C-O 118.715 -1.047 . . . . 0.0 114.225 170.769 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 22.1 m . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 117.67 -1.157 . . . . 0.0 108.097 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -64.29 154.71 34.38 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 119.529 1.058 . . . . 0.0 110.233 -177.658 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -62.34 -21.0 64.95 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -173.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.42 -28.73 55.98 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 119.04 -0.867 . . . . 0.0 112.673 173.255 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.31 -41.96 19.41 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 119.127 1.464 . . . . 0.0 110.654 172.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.6 mt -65.82 -10.57 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.486 1.914 . . . . 0.0 112.465 -177.592 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -114.04 -45.02 3.09 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 127.01 2.124 . . . . 0.0 110.824 168.154 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.93 -38.79 76.29 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.682 0.674 . . . . 0.0 112.837 -176.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -78.21 -11.46 59.93 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 117.789 0.794 . . . . 0.0 112.632 178.452 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 9.7 mm -86.7 -42.37 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-N 119.218 0.917 . . . . 0.0 108.782 176.397 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.7 pt-20 -78.53 -47.35 17.48 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 124.403 1.081 . . . . 0.0 108.706 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -74.16 -13.04 60.75 Favored 'General case' 0 C--N 1.344 0.361 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 170.365 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.95 -53.51 9.35 Favored Glycine 0 C--N 1.342 0.861 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 171.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.536 ' HA ' HD12 ' A' ' 18' ' ' ILE . 22.7 t90 -67.26 -62.65 1.32 Allowed 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 123.381 0.673 . . . . 0.0 109.275 178.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -90.76 23.35 3.14 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.431 0.634 . . . . 0.0 111.511 -165.866 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.13 -27.04 26.9 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.551 1.072 . . . . 0.0 111.339 171.157 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.4 ptm -159.21 -10.71 0.06 Allowed 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 -178.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.536 HD12 ' HA ' ' A' ' 14' ' ' TRP . 58.6 mt -92.21 -44.3 14.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 119.765 1.166 . . . . 0.0 111.647 -159.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -72.29 148.89 44.98 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.453 0.57 . . . . 0.0 111.316 -174.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.914 0 C-N-CA 124.966 1.269 . . . . 0.0 113.17 -176.471 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.438 HG13 ' H ' ' A' ' 2' ' ' LEU 0.284 12.5 p . . . . . 0 N--CA 1.475 0.818 0 CA-C-O 116.348 -1.786 . . . . 0.0 107.577 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.438 ' H ' HG13 ' A' ' 1' ' ' VAL . 2.8 mm? 62.03 174.26 0.13 Allowed 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 126.885 2.074 . . . . 0.0 111.01 -170.467 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.32 -19.96 65.79 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 121.129 -0.982 . . . . 0.0 112.154 178.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -23.14 54.96 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 125.109 1.338 . . . . 0.0 112.906 167.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.37 -47.83 6.7 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.869 1.334 . . . . 0.0 110.693 167.141 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.8 mm -64.24 -24.47 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.138 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.92 -44.79 0.58 Allowed 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 125.908 1.683 . . . . 0.0 111.092 175.177 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.8 -37.63 70.13 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-N 119.035 0.834 . . . . 0.0 113.315 -169.521 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -67.32 -32.1 72.83 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 124.22 1.008 . . . . 0.0 111.832 176.683 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mt -74.52 -29.06 23.13 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 C-N-CA 124.041 0.937 . . . . 0.0 109.351 175.283 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -81.58 -57.72 3.34 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 125.492 1.517 . . . . 0.0 108.366 -174.508 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.4 p30 -65.78 -18.42 65.32 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.561 0.619 . . . . 0.0 111.655 170.716 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.75 -2.57 76.77 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.369 -0.684 . . . . 0.0 113.114 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.4 t90 -128.26 -68.37 0.77 Allowed 'General case' 0 C--O 1.234 0.239 0 C-N-CA 125.534 1.534 . . . . 0.0 109.127 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -77.36 23.71 0.2 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.595 1.558 . . . . 0.0 112.359 -176.091 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.58 -1.73 15.27 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 126.977 2.227 . . . . 0.0 112.112 167.618 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 78.9 mtm -134.93 -9.43 2.34 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 119.035 1.417 . . . . 0.0 114.142 -178.034 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.3 mm -61.41 -33.91 58.9 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 CA-C-N 119.209 0.913 . . . . 0.0 110.402 170.151 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -108.44 89.72 3.08 Favored 'General case' 0 C--N 1.339 0.124 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 159.23 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.003 0 C-N-CA 125.16 1.362 . . . . 0.0 112.331 -178.267 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? 59.35 168.44 0.07 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 127.047 2.139 . . . . 0.0 112.504 -169.64 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -62.55 -23.66 67.11 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -173.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.98 -29.84 59.66 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.217 0.913 . . . . 0.0 112.501 173.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.82 -35.07 22.55 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.877 1.339 . . . . 0.0 111.259 172.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.2 mm -62.91 -33.63 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 123.69 0.796 . . . . 0.0 111.908 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.41 -61.69 1.87 Allowed 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 127.307 2.243 . . . . 0.0 109.484 165.098 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.75 -32.99 66.51 Favored Glycine 0 C--N 1.341 0.83 0 C-N-CA 123.811 0.72 . . . . 0.0 114.003 -164.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -69.02 -31.05 69.58 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.254 1.027 . . . . 0.0 112.029 178.47 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.9 mt -73.2 -35.19 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 123.945 0.898 . . . . 0.0 109.26 174.472 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -78.89 -55.55 5.07 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 125.128 1.371 . . . . 0.0 108.226 -170.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.33 -20.96 66.63 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 122.803 0.441 . . . . 0.0 110.122 171.205 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.18 -57.23 8.74 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.2 t90 -62.29 -60.92 2.88 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.609 1.164 . . . . 0.0 109.046 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -85.61 23.71 1.34 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.384 0.673 . . . . 0.0 111.962 -169.274 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -122.76 -14.94 4.09 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 126.54 2.019 . . . . 0.0 112.098 165.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 26.4 mmt -112.0 -12.0 13.78 Favored 'General case' 0 C--N 1.343 0.316 0 CA-C-N 118.732 1.266 . . . . 0.0 112.246 178.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.1 mm -63.03 -63.14 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 158.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -153.61 176.92 11.52 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 126.414 1.886 . . . . 0.0 107.015 -170.621 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.047 0 C-N-CA 126.71 2.1 . . . . 0.0 112.878 179.227 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.474 0.743 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -61.77 155.27 23.38 Favored 'General case' 0 C--O 1.24 0.569 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 152.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -68.27 -19.36 64.71 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -174.47 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.59 -25.04 57.8 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 124.236 0.922 . . . . 0.0 112.939 176.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.51 -36.84 52.16 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.631 1.215 . . . . 0.0 110.909 172.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.3 mm -65.97 -51.39 61.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-O 122.339 1.066 . . . . 0.0 109.815 179.693 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.34 -52.88 60.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 112.35 -2.204 . . . . 0.0 109.495 169.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.84 -33.25 56.04 Favored Glycine 0 CA--C 1.53 0.976 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.949 -178.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -72.05 -28.11 63.13 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 118.464 1.132 . . . . 0.0 112.465 176.604 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -74.52 -37.17 43.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-N 119.484 1.038 . . . . 0.0 109.433 170.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -74.22 -56.07 5.32 Favored 'General case' 0 C--N 1.334 -0.105 0 C-N-CA 125.135 1.374 . . . . 0.0 108.646 -172.024 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.59 -7.52 33.52 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.103 0.561 . . . . 0.0 110.729 168.147 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.73 -54.35 7.44 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 168.36 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.09 -56.33 23.47 Favored 'General case' 0 C--O 1.233 0.19 0 C-N-CA 125.409 1.484 . . . . 0.0 108.221 173.782 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -81.9 23.33 0.7 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.212 -0.93 . . . . 0.0 112.13 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.25 -21.84 69.36 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 166.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.5 ttt -145.45 -36.15 0.29 Allowed 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.3 mm -74.98 -65.34 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.968 0.413 . . . . 0.0 110.336 -159.095 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -82.85 4.2 26.49 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 -165.852 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.296 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 158.803 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.0 t . . . . . 0 N--CA 1.477 0.876 0 CA-C-O 116.715 -1.612 . . . . 0.0 106.727 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 58.34 173.48 0.06 Allowed 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 125.924 1.69 . . . . 0.0 110.303 -157.075 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -114.52 -12.9 12.23 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -176.505 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.26 -34.72 81.43 Favored Glycine 0 CA--C 1.529 0.967 0 C-N-CA 123.533 0.587 . . . . 0.0 112.922 -174.381 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.25 -30.29 34.15 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.96 0.904 . . . . 0.0 111.659 174.573 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.1 mm -67.71 -39.34 81.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 C-N-CA 123.901 0.881 . . . . 0.0 110.793 -178.878 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.97 -56.76 7.8 Favored 'General case' 0 C--N 1.319 -0.761 0 C-N-CA 127.233 2.213 . . . . 0.0 109.687 164.692 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.53 -33.01 65.58 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.703 -169.271 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -67.4 -27.63 67.24 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.395 1.097 . . . . 0.0 111.989 178.04 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.87 -36.0 62.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 O-C-N 121.527 -0.733 . . . . 0.0 109.179 171.559 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.24 -58.9 2.99 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.354 1.461 . . . . 0.0 108.128 -168.808 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -68.51 -12.76 61.69 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.87 -0.586 . . . . 0.0 112.069 171.988 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.66 -56.82 5.27 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 169.708 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.2 t90 -65.24 -61.34 2.19 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.513 1.125 . . . . 0.0 109.42 -178.415 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -86.69 23.7 1.62 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-O 121.363 0.601 . . . . 0.0 111.469 -172.412 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.38 -38.15 6.79 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.724 1.154 . . . . 0.0 111.21 173.135 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 91.1 mmm -143.33 -9.51 0.75 Allowed 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.804 1.409 . . . . 0.0 114.804 -173.352 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.1 mt -104.74 -56.8 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 119.691 1.132 . . . . 0.0 111.54 -161.558 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.63 178.47 4.84 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 114.762 1.393 . . . . 0.0 114.762 -158.51 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.216 0 C-N-CA 125.096 1.331 . . . . 0.0 114.604 178.037 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 N--CA 1.477 0.915 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -125.84 159.28 32.88 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 172.632 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -61.61 -24.68 66.85 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 112.776 0.658 . . . . 0.0 112.776 -178.201 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.8 -26.72 60.77 Favored Glycine 0 CA--C 1.533 1.176 0 C-N-CA 124.179 0.895 . . . . 0.0 112.814 173.64 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.11 -34.75 37.63 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 118.95 1.375 . . . . 0.0 110.864 173.292 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.6 mm -63.14 -53.57 44.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-O 122.484 1.135 . . . . 0.0 109.694 177.227 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -51.17 -55.24 18.93 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 112.273 -2.24 . . . . 0.0 108.994 169.134 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.38 -33.97 33.05 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.09 0.853 . . . . 0.0 113.249 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -72.62 -39.91 66.88 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.439 1.12 . . . . 0.0 111.892 177.985 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 mt -65.65 -35.29 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 119.164 0.893 . . . . 0.0 109.955 171.55 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -79.57 -55.54 4.95 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 125.59 1.556 . . . . 0.0 108.781 -166.878 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -71.29 -13.28 61.84 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.759 169.591 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.51 -51.16 54.65 Favored Glycine 0 C--N 1.343 0.951 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 169.76 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.2 t90 -65.57 -62.05 1.74 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 124.038 0.935 . . . . 0.0 109.308 173.355 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.42 23.54 0.39 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.385 1.474 . . . . 0.0 112.929 -168.331 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.96 2.09 5.53 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 127.399 2.428 . . . . 0.0 111.922 171.022 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 56.9 mtt -137.47 0.76 2.31 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 118.947 1.373 . . . . 0.0 113.431 -175.465 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.0 mt -59.1 -47.72 89.14 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 119.65 1.114 . . . . 0.0 110.829 -177.187 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.4 t0 27.32 80.86 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 128.831 2.852 . . . . 0.0 114.875 -167.316 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.458 0 CA-C-O 118.064 -1.409 . . . . 0.0 114.79 171.52 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 52.8 t . . . . . 0 N--CA 1.473 0.717 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.3 mm? 59.77 170.38 0.08 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 127.317 2.247 . . . . 0.0 113.062 -169.031 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -63.41 -22.83 67.12 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -174.232 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.4 -28.62 62.28 Favored Glycine 0 CA--C 1.532 1.121 0 C-N-CA 124.103 0.859 . . . . 0.0 112.518 173.757 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.56 -30.82 29.39 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 118.847 1.324 . . . . 0.0 111.465 173.653 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.0 mm -62.59 -51.63 69.82 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-O 122.219 1.009 . . . . 0.0 109.756 175.68 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.81 -53.9 49.24 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 127.299 2.239 . . . . 0.0 109.485 169.24 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.29 -35.4 42.96 Favored Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.024 0.821 . . . . 0.0 113.059 -179.838 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 90.8 t80 -74.9 -22.65 58.5 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.011 0.906 . . . . 0.0 112.725 178.611 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -76.06 -41.23 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-N 119.577 1.08 . . . . 0.0 109.175 165.647 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -72.66 -55.15 7.26 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 125.042 1.337 . . . . 0.0 109.37 -167.597 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -80.54 -2.98 48.45 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 118.217 0.462 . . . . 0.0 111.258 167.901 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.43 -54.86 31.07 Favored Glycine 0 C--N 1.34 0.764 0 N-CA-C 109.035 -1.626 . . . . 0.0 109.035 162.846 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.1 t90 -64.1 -64.99 0.74 Allowed 'General case' 0 C--O 1.237 0.429 0 C-N-CA 123.776 0.83 . . . . 0.0 108.847 171.617 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -89.68 60.77 5.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 122.689 1.233 . . . . 0.0 108.937 -170.44 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.78 -32.05 0.02 OUTLIER Glycine 0 CA--C 1.524 0.642 0 CA-C-N 114.156 -1.383 . . . . 0.0 112.259 170.808 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 85.2 mmm -96.11 -12.36 24.9 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 118.282 1.041 . . . . 0.0 112.227 171.471 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.7 mt -135.06 -63.14 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.435 1.494 . . . . 0.0 108.642 -169.748 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 62.39 144.38 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.881 2.473 . . . . 0.0 113.209 -167.027 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.244 0 N-CA-C 116.52 1.368 . . . . 0.0 116.52 -179.041 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 N--CA 1.477 0.918 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 5.3 mp 59.34 -177.7 0.09 Allowed 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 125.492 1.517 . . . . 0.0 111.617 -174.595 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -60.54 -20.23 59.7 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.287 -0.883 . . . . 0.0 111.855 171.157 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.71 -29.46 61.4 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.407 1.003 . . . . 0.0 112.495 170.632 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.81 -33.7 34.55 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.978 1.389 . . . . 0.0 111.429 172.757 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.8 mm -60.05 -53.87 42.62 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-O 122.277 1.037 . . . . 0.0 109.695 174.98 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.67 -51.99 61.41 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 127.753 2.421 . . . . 0.0 109.767 170.841 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.7 -36.69 49.57 Favored Glycine 0 CA--C 1.534 1.259 0 CA-C-N 118.422 0.555 . . . . 0.0 113.133 177.136 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -77.54 -14.99 59.53 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.739 0.816 . . . . 0.0 113.093 177.9 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mt -82.93 -38.96 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 119.904 1.229 . . . . 0.0 109.496 164.088 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -65.21 -64.15 0.93 Allowed 'General case' 0 CA--C 1.521 -0.152 0 C-N-CA 125.908 1.683 . . . . 0.0 108.204 -173.879 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -79.69 2.51 22.42 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 118.148 0.431 . . . . 0.0 111.461 169.189 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.96 -57.02 12.98 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 162.461 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.6 t90 -68.99 -56.58 7.36 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 171.255 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -78.48 41.84 0.41 Allowed 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.059 0.944 . . . . 0.0 110.878 -177.548 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.67 41.87 2.99 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.548 2.023 . . . . 0.0 109.034 162.49 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.4 tmm? 57.46 29.05 16.4 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.568 1.947 . . . . 0.0 113.133 -174.858 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 70.0 mt -68.74 -51.2 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 O-C-N 121.459 -0.775 . . . . 0.0 109.242 169.768 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -57.87 151.72 17.44 Favored 'General case' 0 C--N 1.342 0.252 0 C-N-CA 123.565 0.746 . . . . 0.0 112.928 -169.272 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.336 0.559 0 C-N-CA 125.329 1.443 . . . . 0.0 110.716 174.265 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.1 mt 59.6 173.52 0.08 Allowed 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 126.084 1.754 . . . . 0.0 112.167 -168.815 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -66.06 -19.62 65.91 Favored 'General case' 0 CA--C 1.537 0.456 0 O-C-N 121.023 -1.048 . . . . 0.0 112.435 179.473 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.34 -21.54 54.1 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 124.742 1.163 . . . . 0.0 112.852 167.136 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.49 -53.02 4.38 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.904 1.352 . . . . 0.0 110.307 164.719 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.1 mm -62.95 -20.8 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -166.427 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -133.6 -47.51 0.82 Allowed 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 125.932 1.693 . . . . 0.0 110.635 170.488 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.87 -31.84 65.21 Favored Glycine 0 CA--C 1.531 1.064 0 CA-C-O 119.333 -0.704 . . . . 0.0 113.935 -168.301 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 t80 -70.48 -33.08 70.84 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.278 1.039 . . . . 0.0 111.567 175.808 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.89 -21.54 22.49 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 124.605 1.162 . . . . 0.0 109.795 177.6 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -92.84 -63.32 1.24 Allowed 'General case' 0 C--O 1.231 0.094 0 C-N-CA 125.255 1.422 . . . . 0.0 107.22 -174.551 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -65.62 -27.81 68.67 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.837 0.855 . . . . 0.0 111.058 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.6 -18.21 66.6 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.904 -0.942 . . . . 0.0 112.311 177.042 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.495 ' HA ' HD12 ' A' ' 18' ' ' ILE . 12.2 t90 -80.77 -67.49 0.77 Allowed 'General case' 0 C--O 1.237 0.403 0 CA-C-N 118.481 1.141 . . . . 0.0 108.229 168.605 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -84.57 23.36 1.15 Allowed 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 121.374 0.607 . . . . 0.0 112.599 -162.828 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.88 -32.45 12.8 Favored Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.477 1.037 . . . . 0.0 111.614 175.096 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.7 mmt -151.14 -33.63 0.15 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -176.019 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.495 HD12 ' HA ' ' A' ' 14' ' ' TRP . 45.8 mt -58.1 -45.17 88.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 C-N-CA 124.3 1.04 . . . . 0.0 112.189 -158.68 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -97.06 3.87 51.63 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.298 0.639 . . . . 0.0 111.636 -177.974 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.922 0 C-N-CA 127.573 2.511 . . . . 0.0 114.847 -162.519 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.8 mm? . . . . . 0 CA--C 1.538 0.509 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -106.19 -10.74 16.32 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.94 -48.04 58.55 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.846 0.736 . . . . 0.0 112.621 -171.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -19.85 58.76 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.353 1.461 . . . . 0.0 112.76 178.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.8 mm -74.67 -8.57 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 C-N-CA 124.41 1.084 . . . . 0.0 110.884 177.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.09 -44.33 4.19 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 127.154 2.182 . . . . 0.0 109.694 160.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.03 -39.22 89.27 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 119.029 0.831 . . . . 0.0 113.264 -173.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -69.62 -26.62 64.52 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 118.164 0.982 . . . . 0.0 112.038 176.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mm -75.76 -35.54 31.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 C-N-CA 123.686 0.795 . . . . 0.0 108.901 178.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -78.79 -49.2 13.4 Favored 'General case' 0 CA--C 1.519 -0.231 0 C-N-CA 125.815 1.646 . . . . 0.0 108.158 -174.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -63.65 -14.69 54.25 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.788 0.435 . . . . 0.0 111.27 167.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.63 -55.51 4.55 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 172.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -62.54 -58.81 6.23 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 125.979 1.712 . . . . 0.0 109.711 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -80.39 23.59 0.49 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.009 0.924 . . . . 0.0 111.759 176.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.5 -19.76 31.48 Favored Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.799 1.19 . . . . 0.0 111.085 159.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 ptt? -162.81 60.62 0.2 Allowed 'General case' 0 C--N 1.346 0.429 0 CA-C-N 118.943 1.372 . . . . 0.0 112.007 -176.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt . . . . . 0 N--CA 1.464 0.226 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 158.876 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.0 mm? . . . . . 0 C--O 1.235 0.321 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -63.36 -20.65 65.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -175.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.19 -30.31 57.66 Favored Glycine 0 CA--C 1.532 1.113 0 CA-C-O 118.999 -0.889 . . . . 0.0 112.463 172.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.98 -32.24 25.09 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 119.118 1.459 . . . . 0.0 111.378 172.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.2 mm -65.87 -28.83 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 123.829 0.851 . . . . 0.0 111.934 178.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -81.55 -53.65 6.09 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 127.675 2.39 . . . . 0.0 110.139 165.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.82 -41.84 36.5 Favored Glycine 0 C--N 1.342 0.881 0 C-N-CA 125.668 1.604 . . . . 0.0 112.928 -173.401 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -75.53 -16.85 60.23 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.6 mt -81.4 -45.71 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.696 0.799 . . . . 0.0 108.896 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -82.46 -38.48 23.88 Favored 'General case' 0 CA--C 1.527 0.07 0 CA-C-O 118.194 -0.908 . . . . 0.0 111.082 -167.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -87.02 1.73 51.91 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.309 0.959 . . . . 0.0 111.059 162.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.78 -45.87 56.1 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 159.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.404 ' HA ' HD12 ' A' ' 18' ' ' ILE . 0.3 OUTLIER -63.4 -64.9 0.77 Allowed 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 167.972 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -81.5 57.45 3.3 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.537 1.535 . . . . 0.0 108.544 -173.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -136.77 -42.48 0.1 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 126.886 2.184 . . . . 0.0 110.443 176.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -145.67 -6.81 0.6 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 115.307 1.595 . . . . 0.0 115.307 -179.082 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.404 HD12 ' HA ' ' A' ' 14' ' ' TRP . 11.8 mt . . . . . 0 N--CA 1.469 0.476 0 CA-C-N 119.751 1.16 . . . . 0.0 111.562 -175.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mp . . . . . 0 C--O 1.234 0.252 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -66.59 -23.8 66.25 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 -170.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -27.24 61.23 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.112 0.863 . . . . 0.0 112.83 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.71 -44.44 20.79 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 118.779 1.29 . . . . 0.0 110.385 172.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.0 mt -60.22 -38.66 78.13 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 C-N-CA 125.671 1.588 . . . . 0.0 111.785 -176.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -74.03 -58.69 3.13 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 127.613 2.365 . . . . 0.0 109.881 168.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -32.82 59.94 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 123.978 0.799 . . . . 0.0 113.883 -166.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.1 t80 -67.64 -36.84 81.52 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.193 0.997 . . . . 0.0 111.772 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.2 mt -71.0 -33.65 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 C-N-CA 124.363 1.065 . . . . 0.0 109.597 177.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -80.3 -50.48 10.12 Favored 'General case' 0 C--N 1.333 -0.149 0 C-N-CA 125.312 1.445 . . . . 0.0 108.179 -170.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -66.05 -19.15 65.76 Favored 'General case' 0 C--N 1.342 0.274 0 CA-C-O 119.394 -0.336 . . . . 0.0 110.691 168.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.08 -50.79 16.25 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 173.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.7 t90 -64.26 -61.32 2.32 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 125.051 1.34 . . . . 0.0 109.167 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -88.94 23.38 2.39 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.786 0.803 . . . . 0.0 111.53 -169.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.07 -13.33 34.05 Favored Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.338 1.447 . . . . 0.0 111.488 171.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.9 ttm -146.67 -34.94 0.27 Allowed 'General case' 0 C--N 1.341 0.238 0 CA-C-N 118.253 1.026 . . . . 0.0 113.724 -177.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.6 mt . . . . . 0 C--N 1.328 -0.333 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -162.962 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 121.302 0.573 . . . . 0.0 111.431 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -59.58 -26.46 65.44 Favored 'General case' 0 N--CA 1.463 0.193 0 O-C-N 121.678 -0.639 . . . . 0.0 111.934 -178.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.55 -26.18 66.22 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 125.285 1.422 . . . . 0.0 112.728 175.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.54 -62.63 1.45 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.37 1.085 . . . . 0.0 109.326 166.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 52.2 mt -61.07 -22.39 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 C-N-CA 126.345 1.858 . . . . 0.0 113.782 -160.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -132.42 -42.88 0.94 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 125.569 1.548 . . . . 0.0 111.028 172.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.94 -36.03 59.82 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 118.814 -0.992 . . . . 0.0 112.931 -175.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -77.35 -19.91 55.58 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 118.692 1.246 . . . . 0.0 112.583 176.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -82.29 -38.51 15.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.028 1.331 . . . . 0.0 108.755 174.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -73.18 -57.96 3.65 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 128.016 2.526 . . . . 0.0 107.593 -175.049 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -69.67 -7.76 41.84 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.045 0.538 . . . . 0.0 111.06 169.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.75 -59.42 4.07 Favored Glycine 0 C--N 1.34 0.777 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 169.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 18.8 t90 -60.27 -56.84 16.61 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 125.54 1.536 . . . . 0.0 109.739 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -85.03 23.65 1.2 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.632 0.773 . . . . 0.0 111.483 -177.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.94 9.82 11.26 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 127.886 2.66 . . . . 0.0 111.656 164.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.5 ptt? -129.93 -20.86 3.08 Favored 'General case' 0 C--N 1.344 0.367 0 CA-C-N 118.088 0.944 . . . . 0.0 113.491 164.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.0 mm . . . . . 0 N--CA 1.469 0.506 0 C-N-CA 123.617 0.767 . . . . 0.0 110.949 172.207 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 55.3 mt . . . . . 0 C--O 1.235 0.326 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -59.19 -26.06 64.49 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -174.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.12 -28.35 63.87 Favored Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.414 1.006 . . . . 0.0 112.778 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.26 -42.14 21.12 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 119.138 1.469 . . . . 0.0 110.516 171.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mt -59.22 -39.96 80.01 Favored 'Isoleucine or valine' 0 C--N 1.342 0.257 0 C-N-CA 124.823 1.249 . . . . 0.0 111.979 -176.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.55 -54.28 6.92 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 127.542 2.337 . . . . 0.0 110.116 169.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.58 -34.34 60.2 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 124.242 0.925 . . . . 0.0 113.642 -170.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -72.17 -23.17 61.24 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 118.407 1.103 . . . . 0.0 112.683 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -79.64 -38.84 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 124.323 1.049 . . . . 0.0 108.784 170.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.44 -55.36 7.15 Favored 'General case' 0 C--O 1.226 -0.17 0 C-N-CA 125.08 1.352 . . . . 0.0 109.052 -172.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -79.82 2.71 22.08 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.451 0.568 . . . . 0.0 111.595 167.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.79 -52.94 22.12 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 159.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -58.49 -63.37 1.3 Allowed 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.484 1.114 . . . . 0.0 108.592 169.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -80.66 56.91 2.78 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.154 2.182 . . . . 0.0 109.109 -176.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -173.29 -22.87 0.02 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.886 3.136 . . . . 0.0 110.794 178.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 33.5 mmt -93.39 -22.71 18.76 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 118.372 1.086 . . . . 0.0 112.569 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 N--CA 1.469 0.503 0 C-N-CA 124.557 1.143 . . . . 0.0 110.745 173.765 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.6 mp . . . . . 0 C--O 1.232 0.172 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 28.8 t80 -71.49 -12.59 61.46 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 176.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.79 -24.6 54.07 Favored Glycine 0 CA--C 1.533 1.188 0 C-N-CA 124.4 1.0 . . . . 0.0 113.523 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -78.31 -43.34 28.18 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.491 1.146 . . . . 0.0 110.83 171.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 18.6 mm -71.58 -9.33 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 126.07 1.748 . . . . 0.0 111.818 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.57 3.35 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 128.188 2.595 . . . . 0.0 109.484 168.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.66 -37.1 91.81 Favored Glycine 0 CA--C 1.529 0.92 0 CA-C-N 118.804 0.729 . . . . 0.0 112.8 -174.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 84.2 t80 -67.29 -25.63 66.13 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.638 0.719 . . . . 0.0 111.655 178.574 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 mm -66.47 -23.46 31.55 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-N 118.898 0.772 . . . . 0.0 109.9 177.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -104.82 -60.87 1.54 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 -172.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -64.25 -25.22 67.96 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 122.949 0.5 . . . . 0.0 112.304 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.85 0.77 86.04 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.078 174.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -127.44 -68.34 0.79 Allowed 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.78 1.632 . . . . 0.0 108.574 -176.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -74.16 23.79 0.08 Allowed 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.923 2.089 . . . . 0.0 112.394 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.24 -33.81 5.57 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 125.209 1.385 . . . . 0.0 111.367 162.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.1 mmm -153.65 64.76 0.73 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.825 1.313 . . . . 0.0 109.746 -173.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.7 mt . . . . . 0 N--CA 1.466 0.35 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 166.367 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.7 mm? . . . . . 0 N--CA 1.462 0.148 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -77.39 -12.96 60.02 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 179.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.71 -42.0 58.31 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.369 0.985 . . . . 0.0 112.986 -170.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.74 -22.41 61.61 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.298 1.439 . . . . 0.0 112.719 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mm -74.35 -5.47 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 C-N-CA 124.645 1.178 . . . . 0.0 110.811 176.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.37 -42.11 3.98 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 126.608 1.963 . . . . 0.0 109.706 160.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.68 -39.51 91.28 Favored Glycine 0 C--N 1.342 0.909 0 CA-C-N 119.23 0.923 . . . . 0.0 112.87 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -75.62 -15.28 60.36 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 117.843 0.821 . . . . 0.0 112.69 177.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.8 mm -85.66 -37.76 12.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 124.699 1.2 . . . . 0.0 108.724 174.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -72.62 -55.75 6.38 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 126.568 1.947 . . . . 0.0 107.886 -177.05 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -69.29 -6.62 30.59 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.558 0.743 . . . . 0.0 111.247 168.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.97 -57.49 3.72 Favored Glycine 0 C--N 1.341 0.82 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 169.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -57.02 -57.01 14.43 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 126.536 1.934 . . . . 0.0 109.283 175.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -83.27 24.38 0.81 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 123.944 0.897 . . . . 0.0 111.612 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -121.47 6.87 10.58 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 127.324 2.392 . . . . 0.0 111.331 164.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.8 mmt -126.58 -36.11 2.29 Favored 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.215 1.406 . . . . 0.0 111.767 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm . . . . . 0 N--CA 1.468 0.432 0 C-N-CA 124.887 1.275 . . . . 0.0 110.704 175.494 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.7 mp . . . . . 0 C--O 1.232 0.163 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -77.9 -12.01 59.94 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 177.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.91 -28.96 61.35 Favored Glycine 0 CA--C 1.531 1.045 0 C-N-CA 124.033 0.825 . . . . 0.0 113.583 -174.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.8 -33.52 27.23 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 118.572 1.186 . . . . 0.0 111.512 173.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.0 mm -73.66 -10.26 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 126.052 1.741 . . . . 0.0 111.609 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.81 -48.82 3.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 127.321 2.248 . . . . 0.0 109.632 164.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.38 -36.05 82.01 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 119.034 0.833 . . . . 0.0 113.33 -172.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -66.79 -31.2 71.67 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.439 1.12 . . . . 0.0 111.618 175.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mm -73.99 -18.14 17.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 124.484 1.114 . . . . 0.0 109.977 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -97.7 -61.21 1.42 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 125.324 1.45 . . . . 0.0 107.337 -174.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -61.65 -30.99 71.08 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.527 0.731 . . . . 0.0 111.761 176.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.43 0.61 63.71 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.122 -0.821 . . . . 0.0 113.433 177.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 17.9 t90 -130.39 -69.65 0.65 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.943 1.297 . . . . 0.0 108.568 -174.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -78.51 23.43 0.31 Allowed 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.294 1.038 . . . . 0.0 112.043 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.02 -2.71 16.08 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 127.416 2.436 . . . . 0.0 112.106 166.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 61.0 mtt -134.09 -10.05 2.62 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.977 1.389 . . . . 0.0 113.382 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.2 mm . . . . . 0 CA--C 1.538 0.491 0 C-N-CA 124.114 0.966 . . . . 0.0 111.957 177.611 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.4 mt . . . . . 0 C--O 1.232 0.157 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -103.0 -9.47 19.77 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.624 0.601 . . . . 0.0 112.624 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.3 -30.73 64.89 Favored Glycine 0 CA--C 1.532 1.108 0 O-C-N 121.399 -0.813 . . . . 0.0 113.945 -170.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.75 30.08 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.855 1.262 . . . . 0.0 111.658 175.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.4 mm -75.46 -5.62 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.814 1.646 . . . . 0.0 111.099 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -110.02 -46.21 3.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.28 1.832 . . . . 0.0 109.922 160.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.37 -36.39 83.58 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 119.23 0.923 . . . . 0.0 113.274 -172.3 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -74.37 -20.08 60.21 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.755 0.778 . . . . 0.0 112.482 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -81.67 -34.5 12.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 124.288 1.035 . . . . 0.0 109.001 174.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -73.98 -56.09 5.36 Favored 'General case' 0 N--CA 1.457 -0.125 0 C-N-CA 125.813 1.645 . . . . 0.0 107.644 -176.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -63.13 -21.27 66.08 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 122.857 0.463 . . . . 0.0 111.0 168.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.73 -9.9 86.66 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-O 119.338 -0.701 . . . . 0.0 112.948 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -114.03 -58.1 2.19 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.916 1.286 . . . . 0.0 109.499 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.8 23.89 0.16 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.928 1.291 . . . . 0.0 112.691 -174.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.37 49.95 3.08 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.146 1.832 . . . . 0.0 111.87 178.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.4 mtm 58.53 73.93 0.46 Allowed 'General case' 0 C--N 1.341 0.214 0 C-N-CA 127.192 2.197 . . . . 0.0 110.468 -175.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 90.6 mt . . . . . 0 CA--C 1.544 0.723 0 C-N-CA 126.892 2.077 . . . . 0.0 112.532 -179.38 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? . . . . . 0 C--O 1.231 0.128 0 N-CA-C 106.63 -1.618 . . . . 0.0 106.63 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -88.62 -9.15 53.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 122.878 0.471 . . . . 0.0 112.134 177.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.61 -32.34 61.29 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 123.976 0.798 . . . . 0.0 114.09 -168.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.19 -28.34 27.4 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.434 1.093 . . . . 0.0 111.952 175.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.2 mm -74.88 -10.92 14.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 125.681 1.592 . . . . 0.0 111.244 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.66 -49.16 3.48 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 126.896 2.078 . . . . 0.0 109.55 162.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.0 -35.88 78.45 Favored Glycine 0 C--N 1.342 0.875 0 CA-C-N 118.988 0.813 . . . . 0.0 113.286 -170.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -70.78 -28.04 64.37 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.338 1.069 . . . . 0.0 112.038 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mm -72.49 -25.28 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 119.066 0.848 . . . . 0.0 109.487 176.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -92.71 -65.6 0.99 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.639 1.575 . . . . 0.0 107.029 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.13 -24.56 67.45 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.623 0.769 . . . . 0.0 110.764 179.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -77.38 -3.29 82.16 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 118.855 -0.97 . . . . 0.0 113.198 176.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.7 t90 -130.78 -74.66 0.53 Allowed 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 118.509 1.155 . . . . 0.0 108.984 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -79.75 23.71 0.42 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.679 1.192 . . . . 0.0 112.404 -172.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.27 -16.43 57.39 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 118.186 -1.341 . . . . 0.0 112.319 170.303 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 45.6 mmm -141.07 9.57 2.12 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 118.612 1.206 . . . . 0.0 113.037 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 5.3 mm . . . . . 0 CA--C 1.536 0.405 0 O-C-N 120.898 -1.126 . . . . 0.0 112.217 -177.37 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.0 mm? . . . . . 0 N--CA 1.468 0.458 0 CA-C-O 121.614 0.721 . . . . 0.0 112.037 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -60.17 -26.65 66.49 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.661 0.615 . . . . 0.0 112.661 -170.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -63.56 -24.13 67.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.859 1.218 . . . . 0.0 112.732 177.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.03 -61.8 1.51 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 118.126 0.963 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 56.9 mt -60.15 -21.95 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 126.398 1.879 . . . . 0.0 113.589 -161.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -131.26 -43.59 1.04 Allowed 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 125.953 1.701 . . . . 0.0 110.84 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.27 -34.35 59.02 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-N 119.067 0.849 . . . . 0.0 113.342 -177.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.0 t80 -75.62 -23.59 56.41 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.624 1.212 . . . . 0.0 112.231 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mm -80.11 -35.12 15.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 125.19 1.396 . . . . 0.0 109.144 175.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -73.69 -59.13 2.86 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 128.026 2.53 . . . . 0.0 106.833 -176.021 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -62.46 -19.13 63.21 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 119.224 -0.417 . . . . 0.0 111.291 170.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.13 -54.24 9.44 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 175.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -62.37 -57.2 12.19 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.53 1.532 . . . . 0.0 109.713 176.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 -80.22 23.41 0.48 Allowed 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.543 1.537 . . . . 0.0 112.857 -166.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.63 -5.66 10.97 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.753 2.121 . . . . 0.0 112.193 166.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 95.7 mmm -127.31 -2.91 6.26 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.714 1.257 . . . . 0.0 113.102 -174.127 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.0 mt . . . . . 0 N--CA 1.469 0.48 0 C-N-CA 124.219 1.008 . . . . 0.0 110.579 -178.776 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? . . . . . 0 CA--C 1.538 0.513 0 CA-C-O 121.662 0.744 . . . . 0.0 112.52 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.3 t80 -58.86 -25.76 63.59 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 123.679 0.792 . . . . 0.0 112.399 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.49 -15.06 51.99 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 125.323 1.439 . . . . 0.0 113.447 172.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -106.31 -55.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.527 1.163 . . . . 0.0 109.867 164.491 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 30.7 mt -61.95 -18.58 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 124.645 1.178 . . . . 0.0 113.677 -167.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -125.02 -43.47 1.97 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 125.697 1.599 . . . . 0.0 110.766 166.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.58 -34.89 78.08 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 119.417 1.008 . . . . 0.0 113.252 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.9 t80 -79.06 -10.69 59.9 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.622 1.211 . . . . 0.0 112.494 175.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.5 mm -87.66 -39.86 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 C-N-CA 124.798 1.239 . . . . 0.0 108.218 169.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -70.5 -59.96 2.54 Favored 'General case' 0 N--CA 1.457 -0.102 0 C-N-CA 126.6 1.96 . . . . 0.0 109.035 -176.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -74.01 -3.01 26.65 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.876 -0.515 . . . . 0.0 111.648 166.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.44 -10.26 74.82 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.495 0.589 . . . . 0.0 112.348 161.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -116.6 -64.22 1.34 Allowed 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 107.226 177.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -80.84 59.3 3.66 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-O 122.4 1.095 . . . . 0.0 109.49 172.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -145.25 13.66 1.86 Allowed Glycine 0 CA--C 1.534 1.225 0 C-N-CA 125.918 1.723 . . . . 0.0 111.765 161.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 25.6 ptt? -170.43 -18.84 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 128.386 2.675 . . . . 0.0 114.111 175.261 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 51.9 mt . . . . . 0 N--CA 1.475 0.806 0 C-N-CA 124.568 1.147 . . . . 0.0 110.338 -176.976 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mp . . . . . 0 C--O 1.234 0.255 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -62.79 -22.79 66.86 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.676 0.79 . . . . 0.0 112.003 172.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.47 -21.47 57.46 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 125.241 1.401 . . . . 0.0 112.895 171.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -85.65 -65.04 1.05 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 118.762 1.281 . . . . 0.0 108.766 163.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 29.1 mt -60.98 -24.5 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 125.509 1.523 . . . . 0.0 113.987 -161.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.44 -47.25 1.87 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 125.83 1.652 . . . . 0.0 110.542 172.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.56 -32.76 65.34 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.935 -0.925 . . . . 0.0 113.631 -172.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -76.37 -23.93 54.15 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 119.136 1.468 . . . . 0.0 112.108 175.073 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mm -71.08 -31.37 44.6 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 O-C-N 120.987 -1.07 . . . . 0.0 108.814 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -101.99 -49.8 3.84 Favored 'General case' 0 C--O 1.225 -0.188 0 C-N-CA 123.805 0.842 . . . . 0.0 110.386 -171.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 25.5 m-80 -86.45 -19.77 29.13 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.4 0.546 . . . . 0.0 111.234 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -96.45 -62.71 0.94 Allowed Glycine 0 C--N 1.34 0.79 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -175.647 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 23.5 t90 -80.23 -68.55 0.67 Allowed 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -79.54 23.45 0.41 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -167.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.69 -6.5 11.43 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 126.828 2.156 . . . . 0.0 112.729 170.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 59.1 mmm -130.19 20.59 5.32 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 118.964 1.382 . . . . 0.0 112.087 -172.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.5 mm . . . . . 0 CA--C 1.537 0.46 0 C-N-CA 123.711 0.805 . . . . 0.0 111.216 -177.137 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.6 mm? . . . . . 0 C--O 1.234 0.276 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -61.49 -22.42 65.08 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.6 -26.22 56.78 Favored Glycine 0 CA--C 1.532 1.1 0 CA-C-O 118.926 -0.93 . . . . 0.0 112.903 172.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.74 -43.74 15.17 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 119.222 1.511 . . . . 0.0 110.356 171.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -64.1 -13.21 13.32 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 C-N-CA 126.653 1.981 . . . . 0.0 112.629 -177.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.39 -48.92 2.99 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 127.59 2.356 . . . . 0.0 110.204 170.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.29 -36.1 81.54 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-N 119.412 1.006 . . . . 0.0 113.082 -174.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -73.7 -18.8 60.96 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 118.031 0.916 . . . . 0.0 112.515 176.018 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -80.98 -39.02 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 CA-C-N 119.431 1.014 . . . . 0.0 108.299 172.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -69.81 -62.41 1.39 Allowed 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 126.598 1.959 . . . . 0.0 107.951 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -64.58 -16.97 63.51 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 119.415 -0.326 . . . . 0.0 111.165 169.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.89 -16.32 66.0 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.747 -1.03 . . . . 0.0 113.37 173.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -127.49 -44.96 1.51 Allowed 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.571 1.185 . . . . 0.0 111.807 174.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -81.13 23.64 0.57 Allowed 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 122.256 1.027 . . . . 0.0 112.164 -162.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.66 -10.94 42.39 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 125.603 1.573 . . . . 0.0 112.227 163.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.5 mmm -111.64 -9.85 14.13 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.851 1.325 . . . . 0.0 113.521 -169.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm . . . . . 0 CA--C 1.533 0.315 0 C-N-CA 124.055 0.942 . . . . 0.0 112.313 -171.51 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? . . . . . 0 N--CA 1.468 0.435 0 CA-C-O 121.616 0.722 . . . . 0.0 110.728 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -84.43 -11.79 55.57 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -178.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.18 -32.57 63.48 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 123.817 0.722 . . . . 0.0 113.167 -174.393 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.07 -33.24 26.45 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.53 1.132 . . . . 0.0 111.629 174.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.1 mm -73.9 -9.1 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 125.644 1.578 . . . . 0.0 111.665 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.39 -50.45 3.22 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 127.479 2.312 . . . . 0.0 109.588 163.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.46 77.98 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 118.994 0.815 . . . . 0.0 113.281 -171.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -69.86 -28.11 65.39 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.198 0.999 . . . . 0.0 112.117 176.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mm -72.47 -25.67 23.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 CA-C-N 118.931 0.787 . . . . 0.0 109.429 176.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -92.91 -63.57 1.2 Allowed 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.225 1.41 . . . . 0.0 107.57 -170.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -68.39 -22.53 64.63 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.156 0.583 . . . . 0.0 110.872 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.94 -6.96 80.52 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.349 -0.695 . . . . 0.0 112.758 174.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.9 t90 -114.1 -76.05 0.59 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.228 1.411 . . . . 0.0 107.436 171.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.67 56.09 3.71 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 122.207 1.003 . . . . 0.0 110.971 -171.776 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.98 -7.97 37.37 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-O 118.659 -1.078 . . . . 0.0 111.73 159.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.0 mmt -148.97 3.05 0.6 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.054 1.341 . . . . 0.0 113.287 -169.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.7 mm . . . . . 0 N--CA 1.464 0.229 0 CA-C-N 120.163 1.347 . . . . 0.0 108.779 -170.38 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.9 mt . . . . . 0 C--O 1.233 0.218 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -65.92 -16.09 63.55 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 176.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.59 -23.5 58.47 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.701 1.143 . . . . 0.0 112.665 167.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.53 -58.31 2.79 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 118.891 1.346 . . . . 0.0 109.152 164.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.8 mm -64.3 -21.49 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -162.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -134.42 -44.75 0.76 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.941 1.696 . . . . 0.0 110.972 172.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.34 -42.57 74.61 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.992 0.815 . . . . 0.0 112.878 -173.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -77.62 -15.9 58.91 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 112.466 177.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.1 mm -71.1 -38.0 69.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 O-C-N 120.453 -1.404 . . . . 0.0 107.867 171.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -94.17 -55.71 3.1 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -167.325 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.0 m-80 -76.62 -20.06 57.14 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.141 0.576 . . . . 0.0 110.71 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.54 -63.88 0.79 Allowed Glycine 0 C--N 1.341 0.86 0 CA-C-O 118.387 -1.229 . . . . 0.0 111.45 -171.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -69.42 -64.06 0.95 Allowed 'General case' 0 C--N 1.341 0.22 0 CA-C-N 118.636 1.218 . . . . 0.0 108.336 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -80.34 23.14 0.51 Allowed 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.561 0.696 . . . . 0.0 112.522 -174.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -99.3 -58.41 0.91 Allowed Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.816 2.151 . . . . 0.0 108.739 162.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.7 ptm -65.06 -18.05 64.97 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 118.38 1.09 . . . . 0.0 113.555 -179.375 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.6 mm . . . . . 0 CA--C 1.539 0.548 0 C-N-CA 123.735 0.814 . . . . 0.0 110.633 169.185 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? . . . . . 0 C--O 1.236 0.367 0 CA-C-O 121.101 0.477 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -62.34 -21.0 64.95 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -173.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.42 -28.73 55.98 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 119.04 -0.867 . . . . 0.0 112.673 173.255 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.31 -41.96 19.41 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 119.127 1.464 . . . . 0.0 110.654 172.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.6 mt -65.82 -10.57 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.486 1.914 . . . . 0.0 112.465 -177.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -114.04 -45.02 3.09 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 127.01 2.124 . . . . 0.0 110.824 168.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.93 -38.79 76.29 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.682 0.674 . . . . 0.0 112.837 -176.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -78.21 -11.46 59.93 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 117.789 0.794 . . . . 0.0 112.632 178.452 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 9.7 mm -86.7 -42.37 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-N 119.218 0.917 . . . . 0.0 108.782 176.397 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.7 pt-20 -78.53 -47.35 17.48 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 124.403 1.081 . . . . 0.0 108.706 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -74.16 -13.04 60.75 Favored 'General case' 0 C--N 1.344 0.361 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 170.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.95 -53.51 9.35 Favored Glycine 0 C--N 1.342 0.861 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 171.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.536 ' HA ' HD12 ' A' ' 18' ' ' ILE . 22.7 t90 -67.26 -62.65 1.32 Allowed 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 123.381 0.673 . . . . 0.0 109.275 178.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -90.76 23.35 3.14 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.431 0.634 . . . . 0.0 111.511 -165.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.13 -27.04 26.9 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.551 1.072 . . . . 0.0 111.339 171.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.4 ptm -159.21 -10.71 0.06 Allowed 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 -178.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.536 HD12 ' HA ' ' A' ' 14' ' ' TRP . 58.6 mt . . . . . 0 N--CA 1.467 0.388 0 CA-C-N 119.765 1.166 . . . . 0.0 111.647 -159.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.8 mm? . . . . . 0 CA--C 1.537 0.456 0 CA-C-O 121.496 0.665 . . . . 0.0 111.01 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.32 -19.96 65.79 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 121.129 -0.982 . . . . 0.0 112.154 178.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -23.14 54.96 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 125.109 1.338 . . . . 0.0 112.906 167.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.37 -47.83 6.7 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.869 1.334 . . . . 0.0 110.693 167.141 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.8 mm -64.24 -24.47 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.92 -44.79 0.58 Allowed 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 125.908 1.683 . . . . 0.0 111.092 175.177 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.8 -37.63 70.13 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-N 119.035 0.834 . . . . 0.0 113.315 -169.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -67.32 -32.1 72.83 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 124.22 1.008 . . . . 0.0 111.832 176.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mt -74.52 -29.06 23.13 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 C-N-CA 124.041 0.937 . . . . 0.0 109.351 175.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -81.58 -57.72 3.34 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 125.492 1.517 . . . . 0.0 108.366 -174.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.4 p30 -65.78 -18.42 65.32 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.561 0.619 . . . . 0.0 111.655 170.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.75 -2.57 76.77 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.369 -0.684 . . . . 0.0 113.114 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.4 t90 -128.26 -68.37 0.77 Allowed 'General case' 0 C--O 1.234 0.239 0 C-N-CA 125.534 1.534 . . . . 0.0 109.127 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -77.36 23.71 0.2 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.595 1.558 . . . . 0.0 112.359 -176.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.58 -1.73 15.27 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 126.977 2.227 . . . . 0.0 112.112 167.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 78.9 mtm -134.93 -9.43 2.34 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 119.035 1.417 . . . . 0.0 114.142 -178.034 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.3 mm . . . . . 0 CA--C 1.537 0.459 0 CA-C-N 119.209 0.913 . . . . 0.0 110.402 170.151 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? . . . . . 0 CA--C 1.538 0.516 0 CA-C-O 121.895 0.855 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -62.55 -23.66 67.11 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -173.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.98 -29.84 59.66 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.217 0.913 . . . . 0.0 112.501 173.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.82 -35.07 22.55 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.877 1.339 . . . . 0.0 111.259 172.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.2 mm -62.91 -33.63 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 123.69 0.796 . . . . 0.0 111.908 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.41 -61.69 1.87 Allowed 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 127.307 2.243 . . . . 0.0 109.484 165.098 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.75 -32.99 66.51 Favored Glycine 0 C--N 1.341 0.83 0 C-N-CA 123.811 0.72 . . . . 0.0 114.003 -164.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -69.02 -31.05 69.58 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.254 1.027 . . . . 0.0 112.029 178.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.9 mt -73.2 -35.19 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 123.945 0.898 . . . . 0.0 109.26 174.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -78.89 -55.55 5.07 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 125.128 1.371 . . . . 0.0 108.226 -170.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.33 -20.96 66.63 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 122.803 0.441 . . . . 0.0 110.122 171.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.18 -57.23 8.74 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.2 t90 -62.29 -60.92 2.88 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.609 1.164 . . . . 0.0 109.046 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -85.61 23.71 1.34 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.384 0.673 . . . . 0.0 111.962 -169.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -122.76 -14.94 4.09 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 126.54 2.019 . . . . 0.0 112.098 165.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 26.4 mmt -112.0 -12.0 13.78 Favored 'General case' 0 C--N 1.343 0.316 0 CA-C-N 118.732 1.266 . . . . 0.0 112.246 178.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.1 mm . . . . . 0 CA--C 1.534 0.346 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 158.814 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? . . . . . 0 C--O 1.24 0.569 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -68.27 -19.36 64.71 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -174.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.59 -25.04 57.8 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 124.236 0.922 . . . . 0.0 112.939 176.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.51 -36.84 52.16 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.631 1.215 . . . . 0.0 110.909 172.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.3 mm -65.97 -51.39 61.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-O 122.339 1.066 . . . . 0.0 109.815 179.693 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.34 -52.88 60.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 112.35 -2.204 . . . . 0.0 109.495 169.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.84 -33.25 56.04 Favored Glycine 0 CA--C 1.53 0.976 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.949 -178.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -72.05 -28.11 63.13 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 118.464 1.132 . . . . 0.0 112.465 176.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -74.52 -37.17 43.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-N 119.484 1.038 . . . . 0.0 109.433 170.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -74.22 -56.07 5.32 Favored 'General case' 0 C--N 1.334 -0.105 0 C-N-CA 125.135 1.374 . . . . 0.0 108.646 -172.024 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.59 -7.52 33.52 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.103 0.561 . . . . 0.0 110.729 168.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.73 -54.35 7.44 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 168.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.09 -56.33 23.47 Favored 'General case' 0 C--O 1.233 0.19 0 C-N-CA 125.409 1.484 . . . . 0.0 108.221 173.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -81.9 23.33 0.7 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.212 -0.93 . . . . 0.0 112.13 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.25 -21.84 69.36 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 166.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.5 ttt -145.45 -36.15 0.29 Allowed 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.3 mm . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 120.968 0.413 . . . . 0.0 110.336 -159.095 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.2 mm? . . . . . 0 CA--C 1.541 0.626 0 CA-C-O 120.851 0.358 . . . . 0.0 110.303 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -114.52 -12.9 12.23 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -176.505 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.26 -34.72 81.43 Favored Glycine 0 CA--C 1.529 0.967 0 C-N-CA 123.533 0.587 . . . . 0.0 112.922 -174.381 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.25 -30.29 34.15 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.96 0.904 . . . . 0.0 111.659 174.573 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.1 mm -67.71 -39.34 81.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 C-N-CA 123.901 0.881 . . . . 0.0 110.793 -178.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.97 -56.76 7.8 Favored 'General case' 0 C--N 1.319 -0.761 0 C-N-CA 127.233 2.213 . . . . 0.0 109.687 164.692 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.53 -33.01 65.58 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.703 -169.271 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -67.4 -27.63 67.24 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.395 1.097 . . . . 0.0 111.989 178.04 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.87 -36.0 62.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 O-C-N 121.527 -0.733 . . . . 0.0 109.179 171.559 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.24 -58.9 2.99 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.354 1.461 . . . . 0.0 108.128 -168.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -68.51 -12.76 61.69 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.87 -0.586 . . . . 0.0 112.069 171.988 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.66 -56.82 5.27 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 169.708 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.2 t90 -65.24 -61.34 2.19 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.513 1.125 . . . . 0.0 109.42 -178.415 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -86.69 23.7 1.62 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-O 121.363 0.601 . . . . 0.0 111.469 -172.412 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.38 -38.15 6.79 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.724 1.154 . . . . 0.0 111.21 173.135 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 91.1 mmm -143.33 -9.51 0.75 Allowed 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.804 1.409 . . . . 0.0 114.804 -173.352 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.1 mt . . . . . 0 N--CA 1.466 0.374 0 CA-C-N 119.691 1.132 . . . . 0.0 111.54 -161.558 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? . . . . . 0 C--O 1.235 0.291 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -61.61 -24.68 66.85 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 112.776 0.658 . . . . 0.0 112.776 -178.201 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.8 -26.72 60.77 Favored Glycine 0 CA--C 1.533 1.176 0 C-N-CA 124.179 0.895 . . . . 0.0 112.814 173.64 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.11 -34.75 37.63 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 118.95 1.375 . . . . 0.0 110.864 173.292 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.6 mm -63.14 -53.57 44.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-O 122.484 1.135 . . . . 0.0 109.694 177.227 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -51.17 -55.24 18.93 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 112.273 -2.24 . . . . 0.0 108.994 169.134 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.38 -33.97 33.05 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.09 0.853 . . . . 0.0 113.249 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -72.62 -39.91 66.88 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.439 1.12 . . . . 0.0 111.892 177.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 mt -65.65 -35.29 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 119.164 0.893 . . . . 0.0 109.955 171.55 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -79.57 -55.54 4.95 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 125.59 1.556 . . . . 0.0 108.781 -166.878 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -71.29 -13.28 61.84 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.759 169.591 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.51 -51.16 54.65 Favored Glycine 0 C--N 1.343 0.951 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 169.76 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.2 t90 -65.57 -62.05 1.74 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 124.038 0.935 . . . . 0.0 109.308 173.355 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.42 23.54 0.39 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.385 1.474 . . . . 0.0 112.929 -168.331 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.96 2.09 5.53 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 127.399 2.428 . . . . 0.0 111.922 171.022 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 56.9 mtt -137.47 0.76 2.31 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 118.947 1.373 . . . . 0.0 113.431 -175.465 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.0 mt . . . . . 0 N--CA 1.472 0.635 0 CA-C-N 119.65 1.114 . . . . 0.0 110.829 -177.187 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.3 mm? . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 121.954 0.883 . . . . 0.0 113.062 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -63.41 -22.83 67.12 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -174.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.4 -28.62 62.28 Favored Glycine 0 CA--C 1.532 1.121 0 C-N-CA 124.103 0.859 . . . . 0.0 112.518 173.757 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.56 -30.82 29.39 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 118.847 1.324 . . . . 0.0 111.465 173.653 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.0 mm -62.59 -51.63 69.82 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-O 122.219 1.009 . . . . 0.0 109.756 175.68 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.81 -53.9 49.24 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 127.299 2.239 . . . . 0.0 109.485 169.24 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.29 -35.4 42.96 Favored Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.024 0.821 . . . . 0.0 113.059 -179.838 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 90.8 t80 -74.9 -22.65 58.5 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.011 0.906 . . . . 0.0 112.725 178.611 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -76.06 -41.23 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-N 119.577 1.08 . . . . 0.0 109.175 165.647 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -72.66 -55.15 7.26 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 125.042 1.337 . . . . 0.0 109.37 -167.597 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -80.54 -2.98 48.45 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 118.217 0.462 . . . . 0.0 111.258 167.901 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.43 -54.86 31.07 Favored Glycine 0 C--N 1.34 0.764 0 N-CA-C 109.035 -1.626 . . . . 0.0 109.035 162.846 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.1 t90 -64.1 -64.99 0.74 Allowed 'General case' 0 C--O 1.237 0.429 0 C-N-CA 123.776 0.83 . . . . 0.0 108.847 171.617 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -89.68 60.77 5.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 122.689 1.233 . . . . 0.0 108.937 -170.44 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.78 -32.05 0.02 OUTLIER Glycine 0 CA--C 1.524 0.642 0 CA-C-N 114.156 -1.383 . . . . 0.0 112.259 170.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 85.2 mmm -96.11 -12.36 24.9 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 118.282 1.041 . . . . 0.0 112.227 171.471 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.7 mt . . . . . 0 CA--C 1.53 0.191 0 C-N-CA 125.435 1.494 . . . . 0.0 108.642 -169.748 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 5.3 mp . . . . . 0 CA--C 1.539 0.549 0 CA-C-O 121.202 0.525 . . . . 0.0 111.617 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -60.54 -20.23 59.7 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.287 -0.883 . . . . 0.0 111.855 171.157 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.71 -29.46 61.4 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.407 1.003 . . . . 0.0 112.495 170.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.81 -33.7 34.55 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.978 1.389 . . . . 0.0 111.429 172.757 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.8 mm -60.05 -53.87 42.62 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-O 122.277 1.037 . . . . 0.0 109.695 174.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.67 -51.99 61.41 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 127.753 2.421 . . . . 0.0 109.767 170.841 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.7 -36.69 49.57 Favored Glycine 0 CA--C 1.534 1.259 0 CA-C-N 118.422 0.555 . . . . 0.0 113.133 177.136 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -77.54 -14.99 59.53 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.739 0.816 . . . . 0.0 113.093 177.9 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mt -82.93 -38.96 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 119.904 1.229 . . . . 0.0 109.496 164.088 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -65.21 -64.15 0.93 Allowed 'General case' 0 CA--C 1.521 -0.152 0 C-N-CA 125.908 1.683 . . . . 0.0 108.204 -173.879 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -79.69 2.51 22.42 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 118.148 0.431 . . . . 0.0 111.461 169.189 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.96 -57.02 12.98 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 162.461 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.6 t90 -68.99 -56.58 7.36 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 171.255 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -78.48 41.84 0.41 Allowed 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.059 0.944 . . . . 0.0 110.878 -177.548 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.67 41.87 2.99 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.548 2.023 . . . . 0.0 109.034 162.49 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.4 tmm? 57.46 29.05 16.4 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.568 1.947 . . . . 0.0 113.133 -174.858 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 70.0 mt . . . . . 0 N--CA 1.467 0.389 0 O-C-N 121.459 -0.775 . . . . 0.0 109.242 169.768 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.1 mt . . . . . 0 N--CA 1.468 0.432 0 CA-C-O 121.364 0.602 . . . . 0.0 112.167 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -66.06 -19.62 65.91 Favored 'General case' 0 CA--C 1.537 0.456 0 O-C-N 121.023 -1.048 . . . . 0.0 112.435 179.473 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.34 -21.54 54.1 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 124.742 1.163 . . . . 0.0 112.852 167.136 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.49 -53.02 4.38 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.904 1.352 . . . . 0.0 110.307 164.719 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.1 mm -62.95 -20.8 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -166.427 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -133.6 -47.51 0.82 Allowed 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 125.932 1.693 . . . . 0.0 110.635 170.488 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.87 -31.84 65.21 Favored Glycine 0 CA--C 1.531 1.064 0 CA-C-O 119.333 -0.704 . . . . 0.0 113.935 -168.301 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 t80 -70.48 -33.08 70.84 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.278 1.039 . . . . 0.0 111.567 175.808 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.89 -21.54 22.49 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 124.605 1.162 . . . . 0.0 109.795 177.6 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -92.84 -63.32 1.24 Allowed 'General case' 0 C--O 1.231 0.094 0 C-N-CA 125.255 1.422 . . . . 0.0 107.22 -174.551 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -65.62 -27.81 68.67 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.837 0.855 . . . . 0.0 111.058 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.6 -18.21 66.6 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.904 -0.942 . . . . 0.0 112.311 177.042 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.495 ' HA ' HD12 ' A' ' 18' ' ' ILE . 12.2 t90 -80.77 -67.49 0.77 Allowed 'General case' 0 C--O 1.237 0.403 0 CA-C-N 118.481 1.141 . . . . 0.0 108.229 168.605 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -84.57 23.36 1.15 Allowed 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 121.374 0.607 . . . . 0.0 112.599 -162.828 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.88 -32.45 12.8 Favored Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.477 1.037 . . . . 0.0 111.614 175.096 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.7 mmt -151.14 -33.63 0.15 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -176.019 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.495 HD12 ' HA ' ' A' ' 14' ' ' TRP . 45.8 mt . . . . . 0 N--CA 1.466 0.373 0 C-N-CA 124.3 1.04 . . . . 0.0 112.189 -158.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.476 0.832 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -67.29 165.78 15.63 Favored 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 138.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -106.19 -10.74 16.32 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.94 -48.04 58.55 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.846 0.736 . . . . 0.0 112.621 -171.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.73 -19.85 58.76 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.353 1.461 . . . . 0.0 112.76 178.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.8 mm -74.67 -8.57 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 C-N-CA 124.41 1.084 . . . . 0.0 110.884 177.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.09 -44.33 4.19 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 127.154 2.182 . . . . 0.0 109.694 160.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.03 -39.22 89.27 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 119.029 0.831 . . . . 0.0 113.264 -173.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -69.62 -26.62 64.52 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 118.164 0.982 . . . . 0.0 112.038 176.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mm -75.76 -35.54 31.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 C-N-CA 123.686 0.795 . . . . 0.0 108.901 178.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -78.79 -49.2 13.4 Favored 'General case' 0 CA--C 1.519 -0.231 0 C-N-CA 125.815 1.646 . . . . 0.0 108.158 -174.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -63.65 -14.69 54.25 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 122.788 0.435 . . . . 0.0 111.27 167.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.63 -55.51 4.55 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 172.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -62.54 -58.81 6.23 Favored 'General case' 0 N--CA 1.455 -0.203 0 C-N-CA 125.979 1.712 . . . . 0.0 109.711 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -80.39 23.59 0.49 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.009 0.924 . . . . 0.0 111.759 176.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.5 -19.76 31.48 Favored Glycine 0 CA--C 1.53 0.97 0 C-N-CA 124.799 1.19 . . . . 0.0 111.085 159.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.9 ptt? -162.81 60.62 0.2 Allowed 'General case' 0 C--N 1.346 0.429 0 CA-C-N 118.943 1.372 . . . . 0.0 112.007 -176.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 17.4 mt -70.88 -67.77 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 158.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -61.43 143.63 55.52 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 171.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.26 0 C-N-CA 125.476 1.513 . . . . 0.0 114.071 -175.488 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.3 p . . . . . 0 N--CA 1.477 0.895 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -65.53 154.75 37.76 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 118.391 0.541 . . . . 0.0 109.633 177.194 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -63.36 -20.65 65.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -175.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.19 -30.31 57.66 Favored Glycine 0 CA--C 1.532 1.113 0 CA-C-O 118.999 -0.889 . . . . 0.0 112.463 172.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.98 -32.24 25.09 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 119.118 1.459 . . . . 0.0 111.378 172.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.2 mm -65.87 -28.83 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 C-N-CA 123.829 0.851 . . . . 0.0 111.934 178.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -81.55 -53.65 6.09 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 127.675 2.39 . . . . 0.0 110.139 165.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -49.82 -41.84 36.5 Favored Glycine 0 C--N 1.342 0.881 0 C-N-CA 125.668 1.604 . . . . 0.0 112.928 -173.401 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 61.4 t80 -75.53 -16.85 60.23 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.6 mt -81.4 -45.71 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 123.696 0.799 . . . . 0.0 108.896 169.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -82.46 -38.48 23.88 Favored 'General case' 0 CA--C 1.527 0.07 0 CA-C-O 118.194 -0.908 . . . . 0.0 111.082 -167.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -87.02 1.73 51.91 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.309 0.959 . . . . 0.0 111.059 162.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.78 -45.87 56.1 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 159.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.404 ' HA ' HD12 ' A' ' 18' ' ' ILE . 0.3 OUTLIER -63.4 -64.9 0.77 Allowed 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 167.972 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -81.5 57.45 3.3 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 125.537 1.535 . . . . 0.0 108.544 -173.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -136.77 -42.48 0.1 Allowed Glycine 0 CA--C 1.526 0.756 0 C-N-CA 126.886 2.184 . . . . 0.0 110.443 176.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -145.67 -6.81 0.6 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 115.307 1.595 . . . . 0.0 115.307 -179.082 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.404 HD12 ' HA ' ' A' ' 14' ' ' TRP . 11.8 mt -66.82 -53.98 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 119.751 1.16 . . . . 0.0 111.562 -175.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -157.83 164.98 36.44 Favored 'General case' 0 CA--C 1.531 0.248 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 -172.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.538 1.495 0 C-N-CA 127.731 2.586 . . . . 0.0 112.448 170.195 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.2 m . . . . . 0 N--CA 1.476 0.837 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mp -136.35 144.09 44.43 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 174.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -66.59 -23.8 66.25 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 -170.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -27.24 61.23 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.112 0.863 . . . . 0.0 112.83 178.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -79.71 -44.44 20.79 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 118.779 1.29 . . . . 0.0 110.385 172.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 21.0 mt -60.22 -38.66 78.13 Favored 'Isoleucine or valine' 0 C--N 1.34 0.167 0 C-N-CA 125.671 1.588 . . . . 0.0 111.785 -176.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -74.03 -58.69 3.13 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 127.613 2.365 . . . . 0.0 109.881 168.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.02 -32.82 59.94 Favored Glycine 0 C--N 1.34 0.795 0 C-N-CA 123.978 0.799 . . . . 0.0 113.883 -166.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.1 t80 -67.64 -36.84 81.52 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.193 0.997 . . . . 0.0 111.772 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.2 mt -71.0 -33.65 52.54 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 C-N-CA 124.363 1.065 . . . . 0.0 109.597 177.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -80.3 -50.48 10.12 Favored 'General case' 0 C--N 1.333 -0.149 0 C-N-CA 125.312 1.445 . . . . 0.0 108.179 -170.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 31.1 m-80 -66.05 -19.15 65.76 Favored 'General case' 0 C--N 1.342 0.274 0 CA-C-O 119.394 -0.336 . . . . 0.0 110.691 168.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.08 -50.79 16.25 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 173.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.7 t90 -64.26 -61.32 2.32 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 125.051 1.34 . . . . 0.0 109.167 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -88.94 23.38 2.39 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.786 0.803 . . . . 0.0 111.53 -169.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.07 -13.33 34.05 Favored Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.338 1.447 . . . . 0.0 111.488 171.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.9 ttm -146.67 -34.94 0.27 Allowed 'General case' 0 C--N 1.341 0.238 0 CA-C-N 118.253 1.026 . . . . 0.0 113.724 -177.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 39.6 mt -95.87 -85.29 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -162.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -75.82 144.51 41.26 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -175.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.559 0 CA-C-O 118.341 -1.255 . . . . 0.0 114.134 -165.256 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 19.1 m . . . . . 0 N--CA 1.476 0.849 0 CA-C-O 116.604 -1.665 . . . . 0.0 107.397 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.8 mp 63.95 170.61 0.17 Allowed 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 126.346 1.859 . . . . 0.0 111.431 -171.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -59.58 -26.46 65.44 Favored 'General case' 0 N--CA 1.463 0.193 0 O-C-N 121.678 -0.639 . . . . 0.0 111.934 -178.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.55 -26.18 66.22 Favored Glycine 0 CA--C 1.53 0.982 0 C-N-CA 125.285 1.422 . . . . 0.0 112.728 175.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -88.54 -62.63 1.45 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.37 1.085 . . . . 0.0 109.326 166.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 52.2 mt -61.07 -22.39 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 C-N-CA 126.345 1.858 . . . . 0.0 113.782 -160.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -132.42 -42.88 0.94 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 125.569 1.548 . . . . 0.0 111.028 172.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.94 -36.03 59.82 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 118.814 -0.992 . . . . 0.0 112.931 -175.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.5 t80 -77.35 -19.91 55.58 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 118.692 1.246 . . . . 0.0 112.583 176.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -82.29 -38.51 15.48 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.028 1.331 . . . . 0.0 108.755 174.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -73.18 -57.96 3.65 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 128.016 2.526 . . . . 0.0 107.593 -175.049 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -69.67 -7.76 41.84 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.045 0.538 . . . . 0.0 111.06 169.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.75 -59.42 4.07 Favored Glycine 0 C--N 1.34 0.777 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 169.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 18.8 t90 -60.27 -56.84 16.61 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 125.54 1.536 . . . . 0.0 109.739 177.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -85.03 23.65 1.2 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.632 0.773 . . . . 0.0 111.483 -177.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.94 9.82 11.26 Favored Glycine 0 CA--C 1.534 1.229 0 C-N-CA 127.886 2.66 . . . . 0.0 111.656 164.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.5 ptt? -129.93 -20.86 3.08 Favored 'General case' 0 C--N 1.344 0.367 0 CA-C-N 118.088 0.944 . . . . 0.0 113.491 164.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.0 mm -61.68 -29.4 46.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 123.617 0.767 . . . . 0.0 110.949 172.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -78.66 3.74 15.55 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 125.365 1.466 . . . . 0.0 113.12 174.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.043 0 C-N-CA 126.076 1.798 . . . . 0.0 113.783 -179.249 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 30.8 m . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 55.3 mt -131.13 165.01 24.23 Favored 'General case' 0 C--O 1.235 0.326 0 C-N-CA 125.704 1.601 . . . . 0.0 106.987 166.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -59.19 -26.06 64.49 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -174.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.12 -28.35 63.87 Favored Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.414 1.006 . . . . 0.0 112.778 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.26 -42.14 21.12 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 119.138 1.469 . . . . 0.0 110.516 171.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 22.6 mt -59.22 -39.96 80.01 Favored 'Isoleucine or valine' 0 C--N 1.342 0.257 0 C-N-CA 124.823 1.249 . . . . 0.0 111.979 -176.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.55 -54.28 6.92 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 127.542 2.337 . . . . 0.0 110.116 169.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.58 -34.34 60.2 Favored Glycine 0 C--N 1.34 0.794 0 C-N-CA 124.242 0.925 . . . . 0.0 113.642 -170.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -72.17 -23.17 61.24 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 118.407 1.103 . . . . 0.0 112.683 178.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -79.64 -38.84 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 C-N-CA 124.323 1.049 . . . . 0.0 108.784 170.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -72.44 -55.36 7.15 Favored 'General case' 0 C--O 1.226 -0.17 0 C-N-CA 125.08 1.352 . . . . 0.0 109.052 -172.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -79.82 2.71 22.08 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.451 0.568 . . . . 0.0 111.595 167.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.79 -52.94 22.12 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 159.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -58.49 -63.37 1.3 Allowed 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.484 1.114 . . . . 0.0 108.592 169.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -80.66 56.91 2.78 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 127.154 2.182 . . . . 0.0 109.109 -176.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -173.29 -22.87 0.02 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 128.886 3.136 . . . . 0.0 110.794 178.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 33.5 mmt -93.39 -22.71 18.76 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 118.372 1.086 . . . . 0.0 112.569 166.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.2 mm -54.46 -42.6 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 C-N-CA 124.557 1.143 . . . . 0.0 110.745 173.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -98.32 4.37 48.66 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 127.324 2.25 . . . . 0.0 112.614 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.799 0 C-N-CA 125.185 1.374 . . . . 0.0 110.761 176.137 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.475 0.819 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.6 mp -140.06 154.11 46.98 Favored 'General case' 0 C--O 1.232 0.172 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 176.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 28.8 t80 -71.49 -12.59 61.46 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 176.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.79 -24.6 54.07 Favored Glycine 0 CA--C 1.533 1.188 0 C-N-CA 124.4 1.0 . . . . 0.0 113.523 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -78.31 -43.34 28.18 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.491 1.146 . . . . 0.0 110.83 171.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 18.6 mm -71.58 -9.33 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 126.07 1.748 . . . . 0.0 111.818 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.15 -51.57 3.35 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 128.188 2.595 . . . . 0.0 109.484 168.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.66 -37.1 91.81 Favored Glycine 0 CA--C 1.529 0.92 0 CA-C-N 118.804 0.729 . . . . 0.0 112.8 -174.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 84.2 t80 -67.29 -25.63 66.13 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 117.638 0.719 . . . . 0.0 111.655 178.574 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.9 mm -66.47 -23.46 31.55 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.428 0 CA-C-N 118.898 0.772 . . . . 0.0 109.9 177.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 58.8 mm-40 -104.82 -60.87 1.54 Allowed 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 -172.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -64.25 -25.22 67.96 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 122.949 0.5 . . . . 0.0 112.304 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.85 0.77 86.04 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.161 -0.799 . . . . 0.0 113.078 174.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -127.44 -68.34 0.79 Allowed 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.78 1.632 . . . . 0.0 108.574 -176.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -74.16 23.79 0.08 Allowed 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.923 2.089 . . . . 0.0 112.394 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.24 -33.81 5.57 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 125.209 1.385 . . . . 0.0 111.367 162.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.1 mmm -153.65 64.76 0.73 Allowed 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 118.825 1.313 . . . . 0.0 109.746 -173.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 25.7 mt -71.74 -54.59 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 166.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.8 t0 -80.24 155.56 27.28 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.808 0.813 . . . . 0.0 111.118 -174.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.271 0 C-N-CA 126.996 2.236 . . . . 0.0 112.11 169.899 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.477 0.919 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -113.14 153.42 28.29 Favored 'General case' 0 N--CA 1.462 0.148 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 171.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -77.39 -12.96 60.02 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 179.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.71 -42.0 58.31 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.369 0.985 . . . . 0.0 112.986 -170.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.74 -22.41 61.61 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 125.298 1.439 . . . . 0.0 112.719 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.8 mm -74.35 -5.47 6.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 C-N-CA 124.645 1.178 . . . . 0.0 110.811 176.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.37 -42.11 3.98 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 126.608 1.963 . . . . 0.0 109.706 160.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.68 -39.51 91.28 Favored Glycine 0 C--N 1.342 0.909 0 CA-C-N 119.23 0.923 . . . . 0.0 112.87 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 57.6 t80 -75.62 -15.28 60.36 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 117.843 0.821 . . . . 0.0 112.69 177.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.8 mm -85.66 -37.76 12.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 124.699 1.2 . . . . 0.0 108.724 174.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -72.62 -55.75 6.38 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 126.568 1.947 . . . . 0.0 107.886 -177.05 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -69.29 -6.62 30.59 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.558 0.743 . . . . 0.0 111.247 168.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.97 -57.49 3.72 Favored Glycine 0 C--N 1.341 0.82 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 169.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -57.02 -57.01 14.43 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 126.536 1.934 . . . . 0.0 109.283 175.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -83.27 24.38 0.81 Allowed 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 123.944 0.897 . . . . 0.0 111.612 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -121.47 6.87 10.58 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 127.324 2.392 . . . . 0.0 111.331 164.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.8 mmt -126.58 -36.11 2.29 Favored 'General case' 0 C--N 1.344 0.366 0 C-N-CA 125.215 1.406 . . . . 0.0 111.767 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 24.1 mm -61.6 -35.48 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 C-N-CA 124.887 1.275 . . . . 0.0 110.704 175.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -91.51 4.15 53.27 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 126.443 1.897 . . . . 0.0 112.353 177.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.922 0 C-N-CA 126.174 1.845 . . . . 0.0 115.185 -159.191 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 48.7 t . . . . . 0 N--CA 1.476 0.839 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.7 mp -139.06 154.06 48.14 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 172.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -77.9 -12.01 59.94 Favored 'General case' 0 CA--C 1.535 0.38 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 177.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.91 -28.96 61.35 Favored Glycine 0 CA--C 1.531 1.045 0 C-N-CA 124.033 0.825 . . . . 0.0 113.583 -174.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.8 -33.52 27.23 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 118.572 1.186 . . . . 0.0 111.512 173.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 19.0 mm -73.66 -10.26 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 126.052 1.741 . . . . 0.0 111.609 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.81 -48.82 3.54 Favored 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 127.321 2.248 . . . . 0.0 109.632 164.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.38 -36.05 82.01 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-N 119.034 0.833 . . . . 0.0 113.33 -172.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -66.79 -31.2 71.67 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.439 1.12 . . . . 0.0 111.618 175.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mm -73.99 -18.14 17.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 124.484 1.114 . . . . 0.0 109.977 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -97.7 -61.21 1.42 Allowed 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 125.324 1.45 . . . . 0.0 107.337 -174.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -61.65 -30.99 71.08 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.527 0.731 . . . . 0.0 111.761 176.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.43 0.61 63.71 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.122 -0.821 . . . . 0.0 113.433 177.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 17.9 t90 -130.39 -69.65 0.65 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.943 1.297 . . . . 0.0 108.568 -174.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -78.51 23.43 0.31 Allowed 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.294 1.038 . . . . 0.0 112.043 -178.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.02 -2.71 16.08 Favored Glycine 0 CA--C 1.532 1.128 0 C-N-CA 127.416 2.436 . . . . 0.0 112.106 166.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 61.0 mtt -134.09 -10.05 2.62 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 118.977 1.389 . . . . 0.0 113.382 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.2 mm -68.87 -27.07 34.25 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 C-N-CA 124.114 0.966 . . . . 0.0 111.957 177.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -70.14 109.3 4.54 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.972 0.805 . . . . 0.0 110.122 176.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.902 0 C-N-CA 125.447 1.499 . . . . 0.0 111.144 169.249 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 19.3 m . . . . . 0 N--CA 1.476 0.863 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.4 mt -139.07 160.15 40.47 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 125.442 1.497 . . . . 0.0 107.706 174.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -103.0 -9.47 19.77 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 112.624 0.601 . . . . 0.0 112.624 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.3 -30.73 64.89 Favored Glycine 0 CA--C 1.532 1.108 0 O-C-N 121.399 -0.813 . . . . 0.0 113.945 -170.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.75 30.08 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.855 1.262 . . . . 0.0 111.658 175.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.4 mm -75.46 -5.62 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 125.814 1.646 . . . . 0.0 111.099 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -110.02 -46.21 3.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 126.28 1.832 . . . . 0.0 109.922 160.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.37 -36.39 83.58 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 119.23 0.923 . . . . 0.0 113.274 -172.3 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -74.37 -20.08 60.21 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 117.755 0.778 . . . . 0.0 112.482 176.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -81.67 -34.5 12.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 124.288 1.035 . . . . 0.0 109.001 174.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -73.98 -56.09 5.36 Favored 'General case' 0 N--CA 1.457 -0.125 0 C-N-CA 125.813 1.645 . . . . 0.0 107.644 -176.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -63.13 -21.27 66.08 Favored 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 122.857 0.463 . . . . 0.0 111.0 168.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.73 -9.9 86.66 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-O 119.338 -0.701 . . . . 0.0 112.948 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -114.03 -58.1 2.19 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.916 1.286 . . . . 0.0 109.499 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.8 23.89 0.16 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 124.928 1.291 . . . . 0.0 112.691 -174.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.37 49.95 3.08 Favored Glycine 0 CA--C 1.528 0.871 0 C-N-CA 126.146 1.832 . . . . 0.0 111.87 178.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 75.4 mtm 58.53 73.93 0.46 Allowed 'General case' 0 C--N 1.341 0.214 0 C-N-CA 127.192 2.197 . . . . 0.0 110.468 -175.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 90.6 mt -52.53 -27.81 11.67 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.723 0 C-N-CA 126.892 2.077 . . . . 0.0 112.532 -179.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.8 t70 63.69 -168.45 0.2 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 125.613 1.565 . . . . 0.0 110.119 -166.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.172 0 C-N-CA 125.303 1.43 . . . . 0.0 113.679 178.975 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 23.9 m . . . . . 0 N--CA 1.477 0.904 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -127.57 154.52 45.1 Favored 'General case' 0 C--O 1.231 0.128 0 N-CA-C 106.63 -1.618 . . . . 0.0 106.63 169.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -88.62 -9.15 53.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 122.878 0.471 . . . . 0.0 112.134 177.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.61 -32.34 61.29 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 123.976 0.798 . . . . 0.0 114.09 -168.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.19 -28.34 27.4 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.434 1.093 . . . . 0.0 111.952 175.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.2 mm -74.88 -10.92 14.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 125.681 1.592 . . . . 0.0 111.244 -179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.66 -49.16 3.48 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 126.896 2.078 . . . . 0.0 109.55 162.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.0 -35.88 78.45 Favored Glycine 0 C--N 1.342 0.875 0 CA-C-N 118.988 0.813 . . . . 0.0 113.286 -170.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -70.78 -28.04 64.37 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 118.338 1.069 . . . . 0.0 112.038 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.4 mm -72.49 -25.28 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 119.066 0.848 . . . . 0.0 109.487 176.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -92.71 -65.6 0.99 Allowed 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 125.639 1.575 . . . . 0.0 107.029 -171.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.13 -24.56 67.45 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.623 0.769 . . . . 0.0 110.764 179.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -77.38 -3.29 82.16 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 118.855 -0.97 . . . . 0.0 113.198 176.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.7 t90 -130.78 -74.66 0.53 Allowed 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 118.509 1.155 . . . . 0.0 108.984 179.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -79.75 23.71 0.42 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.679 1.192 . . . . 0.0 112.404 -172.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.27 -16.43 57.39 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 118.186 -1.341 . . . . 0.0 112.319 170.303 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 45.6 mmm -141.07 9.57 2.12 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 118.612 1.206 . . . . 0.0 113.037 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 5.3 mm -65.89 -28.98 45.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 O-C-N 120.898 -1.126 . . . . 0.0 112.217 -177.37 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 49.55 14.75 0.12 Allowed 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 129.049 2.94 . . . . 0.0 116.703 162.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.089 0 C-N-CA 125.35 1.452 . . . . 0.0 115.172 -170.153 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 15.6 m . . . . . 0 N--CA 1.478 0.939 0 CA-C-O 118.489 -0.767 . . . . 0.0 109.391 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.0 mm? 61.37 167.56 0.1 Allowed 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 127.222 2.209 . . . . 0.0 112.037 -170.155 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -60.17 -26.65 66.49 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.661 0.615 . . . . 0.0 112.661 -170.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -63.56 -24.13 67.55 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.859 1.218 . . . . 0.0 112.732 177.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.03 -61.8 1.51 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 118.126 0.963 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 56.9 mt -60.15 -21.95 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 C-N-CA 126.398 1.879 . . . . 0.0 113.589 -161.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -131.26 -43.59 1.04 Allowed 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 125.953 1.701 . . . . 0.0 110.84 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.27 -34.35 59.02 Favored Glycine 0 CA--C 1.53 0.993 0 CA-C-N 119.067 0.849 . . . . 0.0 113.342 -177.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.0 t80 -75.62 -23.59 56.41 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.624 1.212 . . . . 0.0 112.231 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.3 mm -80.11 -35.12 15.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 C-N-CA 125.19 1.396 . . . . 0.0 109.144 175.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -73.69 -59.13 2.86 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 128.026 2.53 . . . . 0.0 106.833 -176.021 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -62.46 -19.13 63.21 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 119.224 -0.417 . . . . 0.0 111.291 170.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.13 -54.24 9.44 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 175.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -62.37 -57.2 12.19 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.53 1.532 . . . . 0.0 109.713 176.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 -80.22 23.41 0.48 Allowed 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.543 1.537 . . . . 0.0 112.857 -166.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -119.63 -5.66 10.97 Favored Glycine 0 CA--C 1.532 1.139 0 C-N-CA 126.753 2.121 . . . . 0.0 112.193 166.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 95.7 mmm -127.31 -2.91 6.26 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 118.714 1.257 . . . . 0.0 113.102 -174.127 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.0 mt -52.77 -47.74 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 C-N-CA 124.219 1.008 . . . . 0.0 110.579 -178.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -117.71 89.26 3.08 Favored 'General case' 0 N--CA 1.455 -0.196 0 C-N-CA 126.384 1.874 . . . . 0.0 106.124 174.052 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 0.381 0 N-CA-C 107.116 -2.394 . . . . 0.0 107.116 -173.011 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 N--CA 1.476 0.864 0 CA-C-O 118.675 -0.679 . . . . 0.0 109.295 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? 59.31 -179.02 0.08 Allowed 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 126.145 1.778 . . . . 0.0 112.52 179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.3 t80 -58.86 -25.76 63.59 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 123.679 0.792 . . . . 0.0 112.399 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.49 -15.06 51.99 Favored Glycine 0 CA--C 1.533 1.195 0 C-N-CA 125.323 1.439 . . . . 0.0 113.447 172.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -106.31 -55.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 118.527 1.163 . . . . 0.0 109.867 164.491 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 30.7 mt -61.95 -18.58 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 124.645 1.178 . . . . 0.0 113.677 -167.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -125.02 -43.47 1.97 Allowed 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 125.697 1.599 . . . . 0.0 110.766 166.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.58 -34.89 78.08 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 119.417 1.008 . . . . 0.0 113.252 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.9 t80 -79.06 -10.69 59.9 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.622 1.211 . . . . 0.0 112.494 175.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.5 mm -87.66 -39.86 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 C-N-CA 124.798 1.239 . . . . 0.0 108.218 169.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -70.5 -59.96 2.54 Favored 'General case' 0 N--CA 1.457 -0.102 0 C-N-CA 126.6 1.96 . . . . 0.0 109.035 -176.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -74.01 -3.01 26.65 Favored 'General case' 0 CA--C 1.535 0.391 0 O-C-N 121.876 -0.515 . . . . 0.0 111.648 166.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.44 -10.26 74.82 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.495 0.589 . . . . 0.0 112.348 161.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -116.6 -64.22 1.34 Allowed 'General case' 0 N--CA 1.45 -0.434 0 C-N-CA 126.79 2.036 . . . . 0.0 107.226 177.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.4 mt-10 -80.84 59.3 3.66 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-O 122.4 1.095 . . . . 0.0 109.49 172.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -145.25 13.66 1.86 Allowed Glycine 0 CA--C 1.534 1.225 0 C-N-CA 125.918 1.723 . . . . 0.0 111.765 161.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 25.6 ptt? -170.43 -18.84 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 128.386 2.675 . . . . 0.0 114.111 175.261 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 51.9 mt -100.78 -22.84 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 124.568 1.147 . . . . 0.0 110.338 -176.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -49.86 114.1 1.0 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 127.806 2.442 . . . . 0.0 109.598 164.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.721 0 N-CA-C 107.099 -2.4 . . . . 0.0 107.099 -162.714 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 61.1 t . . . . . 0 N--CA 1.476 0.855 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mp -140.3 157.52 45.44 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 174.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -62.79 -22.79 66.86 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.676 0.79 . . . . 0.0 112.003 172.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.47 -21.47 57.46 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 125.241 1.401 . . . . 0.0 112.895 171.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -85.65 -65.04 1.05 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 118.762 1.281 . . . . 0.0 108.766 163.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 29.1 mt -60.98 -24.5 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 125.509 1.523 . . . . 0.0 113.987 -161.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.44 -47.25 1.87 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 125.83 1.652 . . . . 0.0 110.542 172.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.56 -32.76 65.34 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-O 118.935 -0.925 . . . . 0.0 113.631 -172.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 64.2 t80 -76.37 -23.93 54.15 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 119.136 1.468 . . . . 0.0 112.108 175.073 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mm -71.08 -31.37 44.6 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 O-C-N 120.987 -1.07 . . . . 0.0 108.814 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -101.99 -49.8 3.84 Favored 'General case' 0 C--O 1.225 -0.188 0 C-N-CA 123.805 0.842 . . . . 0.0 110.386 -171.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 25.5 m-80 -86.45 -19.77 29.13 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.4 0.546 . . . . 0.0 111.234 -179.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -96.45 -62.71 0.94 Allowed Glycine 0 C--N 1.34 0.79 0 N-CA-C 110.23 -1.148 . . . . 0.0 110.23 -175.647 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 23.5 t90 -80.23 -68.55 0.67 Allowed 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -79.54 23.45 0.41 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.356 0.872 . . . . 0.0 113.356 -167.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.69 -6.5 11.43 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 126.828 2.156 . . . . 0.0 112.729 170.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 59.1 mmm -130.19 20.59 5.32 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 118.964 1.382 . . . . 0.0 112.087 -172.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.5 mm -68.94 -27.38 35.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 C-N-CA 123.711 0.805 . . . . 0.0 111.216 -177.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 50.14 4.03 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 131.103 3.761 . . . . 0.0 117.846 169.045 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.009 0 C-N-CA 128.953 3.168 . . . . 0.0 112.695 178.17 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.478 0.935 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -122.96 158.93 29.38 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 170.326 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.5 t80 -61.49 -22.42 65.08 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.6 -26.22 56.78 Favored Glycine 0 CA--C 1.532 1.1 0 CA-C-O 118.926 -0.93 . . . . 0.0 112.903 172.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.74 -43.74 15.17 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 119.222 1.511 . . . . 0.0 110.356 171.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 17.1 mt -64.1 -13.21 13.32 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 C-N-CA 126.653 1.981 . . . . 0.0 112.629 -177.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.39 -48.92 2.99 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 127.59 2.356 . . . . 0.0 110.204 170.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.29 -36.1 81.54 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-N 119.412 1.006 . . . . 0.0 113.082 -174.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -73.7 -18.8 60.96 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 118.031 0.916 . . . . 0.0 112.515 176.018 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.3 mm -80.98 -39.02 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 CA-C-N 119.431 1.014 . . . . 0.0 108.299 172.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -69.81 -62.41 1.39 Allowed 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 126.598 1.959 . . . . 0.0 107.951 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -64.58 -16.97 63.51 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 119.415 -0.326 . . . . 0.0 111.165 169.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.89 -16.32 66.0 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-O 118.747 -1.03 . . . . 0.0 113.37 173.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -127.49 -44.96 1.51 Allowed 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.571 1.185 . . . . 0.0 111.807 174.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -81.13 23.64 0.57 Allowed 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 122.256 1.027 . . . . 0.0 112.164 -162.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -100.66 -10.94 42.39 Favored Glycine 0 CA--C 1.532 1.135 0 C-N-CA 125.603 1.573 . . . . 0.0 112.227 163.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 82.5 mmm -111.64 -9.85 14.13 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 118.851 1.325 . . . . 0.0 113.521 -169.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 47.5 mm -85.51 -24.38 6.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 C-N-CA 124.055 0.942 . . . . 0.0 112.313 -171.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -70.96 151.02 45.11 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-O 122.151 0.977 . . . . 0.0 110.935 -178.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.051 0 C-N-CA 125.48 1.514 . . . . 0.0 111.8 166.065 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.4 m . . . . . 0 N--CA 1.477 0.899 0 CA-C-O 118.424 -0.798 . . . . 0.0 108.868 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? 64.24 154.65 0.06 Allowed 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 127.342 2.257 . . . . 0.0 110.728 -161.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -84.43 -11.79 55.57 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 -178.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.18 -32.57 63.48 Favored Glycine 0 CA--C 1.531 1.066 0 C-N-CA 123.817 0.722 . . . . 0.0 113.167 -174.393 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.07 -33.24 26.45 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.53 1.132 . . . . 0.0 111.629 174.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 20.1 mm -73.9 -9.1 12.61 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 125.644 1.578 . . . . 0.0 111.665 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -105.39 -50.45 3.22 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 127.479 2.312 . . . . 0.0 109.588 163.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -58.21 -35.46 77.98 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 118.994 0.815 . . . . 0.0 113.281 -171.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 81.6 t80 -69.86 -28.11 65.39 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.198 0.999 . . . . 0.0 112.117 176.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mm -72.47 -25.67 23.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 CA-C-N 118.931 0.787 . . . . 0.0 109.429 176.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -92.91 -63.57 1.2 Allowed 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.225 1.41 . . . . 0.0 107.57 -170.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -68.39 -22.53 64.63 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.156 0.583 . . . . 0.0 110.872 178.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.94 -6.96 80.52 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.349 -0.695 . . . . 0.0 112.758 174.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 10.9 t90 -114.1 -76.05 0.59 Allowed 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.228 1.411 . . . . 0.0 107.436 171.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.67 56.09 3.71 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 122.207 1.003 . . . . 0.0 110.971 -171.776 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -104.98 -7.97 37.37 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-O 118.659 -1.078 . . . . 0.0 111.73 159.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 21.0 mmt -148.97 3.05 0.6 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 125.054 1.341 . . . . 0.0 113.287 -169.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.7 mm -88.94 -46.87 15.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 CA-C-N 120.163 1.347 . . . . 0.0 108.779 -170.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.2 t70 50.41 -143.85 0.56 Allowed 'General case' 0 CA--C 1.547 0.842 0 C-N-CA 124.524 1.13 . . . . 0.0 109.854 -168.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.163 0 C-N-CA 126.034 1.778 . . . . 0.0 112.184 -169.309 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.7 p . . . . . 0 N--CA 1.477 0.892 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.9 mt -136.13 162.92 31.59 Favored 'General case' 0 C--O 1.233 0.218 0 C-N-CA 125.006 1.323 . . . . 0.0 108.231 176.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -65.92 -16.09 63.55 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 176.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.59 -23.5 58.47 Favored Glycine 0 CA--C 1.533 1.208 0 C-N-CA 124.701 1.143 . . . . 0.0 112.665 167.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.53 -58.31 2.79 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 118.891 1.346 . . . . 0.0 109.152 164.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.8 mm -64.3 -21.49 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -162.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -134.42 -44.75 0.76 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 125.941 1.696 . . . . 0.0 110.972 172.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.34 -42.57 74.61 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-N 118.992 0.815 . . . . 0.0 112.878 -173.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -77.62 -15.9 58.91 Favored 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 124.462 1.105 . . . . 0.0 112.466 177.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.1 mm -71.1 -38.0 69.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 O-C-N 120.453 -1.404 . . . . 0.0 107.867 171.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -94.17 -55.71 3.1 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -167.325 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.0 m-80 -76.62 -20.06 57.14 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.141 0.576 . . . . 0.0 110.71 178.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.54 -63.88 0.79 Allowed Glycine 0 C--N 1.341 0.86 0 CA-C-O 118.387 -1.229 . . . . 0.0 111.45 -171.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -69.42 -64.06 0.95 Allowed 'General case' 0 C--N 1.341 0.22 0 CA-C-N 118.636 1.218 . . . . 0.0 108.336 175.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -80.34 23.14 0.51 Allowed 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 121.561 0.696 . . . . 0.0 112.522 -174.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -99.3 -58.41 0.91 Allowed Glycine 0 CA--C 1.524 0.631 0 C-N-CA 126.816 2.151 . . . . 0.0 108.739 162.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.7 ptm -65.06 -18.05 64.97 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 118.38 1.09 . . . . 0.0 113.555 -179.375 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.6 mm -57.55 -31.37 38.99 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 123.735 0.814 . . . . 0.0 110.633 169.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.7 t0 -79.47 63.27 4.02 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 119.365 0.984 . . . . 0.0 110.332 175.065 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.105 0 CA-C-O 118.715 -1.047 . . . . 0.0 114.225 170.769 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 22.1 m . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 117.67 -1.157 . . . . 0.0 108.097 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -64.29 154.71 34.38 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 119.529 1.058 . . . . 0.0 110.233 -177.658 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -62.34 -21.0 64.95 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -173.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.42 -28.73 55.98 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 119.04 -0.867 . . . . 0.0 112.673 173.255 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.31 -41.96 19.41 Favored 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 119.127 1.464 . . . . 0.0 110.654 172.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.6 mt -65.82 -10.57 10.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.549 0 C-N-CA 126.486 1.914 . . . . 0.0 112.465 -177.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -114.04 -45.02 3.09 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 127.01 2.124 . . . . 0.0 110.824 168.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.93 -38.79 76.29 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.682 0.674 . . . . 0.0 112.837 -176.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -78.21 -11.46 59.93 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 117.789 0.794 . . . . 0.0 112.632 178.452 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 9.7 mm -86.7 -42.37 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-N 119.218 0.917 . . . . 0.0 108.782 176.397 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.7 pt-20 -78.53 -47.35 17.48 Favored 'General case' 0 CA--C 1.527 0.093 0 C-N-CA 124.403 1.081 . . . . 0.0 108.706 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -74.16 -13.04 60.75 Favored 'General case' 0 C--N 1.344 0.361 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 170.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.95 -53.51 9.35 Favored Glycine 0 C--N 1.342 0.861 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 171.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.536 ' HA ' HD12 ' A' ' 18' ' ' ILE . 22.7 t90 -67.26 -62.65 1.32 Allowed 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 123.381 0.673 . . . . 0.0 109.275 178.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -90.76 23.35 3.14 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.431 0.634 . . . . 0.0 111.511 -165.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.13 -27.04 26.9 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 124.551 1.072 . . . . 0.0 111.339 171.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.4 ptm -159.21 -10.71 0.06 Allowed 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 -178.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.536 HD12 ' HA ' ' A' ' 14' ' ' TRP . 58.6 mt -92.21 -44.3 14.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 119.765 1.166 . . . . 0.0 111.647 -159.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -72.29 148.89 44.98 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-N 118.453 0.57 . . . . 0.0 111.316 -174.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.914 0 C-N-CA 124.966 1.269 . . . . 0.0 113.17 -176.471 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.438 HG13 ' H ' ' A' ' 2' ' ' LEU 0.284 12.5 p . . . . . 0 N--CA 1.475 0.818 0 CA-C-O 116.348 -1.786 . . . . 0.0 107.577 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.438 ' H ' HG13 ' A' ' 1' ' ' VAL . 2.8 mm? 62.03 174.26 0.13 Allowed 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 126.885 2.074 . . . . 0.0 111.01 -170.467 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -64.32 -19.96 65.79 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 121.129 -0.982 . . . . 0.0 112.154 178.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.7 -23.14 54.96 Favored Glycine 0 CA--C 1.533 1.178 0 C-N-CA 125.109 1.338 . . . . 0.0 112.906 167.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.37 -47.83 6.7 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 118.869 1.334 . . . . 0.0 110.693 167.141 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.8 mm -64.24 -24.47 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.92 -44.79 0.58 Allowed 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 125.908 1.683 . . . . 0.0 111.092 175.177 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -55.8 -37.63 70.13 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-N 119.035 0.834 . . . . 0.0 113.315 -169.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -67.32 -32.1 72.83 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 124.22 1.008 . . . . 0.0 111.832 176.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.0 mt -74.52 -29.06 23.13 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 C-N-CA 124.041 0.937 . . . . 0.0 109.351 175.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -81.58 -57.72 3.34 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 125.492 1.517 . . . . 0.0 108.366 -174.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 18.4 p30 -65.78 -18.42 65.32 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 118.561 0.619 . . . . 0.0 111.655 170.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.75 -2.57 76.77 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 119.369 -0.684 . . . . 0.0 113.114 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 13.4 t90 -128.26 -68.37 0.77 Allowed 'General case' 0 C--O 1.234 0.239 0 C-N-CA 125.534 1.534 . . . . 0.0 109.127 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -77.36 23.71 0.2 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.595 1.558 . . . . 0.0 112.359 -176.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -118.58 -1.73 15.27 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 126.977 2.227 . . . . 0.0 112.112 167.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 78.9 mtm -134.93 -9.43 2.34 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 119.035 1.417 . . . . 0.0 114.142 -178.034 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 34.3 mm -61.41 -33.91 58.9 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 CA-C-N 119.209 0.913 . . . . 0.0 110.402 170.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -108.44 89.72 3.08 Favored 'General case' 0 C--N 1.339 0.124 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 159.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.003 0 C-N-CA 125.16 1.362 . . . . 0.0 112.331 -178.267 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.5 mm? 59.35 168.44 0.07 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 127.047 2.139 . . . . 0.0 112.504 -169.64 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 t80 -62.55 -23.66 67.11 Favored 'General case' 0 N--CA 1.464 0.247 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -173.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.98 -29.84 59.66 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.217 0.913 . . . . 0.0 112.501 173.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.82 -35.07 22.55 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.877 1.339 . . . . 0.0 111.259 172.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 43.2 mm -62.91 -33.63 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 C-N-CA 123.69 0.796 . . . . 0.0 111.908 179.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.41 -61.69 1.87 Allowed 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 127.307 2.243 . . . . 0.0 109.484 165.098 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.75 -32.99 66.51 Favored Glycine 0 C--N 1.341 0.83 0 C-N-CA 123.811 0.72 . . . . 0.0 114.003 -164.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -69.02 -31.05 69.58 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 118.254 1.027 . . . . 0.0 112.029 178.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 8.9 mt -73.2 -35.19 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 123.945 0.898 . . . . 0.0 109.26 174.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -78.89 -55.55 5.07 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 125.128 1.371 . . . . 0.0 108.226 -170.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -65.33 -20.96 66.63 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 122.803 0.441 . . . . 0.0 110.122 171.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.18 -57.23 8.74 Favored Glycine 0 C--N 1.34 0.767 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 22.2 t90 -62.29 -60.92 2.88 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.609 1.164 . . . . 0.0 109.046 179.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -85.61 23.71 1.34 Allowed 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.384 0.673 . . . . 0.0 111.962 -169.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -122.76 -14.94 4.09 Favored Glycine 0 CA--C 1.531 1.063 0 C-N-CA 126.54 2.019 . . . . 0.0 112.098 165.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 26.4 mmt -112.0 -12.0 13.78 Favored 'General case' 0 C--N 1.343 0.316 0 CA-C-N 118.732 1.266 . . . . 0.0 112.246 178.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.1 mm -63.03 -63.14 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 158.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -153.61 176.92 11.52 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 126.414 1.886 . . . . 0.0 107.015 -170.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.047 0 C-N-CA 126.71 2.1 . . . . 0.0 112.878 179.227 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.474 0.743 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -61.77 155.27 23.38 Favored 'General case' 0 C--O 1.24 0.569 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 152.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -68.27 -19.36 64.71 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -174.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.59 -25.04 57.8 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 124.236 0.922 . . . . 0.0 112.939 176.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -77.51 -36.84 52.16 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.631 1.215 . . . . 0.0 110.909 172.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.3 mm -65.97 -51.39 61.24 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 CA-C-O 122.339 1.066 . . . . 0.0 109.815 179.693 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.34 -52.88 60.19 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 112.35 -2.204 . . . . 0.0 109.495 169.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -54.84 -33.25 56.04 Favored Glycine 0 CA--C 1.53 0.976 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.949 -178.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -72.05 -28.11 63.13 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 118.464 1.132 . . . . 0.0 112.465 176.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.4 mt -74.52 -37.17 43.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 CA-C-N 119.484 1.038 . . . . 0.0 109.433 170.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -74.22 -56.07 5.32 Favored 'General case' 0 C--N 1.334 -0.105 0 C-N-CA 125.135 1.374 . . . . 0.0 108.646 -172.024 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.59 -7.52 33.52 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.103 0.561 . . . . 0.0 110.729 168.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.73 -54.35 7.44 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 168.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -58.09 -56.33 23.47 Favored 'General case' 0 C--O 1.233 0.19 0 C-N-CA 125.409 1.484 . . . . 0.0 108.221 173.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -81.9 23.33 0.7 Allowed 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.212 -0.93 . . . . 0.0 112.13 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.25 -21.84 69.36 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.312 -1.115 . . . . 0.0 110.312 166.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 19.5 ttt -145.45 -36.15 0.29 Allowed 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 176.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 19.3 mm -74.98 -65.34 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.968 0.413 . . . . 0.0 110.336 -159.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -82.85 4.2 26.49 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 -165.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.296 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 158.803 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.0 t . . . . . 0 N--CA 1.477 0.876 0 CA-C-O 116.715 -1.612 . . . . 0.0 106.727 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 58.34 173.48 0.06 Allowed 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 125.924 1.69 . . . . 0.0 110.303 -157.075 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -114.52 -12.9 12.23 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -176.505 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.26 -34.72 81.43 Favored Glycine 0 CA--C 1.529 0.967 0 C-N-CA 123.533 0.587 . . . . 0.0 112.922 -174.381 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -81.25 -30.29 34.15 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 123.96 0.904 . . . . 0.0 111.659 174.573 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 31.1 mm -67.71 -39.34 81.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.149 0 C-N-CA 123.901 0.881 . . . . 0.0 110.793 -178.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.97 -56.76 7.8 Favored 'General case' 0 C--N 1.319 -0.761 0 C-N-CA 127.233 2.213 . . . . 0.0 109.687 164.692 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.53 -33.01 65.58 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.703 -169.271 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -67.4 -27.63 67.24 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 118.395 1.097 . . . . 0.0 111.989 178.04 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.9 mt -70.87 -36.0 62.35 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 O-C-N 121.527 -0.733 . . . . 0.0 109.179 171.559 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -79.24 -58.9 2.99 Favored 'General case' 0 N--CA 1.457 -0.104 0 C-N-CA 125.354 1.461 . . . . 0.0 108.128 -168.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 19.9 p30 -68.51 -12.76 61.69 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.87 -0.586 . . . . 0.0 112.069 171.988 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.66 -56.82 5.27 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 169.708 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 19.2 t90 -65.24 -61.34 2.19 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.513 1.125 . . . . 0.0 109.42 -178.415 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -86.69 23.7 1.62 Allowed 'General case' 0 CA--C 1.534 0.356 0 CA-C-O 121.363 0.601 . . . . 0.0 111.469 -172.412 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.38 -38.15 6.79 Favored Glycine 0 CA--C 1.526 0.757 0 C-N-CA 124.724 1.154 . . . . 0.0 111.21 173.135 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 91.1 mmm -143.33 -9.51 0.75 Allowed 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 114.804 1.409 . . . . 0.0 114.804 -173.352 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 75.1 mt -104.74 -56.8 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 119.691 1.132 . . . . 0.0 111.54 -161.558 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.63 178.47 4.84 Favored 'General case' 0 CA--C 1.529 0.15 0 N-CA-C 114.762 1.393 . . . . 0.0 114.762 -158.51 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.216 0 C-N-CA 125.096 1.331 . . . . 0.0 114.604 178.037 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 N--CA 1.477 0.915 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -125.84 159.28 32.88 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 172.632 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -61.61 -24.68 66.85 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 112.776 0.658 . . . . 0.0 112.776 -178.201 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.8 -26.72 60.77 Favored Glycine 0 CA--C 1.533 1.176 0 C-N-CA 124.179 0.895 . . . . 0.0 112.814 173.64 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.11 -34.75 37.63 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 118.95 1.375 . . . . 0.0 110.864 173.292 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 39.6 mm -63.14 -53.57 44.51 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-O 122.484 1.135 . . . . 0.0 109.694 177.227 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -51.17 -55.24 18.93 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 112.273 -2.24 . . . . 0.0 108.994 169.134 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.38 -33.97 33.05 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 124.09 0.853 . . . . 0.0 113.249 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 78.3 t80 -72.62 -39.91 66.88 Favored 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.439 1.12 . . . . 0.0 111.892 177.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 mt -65.65 -35.29 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 119.164 0.893 . . . . 0.0 109.955 171.55 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -79.57 -55.54 4.95 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 125.59 1.556 . . . . 0.0 108.781 -166.878 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -71.29 -13.28 61.84 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.759 169.591 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.51 -51.16 54.65 Favored Glycine 0 C--N 1.343 0.951 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 169.76 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.2 t90 -65.57 -62.05 1.74 Allowed 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 124.038 0.935 . . . . 0.0 109.308 173.355 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -79.42 23.54 0.39 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.385 1.474 . . . . 0.0 112.929 -168.331 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.96 2.09 5.53 Favored Glycine 0 CA--C 1.531 1.082 0 C-N-CA 127.399 2.428 . . . . 0.0 111.922 171.022 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 56.9 mtt -137.47 0.76 2.31 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-N 118.947 1.373 . . . . 0.0 113.431 -175.465 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.0 mt -59.1 -47.72 89.14 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 119.65 1.114 . . . . 0.0 110.829 -177.187 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.4 t0 27.32 80.86 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 128.831 2.852 . . . . 0.0 114.875 -167.316 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.458 0 CA-C-O 118.064 -1.409 . . . . 0.0 114.79 171.52 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 52.8 t . . . . . 0 N--CA 1.473 0.717 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.3 mm? 59.77 170.38 0.08 Allowed 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 127.317 2.247 . . . . 0.0 113.062 -169.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -63.41 -22.83 67.12 Favored 'General case' 0 CA--C 1.53 0.201 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 -174.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.4 -28.62 62.28 Favored Glycine 0 CA--C 1.532 1.121 0 C-N-CA 124.103 0.859 . . . . 0.0 112.518 173.757 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -82.56 -30.82 29.39 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 118.847 1.324 . . . . 0.0 111.465 173.653 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.0 mm -62.59 -51.63 69.82 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.299 0 CA-C-O 122.219 1.009 . . . . 0.0 109.756 175.68 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.81 -53.9 49.24 Favored 'General case' 0 C--N 1.316 -0.868 0 C-N-CA 127.299 2.239 . . . . 0.0 109.485 169.24 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.29 -35.4 42.96 Favored Glycine 0 CA--C 1.531 1.038 0 C-N-CA 124.024 0.821 . . . . 0.0 113.059 -179.838 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 90.8 t80 -74.9 -22.65 58.5 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.011 0.906 . . . . 0.0 112.725 178.611 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 mt -76.06 -41.23 38.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-N 119.577 1.08 . . . . 0.0 109.175 165.647 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -72.66 -55.15 7.26 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 125.042 1.337 . . . . 0.0 109.37 -167.597 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.8 m120 -80.54 -2.98 48.45 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 118.217 0.462 . . . . 0.0 111.258 167.901 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.43 -54.86 31.07 Favored Glycine 0 C--N 1.34 0.764 0 N-CA-C 109.035 -1.626 . . . . 0.0 109.035 162.846 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 21.1 t90 -64.1 -64.99 0.74 Allowed 'General case' 0 C--O 1.237 0.429 0 C-N-CA 123.776 0.83 . . . . 0.0 108.847 171.617 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -89.68 60.77 5.2 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 122.689 1.233 . . . . 0.0 108.937 -170.44 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.78 -32.05 0.02 OUTLIER Glycine 0 CA--C 1.524 0.642 0 CA-C-N 114.156 -1.383 . . . . 0.0 112.259 170.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 85.2 mmm -96.11 -12.36 24.9 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 118.282 1.041 . . . . 0.0 112.227 171.471 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.7 mt -135.06 -63.14 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.435 1.494 . . . . 0.0 108.642 -169.748 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 62.39 144.38 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.881 2.473 . . . . 0.0 113.209 -167.027 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.244 0 N-CA-C 116.52 1.368 . . . . 0.0 116.52 -179.041 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 N--CA 1.477 0.918 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 5.3 mp 59.34 -177.7 0.09 Allowed 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 125.492 1.517 . . . . 0.0 111.617 -174.595 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -60.54 -20.23 59.7 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.287 -0.883 . . . . 0.0 111.855 171.157 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.71 -29.46 61.4 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 124.407 1.003 . . . . 0.0 112.495 170.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -80.81 -33.7 34.55 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.978 1.389 . . . . 0.0 111.429 172.757 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 40.8 mm -60.05 -53.87 42.62 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.269 0 CA-C-O 122.277 1.037 . . . . 0.0 109.695 174.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.67 -51.99 61.41 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 127.753 2.421 . . . . 0.0 109.767 170.841 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.7 -36.69 49.57 Favored Glycine 0 CA--C 1.534 1.259 0 CA-C-N 118.422 0.555 . . . . 0.0 113.133 177.136 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -77.54 -14.99 59.53 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.739 0.816 . . . . 0.0 113.093 177.9 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.5 mt -82.93 -38.96 15.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 119.904 1.229 . . . . 0.0 109.496 164.088 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -65.21 -64.15 0.93 Allowed 'General case' 0 CA--C 1.521 -0.152 0 C-N-CA 125.908 1.683 . . . . 0.0 108.204 -173.879 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -79.69 2.51 22.42 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 118.148 0.431 . . . . 0.0 111.461 169.189 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.96 -57.02 12.98 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 162.461 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.6 t90 -68.99 -56.58 7.36 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 171.255 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -78.48 41.84 0.41 Allowed 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.059 0.944 . . . . 0.0 110.878 -177.548 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.67 41.87 2.99 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.548 2.023 . . . . 0.0 109.034 162.49 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 2.4 tmm? 57.46 29.05 16.4 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 126.568 1.947 . . . . 0.0 113.133 -174.858 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 70.0 mt -68.74 -51.2 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 O-C-N 121.459 -0.775 . . . . 0.0 109.242 169.768 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -57.87 151.72 17.44 Favored 'General case' 0 C--N 1.342 0.252 0 C-N-CA 123.565 0.746 . . . . 0.0 112.928 -169.272 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.336 0.559 0 C-N-CA 125.329 1.443 . . . . 0.0 110.716 174.265 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.1 mt 59.6 173.52 0.08 Allowed 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 126.084 1.754 . . . . 0.0 112.167 -168.815 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -66.06 -19.62 65.91 Favored 'General case' 0 CA--C 1.537 0.456 0 O-C-N 121.023 -1.048 . . . . 0.0 112.435 179.473 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -59.34 -21.54 54.1 Favored Glycine 0 CA--C 1.533 1.173 0 C-N-CA 124.742 1.163 . . . . 0.0 112.852 167.136 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.49 -53.02 4.38 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 118.904 1.352 . . . . 0.0 110.307 164.719 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 45.1 mm -62.95 -20.8 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -166.427 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -133.6 -47.51 0.82 Allowed 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 125.932 1.693 . . . . 0.0 110.635 170.488 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.87 -31.84 65.21 Favored Glycine 0 CA--C 1.531 1.064 0 CA-C-O 119.333 -0.704 . . . . 0.0 113.935 -168.301 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.0 t80 -70.48 -33.08 70.84 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.278 1.039 . . . . 0.0 111.567 175.808 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.9 mt -70.89 -21.54 22.49 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 124.605 1.162 . . . . 0.0 109.795 177.6 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -92.84 -63.32 1.24 Allowed 'General case' 0 C--O 1.231 0.094 0 C-N-CA 125.255 1.422 . . . . 0.0 107.22 -174.551 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -65.62 -27.81 68.67 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.837 0.855 . . . . 0.0 111.058 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.6 -18.21 66.6 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.904 -0.942 . . . . 0.0 112.311 177.042 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.495 ' HA ' HD12 ' A' ' 18' ' ' ILE . 12.2 t90 -80.77 -67.49 0.77 Allowed 'General case' 0 C--O 1.237 0.403 0 CA-C-N 118.481 1.141 . . . . 0.0 108.229 168.605 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -84.57 23.36 1.15 Allowed 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 121.374 0.607 . . . . 0.0 112.599 -162.828 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.88 -32.45 12.8 Favored Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.477 1.037 . . . . 0.0 111.614 175.096 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 20.7 mmt -151.14 -33.63 0.15 Allowed 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -176.019 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.495 HD12 ' HA ' ' A' ' 14' ' ' TRP . 45.8 mt -58.1 -45.17 88.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 C-N-CA 124.3 1.04 . . . . 0.0 112.189 -158.68 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -97.06 3.87 51.63 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.298 0.639 . . . . 0.0 111.636 -177.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.922 0 C-N-CA 127.573 2.511 . . . . 0.0 114.847 -162.519 . . . . . . . . 0 0 . 1 stop_ save_